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Introduction
As medical care improved outstandingly and is available to nearly everybody in the
industrialized countries and rescued countless people with life threatening diseases in their
middle age, life expectancy increased dramatically within the last century. Therefore, aging
and age-related diseases are becoming more and more important for our society and our
health care system. Not only the costs of retirement and care facilities explode with rising life
span, moreover especially the costs of the medical care are an essential problem for the whole
community.
Nevertheless, elderly people provide a very important impact and benefit to human social life,
ethnic culture and family bands. ‘Healthy aging’, therefore, is one of the major aims for
modern medicine.
Hallmarks of age-related health problems are degenerative and/or atrophic changes of several
tissues. Degeneration most likely occurs due to increased damage of differentiated cells that
are often substituted by connective tissue or inappropriate origin tissue only, thereby leading
to atrophy. Many theories try to explain why in the aged organisms the number of damaged
cells increases. The most important of those theories relates to the phenomenon that the
detoxifying system against reactive oxygen species (ROS), that are generated during aerobic
metabolism, decreases or becomes impaired with aging.
Aging
Aging is a condition associated with many social changes likely to induce psychological
stress. Many behavioral changes that normally occur over 65 years of age are also related with
changes in life-style. Retirement represents ‘per se’ a stressing event. The income is less than
that of the mean working population, leading to reduced expensive habits and increased
economic troubles. In addition, progressive loneliness caused by the death of the spouse,
death of friends and/or being forsaken by children and ancestors, generates a situation of
isolation (Guidi  et al.,  1998). Age-dependent neurological, articular, and muscular
modifications and diseases can cause a progressive loss of motility and disability. In modern
society, ‘efficiency’ is a fundamental quality of life, thus the old age period of
‘unproductivity’ can be perceived as a condition of uselessness (Blazer and Williams, 1980).
The outcome of all these psychosocial changes can be a condition of psychological stress
which, depending on personality features and previous experiences, can be perceived asINTRODUCTION
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uncontrollable and lead in some cases, on a long term, to clinically relevant depression (Guidi
et al., 1998). However, acute and chronic stress have a strong impact on immune function
(summarized in Guidi et al., 1998).
Molecular aspects of aging
The lifespan or life-expectancy of a cell or an organism, respectively, is biologically
terminated. At the end of each chromosome, there are telomeres, which regulate lifespan by
modulating genomic silencing. Telomere shortening has been observed in somatic cells of
aging humans and in primary cells as they divide in culture (Nicanor et al., 1997). Loss of
telomeric DNA and gradual shortening of telomeres have been proposed to result, after a
certain number of cell divisions, the inability of cells to divide again. Loss of telomeric
repeats is not an in vitro phenomenon as it is also observed in human cells in vivo (Pawelec et
al., 1999). Telomere shortening might therefore act as a mechanism counting the number of
cell divisions that a cell population has experienced. Telomere length in human blood cells in
vivo was shown to be related to donor age (Freedman et al., 1994). Telomere attrition occurs
more rapidly in premature aging syndromes, e.g. Hutchinson-Gilford progeria (Allsopp et al.,
1992) or trisomy-21 (Vaziri et al., 1993).This shortening is due to the absence of telomerase
in aging cells, which leads to a progressive loss of DNA sequences at the ends of replicated
chromosomes. It has been suggested that telomere shortening serves as a mitotic clock,
eventually triggering the senescence of cells and aging in people (Thoman and Weigle, 1989).
Short telomeres could stop cell division by cell cycle arrest, by making damage to
chromosomes in mitosis, or by deletion of telomere-proximal genes. In many tumor cell lines
telomerase activity has been restored during immortalization (Tielen et al., 1993).
Besides the biological termination of cell replication, there are other factors contributing to
aging and senescence, which are specially relevant for post-mitotic cells like oxidative stress.
Under normal physiological conditions, the oxygen consumption by cells with aerobic
metabolism always generates potentially deleterious ROS, which are usually detoxified by
several enzymes and physiological antioxidants. A mismatch between production and
detoxification of ROS leads to oxidative stress and consequently to cellular damage.
Increasing with age, oxidative stress is a major causal factor of cellular damage and enhanced
programmed cell death in many aging tissues including brain and immune system. The
mitochondrial chain failure has been implicated as a factor in the aging process (Miquel et al.,INTRODUCTION
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1980). It has been proposed that accumulation of mitochondrial mutations may underlie this
phenomenon (Wallace, 1992).  Furthermore, elevated generation and dysfunctional
elimination of ROS in cells from aged individuals seem to be involved in senescence and can
trigger programmed cell death.
Damaged or presumably dysfunctional cells are eliminated to maintain the common wealth of
the whole organism. In fact, these cells are not subject to an execution, they recognize that
they are damaged and perform their own suicide, called apoptosis or programmed cell death
(PCD).
Brain aging
The brain mainly consists of neurons, however, a smaller proportion of brain tissue is of non-
neuronal origin, the so-called glia or glial cells. The glia (from Greek, meaning ‘glue’) was
first recognized in the 1800s. Initially biologists mistakenly thought of the glia as a single unit
that served only as the uninteresting putty between neurons and spinal cord. But the 1920
microscopists had identified three kinds of glial cells: astrocytes, oligodendrocytes and
microglia. In the 1970s it was found that astrocytes can sop up excessive neurotransmitters in
order to protect neuron from to much stimulation while oligodendrocytes produce the myelin
sheath that insulates axons (Streit and Kincaid-Colton, 1995). All cell types provide important
immunological activity.
Neurons are mostly post-mitotic structure and usually do not proliferate anymore. Vascular
changes in aging occur in brain blood vessels as in the periphery, resulting in a lower supply
of nutrients and oxygen to brain cells. Neurons are cells that get rather old, as their plasticity
stores memories, that shall survive for a life-time. Malnutrition of neurons due to vascular
insults is a major reason for vascular dementia.
Glial activation occurs even in healthy aging. Lost neurons are substituted by glia in the aging
brain, thus gliosis (enhanced activation and proliferation of glia) seems to be one consequence
for loss of neurons.
Apoptosis in aging
The only type of cell death recognized in classical pathology was necrosis. This is an
involution phenomenon produced by severe injury to the cells. Its occurrence is usuallyINTRODUCTION
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accompanied by inflammation with redness and swelling of the surrounding tissue. Necrosis
is, therefore, unlikely to account for deletion of cells in normal animals.
The vision of naturally occurring cell death changed completely in 1972 when John Kerr et al.
(1972) described that natural cell death is not an involution or a degeneration of tissues, but an
active, inherently programmed phenomenon essential for organ development. They termed
this process ‘apoptosis’, a word used in classical Greek for the falling of leaves from trees.
During the development of an animal from a single cell, the fertilized egg divides, and than
the daughter cells divide, over and over again, generating a large number of cells, as many as
10
13 (ten million million) in humans. Then each single cell undergoes differentiation i.e. takes
on specific characteristics, such as becoming a nerve cell or muscle cell or a immune cell.
Furthermore, all of these cells must interact so as to form groups of cells with the proper
structure, like an arm or a leg, and correct interconnections as in the highly complex brain.
These processes of cell division, cell differentiation and morphogenesis constitute the basic
events of development and define the basic problems of developmental biology. In addition to
these processes, there is another event that appears to be universal among developing animals,
the process of cell death. Quite remarkably, many of the cells, that are generated as animals
develop do not survive to form part of the animal, but instead die, often before they have had
a chance to do anything.
It is apoptosis that removes tissues not needed and sculpts the body during fetal development.
The formation of fingers, for example, occurs in the embryo by removal of interdigital
webbed regions of the hand that starts as a paddle shaped structure or, as another example, the
loss of the tail of the tadpole when it turns into a frog. Moreover, apoptosis is of extreme
importance in natural tumor defense. Immunity relies on apoptosis to eliminate self-reacting
lymphocytes, to induce suicide in virus-infected cells, and to eliminate normal activated
lymphocytes after they have done their job in order to terminate an immune response.
Apoptosis is perhaps the most revolutionary concept ever introduced in biological sciences,
because it shows that death is an integral part of life and that active and well programmed
death is necessarily required for life to progress (Rappuoli, 2000). The new vision of cell
death, now seen as active, programmed morphological event involved in cell turn over in
healthy adult tissues and responsible for focal cell elimination during development took
almost a decade to enter into the molecular world. This happened when genes of the nematode
Caenorhabditis elegans (C. elegans) dedicated to apoptosis were identified and showed that
cell death is the result of a programmed intracellular cascade of genetically determined stepsINTRODUCTION
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(Ellis and Horvitz, 1986). The two genes named ced3 and ced4 (where ced stands for cell
death) were shown to be essential for the death of the 131 cells, that usually get lost during the
normal development of the 1000-cells-worm.
Today, the occurrence of apoptosis in various physiological and pathological situations is
confirmed and the programmed cell death is a subject of countless research studies to
elucidate the underlying mechanism of human patho-biochemistry.
Apoptosis is generally conceived as a strictly regulated (‘programmed’) device for the
removal of superfluous, aged, or damaged cells. It is fundamental for development,
throughout embryogenesis, organ metamorphosis, and organogenesis, including synaptic
interaction of neurons, and repertoire selection of T lymphocytes (Penninger and Kroemer,
1998). Increased resistance to apoptosis induction may lead to the persistence of severe
damaged or mutated cells, thereby preceding to cancer, or of self reactive immune cells,
leading to autoimmune diseases. In contrast, an enhanced susceptibility to apoptosis can cause
degenerative diseases or functional immunodeficiency. In post-mitotic tissues cell
replacement is not possible in response to damage, so the feasible outcomes are either
complete repair, continued survival of a dysfunctional cell, or apoptosis.
The major source of most cell damage is assumed to be oxidative stress due to mitochondrial
production of ROS. ROS presumably affect DNA, but also proteins and lipids. Maintenance
of mitochondrial membrane integrity is also compromised by oxidative stress. Oxidative
stress is responsible for the mitochondrial permeability transition, mitochondrial
depolarization, decrease in ATP levels, and finally apoptotic cell death (Warner 1999).
Possibly related to limited synthesis of ATP, the mitochondrial membrane may become
permeable to cytochrome c, thereby initiating apoptosis. The antiapoptotic protein Bcl-2
inhibits apoptosis by blocking the release of cytochrome c (Yang et al., 1997). Apoptotic cell
death is associated with major changes in the redox status including a loss of nonoxidized
glutathione (Macho et al., 1997) which may be oxidized during the process of apoptosis,
increased production and/or reduced detoxification of reactive oxygen species (Zamzami et
al., 1995), and oxidation of cellular constituents including membrane lipids (Hockenberry et
al., 1993).
During apoptosis, DNA fragmentation occurs via the activation of nucleases that generate
mono- and oligomers of 180 – 200 bp corresponding to the length of the nucleosome.INTRODUCTION
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Apoptosis can play a role in aging: elimination of damaged and presumably dysfunctional
cells (e.g., lymphocytes) which can then be replaced by cell proliferation, thereby maintaining
homeostasis and elimination of essential post-mitotic cells (e.g., neurons) which cannot be
replaced so easily, thereby leading to pathology. Evidences indicate the age-related decreased
susceptibility for apoptosis, although the molecular basis for these decreases appears to be
different. Fibroblasts (and neurons) lose the ability to downregulate Bcl-2 in response to an
apoptotic signal; thus, apoptosis is blocked even though an initiating signal has been received.
In contrast, lymphocytes are not able to initiate the signal due to downregulation of the cell
surface receptor Fas. There is limited information available for other tissue types, and nothing
is known about why and how these age-related changes occur. An interesting observation, but
not necessarily a crucial one, is that the frequency of upregulation of the Bcl-2 gene due to
chromosome translocation increases with age. The role of apoptosis in regulating cell number
is also a promising area of research. The studies on liver damage and neoplastic lesions
suggest an extremely important role for apoptosis in controlling cancer. Apoptosis appears to
be either ‘on’ or ‘off’ in cells, while the basic cell-killing machinery may often be present, but
in an inactive form (Warner, 1997).
However, apoptosis is strictly linked to normal development and most of the physiological
aspects of life in humans, animals and plants. Hence any unbalance in this process may lead
to diseases such as tumors, degenerative disorders, and infections. The precise molecular
knowledge of the fundamental events involved in apoptosis are today subject of intensive
studies aiming at the development of drugs that may prevent or induce apoptosis to treat many
diseases.
Alzheimer’s diseases: an age-related neurodegenerative disorder
Alzheimer's disease (AD) is a neurodegenerative disorder that is characterized by global
cognitive decline including a progressive loss of memory, orientation, and reasoning. Alois
Alzheimer extensively described a dementive syndrome of his patient Auguste D. whom he
treated as neurologist and psychiatrist in Frankfurt am Main at the beginning of the last
century (Alzheimer, 1907). He recorded a rapidly progredient memory loss of the 52 year old
women. After her death, he examined her brain and found histological changes, that are
specifically for AD.
Since the time of the discovery of the disease up to now, life expectancy further increased.
Consequently, every 10
th person over 65 years is affected by the dementia of Alzheimer’sINTRODUCTION
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type (DAT) and further 10% with every decade. An irreversible loss of cognitive and mental
abilities is the prognosis of this disorder. In later stages, AD patients are helpless and require
full-time nursing care. Besides the personal and familial tragedies that are one aspect of the
dementia, AD is a financial problem of health service and thereby a burden for the whole
social community. And this cost will raise as more and more persons are aging and becoming
elderly.
AD is a progressive neurodegenerative disorder with disastrous  consequences, clinically
characterized by a slow onset, the progress is associated with a loss of cognitive function and
a fatal mental dysfunction. Histologically, the neurodegeneration is distinguished by
neuropathological changes, protein deposits, mainly consisting of  b-amyloid (Ab) in the
hippocampus, parietotemporal regions and cerebral cortex. The brains of AD patients contain
abundant amounts of neurofibrillary tangles (NFT) and Ab in the form of senile plaques and
deposits in cerebral blood vessels.
Pathological changes in AD brain
The major histopathological lesions in AD brain are neurofibrillary tangles and plaques.
Figure 1. Pathological hallmarks in AD brain: a plaque, mainly consisting of Ab (left).
The dense amyloid core is surrounded by an amyloid halo. Neurofibrillary tangles
(right) are formed by dead neuron cell bodies due to cytoskeletal changes, for instance
hyperphosphorylation of t-protein (picture taken from Arendt, 1999).INTRODUCTION
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Neurofibrillary tangles
Tau (t) is a microtubule-associated protein that, in a hyperphosphorylated form, comprises the
main component of the paired helical filaments and neurofibrillary tangles found in AD brain.
It is therefore important to understand the normal functioning and processing of t protein, and
the abnormal posttranslational processing of t in AD pathology. Mutations in the t gene have
been found in several non-AD, autosomal dominant neurodegenerative disorders that exhibit
extensive neurofibrillary pathology (Johnson and Harrtigon, 1998). In addition, there is
increasing evidence that t may be involved in signal transduction, organelle transport, and cell
growth, independent of its microtubule-binding functions.
In Alzheimer’s Disease brain t is abnormally phosphorylated. This hyperphosphorylated form
of t is the major component of the paired helical filaments (PHFs) and neurofibrillary tangles
(NFTs) found in the AD brain. The mechanisms underlying the abnormal phosphorylation and
accumulation of t in AD are still under investigation (Johnson and Harrtigon, 1998).
Although phosphorylation of specific sites may facilitate the aggregation of t into filaments in
AD brain, it is likely that other factors contribute to this process. For example, incubation of
non-phosphorylated t with sulfated glycosaminoglycans, such as heparin or heparan sulfate,
resulted in the formation of PHF-like structures (Arrasate et al., 1997). In addition, the repeat
region of t was essential for the induction of PHF formation (Goedert et al., 1996). Heparin
also prevented  t from binding to microtubules and promoted microtubule disassembly.
Additionally, there is some evidence to suggest that heparan sulfate and t may colocalize in
NFT-containing neurons in AD brain (Goedert  et al.,  1996). Considering this, it was
hypothesized that an increase in sulphated glycosaminoglycans within the cytoplasm of nerve
cells may trigger the hyperphosphorylation of  t, destabilize microtubules and induce
assembly of PHFs.INTRODUCTION
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Figure 2. Molecular mechanisms of tangle formation. t-proteins stabilizes microtubles
in axonal endings. Higher glutamate concentrations in AD brains induce
hyperphosphorylation of  t-protein, thereby destroying cytoskeletal structure. As a
consequence, the axonal endings degenerates, t-protein is distributed into the cell body
and initiate the evolution of tangles (adapted from Haass, 1999).
Amyloid plaques
A major feature of Alzheimer's disease (AD) is the region-specific formation of senile plaques
in the brain. An amyloid deposit composed mainly of b-amyloid occupying the plaque center.
Ab is a peptide of 40 to 43 residues derived from a larger amyloid precursor protein (APP)
located on chromosome 21 (Selkoe, 1994). Individuals with Down’s syndrome (DS; trisomy
21) develop quite early an AD-like pathology, which might be due to a gene-dose effect of
APP (Pallister et al.,  1997).
Senile plaques formation occurs age-dependent in physiological aging. However, when senile
plaques transform into neuritic plaques, sites of inflammation form around the plaque
involving mostly parts of the innate immunity (see ChapterINTRODUCTION
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Neuroinflammation in AD).
Moreover, AD is mainly characterized by a dramatic loss of neurons and synaptic contacts in
the affected brain areas. Loss of cholinergic neurons seem to be specially associated typical
clinical symptoms, like memory deficits, impaired attention, cognitive decline, and reduced
learning abilities. A b-toxicity and neuroinflammation elevate glutamate levels in neural
tissue that further damage the insulted neurons. Mainly in later stages of the disorder,
degeneration of dopaminergic neurons are involved as well, and Parkinson’s-like symptoms
with extrapyramidal impairment may occur (Kornhuber et al.,  1999).
Molecular mechanisms and genetical risks of AD pathology
While the etiological events that lead to AD remain unresolved, a small percentage of AD has
been shown to be of genetic origin (Tanzi et al., 1994; Wasco and Tanzi, 1995) and is termed
familial Alzheimer's disease (FAD). FAD is a genetically heterogeneous disorder that can be
categorized according to age-of-onset using 60 years as the cut-off for "early-onset" versus
"late-onset" FAD. The gene defects responsible for early-onset (under 60 years) FAD are
located on chromosomes 1, 14, and 21 and include the genes for presenilin 2 (PS2), presenilin
1 (PS1), and amyloid ß protein precursor (APP), respectively. In addition, a genetic "risk
factor" for late-onset FAD (over 60 years old), the apolipoprotein E (ApoE) on chromosome
19 has been identified (Saunders et al., 1993).
Amyloid-Precursor protein (APP)
APP is a transmembrane protein with various isoforms that result from alternative splicing
(Selkoe, 1994). The Ab peptide is generated by processing through b- and g-secretases. By
cleavage within the Ab region of APP by a-secretase, the long N-terminal fragment (secreted
APP, sAPP) is secreted into the extracellular space. It is found in plasma and cerebrospinal
fluid (Ghiso  et al.,  1989; Podlisny  et al.,  1990). Considering the abundance of both
membrane-bound APP and sAPP, they are likely to have significant biological functions.
Conversely, proposed functions for sAPP include the regulation of blood coagulation (Van
Nostrand  et al.,  1990), wound-healing (Cunningham  et al.,  1991), extracellular protease
activity (Van Nostrand  et al., 1989), neurite extension (Robakis  et al.,  1990), cell
adhesiveness (Schubert et al., 1989), cell growth, (Bhasin  et al., 1991), and differentiationINTRODUCTION
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(Yamamoto  et al., 1994). Many different types of cells synthesize APP. In neurons it is
abundantly located in the synaptic zone (Schubert, 1991). Different cell types produce
different isoforms of APP. Differentiated neurons produce mainly the APP695 form whereas
non-neuronal cells produce the Kunitz-type protease inhibitor (KPI)-containing forms of APP
(Selkoe, 1994). Activated leukocytes display elevated levels of APP (Monning et al., 1992;
1990).
In vitro studies demonstrated that Ab may cause neuronal death, supporting the hypothetical
involvement of Ab in neurodegeneration in AD. To explain massive neuronal loss in the brain
of AD patients, several models have been proposed placing Ab as a principal culprit (Citron
et al.,  1992; Mattson  et al.,  1992; Pike  et al.,  1993; Yankner  et al.,  1989). Possible
mechanisms of Ab toxicity include kinase activation (Zhang et al., 1994), generation of free
radicals (Behl and Schubert, 1993), and enhancement of glutamate toxicity (Mattson  et al.,
1992). Because APP plays a role in cell growth and neuronal maintenance and differentiation,
understanding the relationship between sAPP's neurotrophic function and Ab neurotoxicity is
important. sAPP treatment could reduce the effect of Ab on neurons (Goodman and Mattson,
1994) which suggests that the neurotrophic effect of sAPP is sufficient to overcome A b
toxicity under normal conditions.
There have also been numerous studies examining the possible effects of  Ab on  t
phosphorylation. Treatment of fetal rat hippocampal and human cortical neurons with fibrillar
Ab resulted in an increase of  t phosphorylation. The phosphorylation of t in response to
Ab treatment resulted in a loss of microtubule binding capacity and accumulation of t in the
somatodendritic compartment (Busciglio et al.,  1995). One possible mechanism by which
Ab may induce increases in t phosphorylation is by perturbing calcium homeostasis which
would result in inappropriate increases in the activities of certain protein kinases contributing
to t hyperphosphorylation. Further, it has been hypothesized that Ab-induced perturbation of
calcium homeostasis could make the cells more vulnerable to other potentially ‘toxic‘ stimuli,
including glutamate. Treatment of neuronal cells with  Ab resulted in elevated intracellular
calcium levels over those of resting cells (Hartmann et al., 1994a, 1994b, 1994c; Müller et al.,
1996). Addition of  Ab also made the cells more vulnerable to neurotoxicity induced by
glutamate, kainate or N-methyl-D-aspartate (NMDA; Mattson  et al., 1992; Mattson  et al.,
1993).INTRODUCTION
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The first gene defects causing early-onset FAD were found in the APP gene (Goate et al.,
1991; Mullen et al.,  1992) and all six are missense mutations lying within or close to the
domain encoding the Aß peptide, the major component of amyloid in AD. The APP mutations
account for a very small proportion (2-3 %) of all published cases of FAD (Tanzi  et al.,
1992) and 5-7 % of reported cases of early-onset FAD. The pathogenicity of these mutations
has been strongly supported by the fact that they are virtually 100 % penetrant in FAD
kindred where they occur in affected or at-risk individuals, but are absent in age-matched
controls. Moreover, transgenic mice expressing the APPV717F ‘London’ mutation produce
numerous Aß deposits in the form of classical senile plaques and the brains of these animals
exhibit other neuropathological features of AD including neuronal and synaptic loss and
gliosis (Games et al.,  1995). FAD mutations in APP have been shown to affect the release of
Aß in transfected cells and carrier fibroblasts (Cai et al.,  1993; Suzuki et al.,  1994; Citron et
al.,  1992). While the APP codon 717 mutations are associated with overproduction of Aß42
(increased ratio of Aß42:Aß40), the ‘Swedish’ FAD double missense mutant leads to an
increase in total Aß secretion. The Swedish mutant involves the substitution of the two N-
terminal amino acids of the Aß domain presumably rendering APP more susceptible to ß-
secretase activity. Additionally, studies of polarized cells have revealed that while up to 90 %
of a-secretase-cleaved APP is normally released from the basolateral surface (see Figure 4;
Haass et al., 1994), APP carrying the Swedish mutation is released primarily from the apical
surface. (Selkoe et al., 1995). Therefore, FAD mutations in the APP gene appear to affect
both Aß release and the trafficking of APP, intracellularly.
Figure 3. Molecular mechanisms of plaque evolution in AD brains (for details see text).
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Presenilins (PS)
The largest portion of early-onset FAD cases have been associated with mutations in the
presenilin genes, PS1 and PS2 (Sherrington et al., 1995;  Levy-Lehad et al., 1995; Li et al.,
1995; Rogaev et al., 1995). PS1 encodes a 467 amino acid polypeptide predicted to contain
between 7-9 transmembrane spanning domains (Sherrington et al., 1995; Slunt et al., 1995)
and includes a hydrophilic ‘loop’ region (amino acids 267-403). Plasma and fibroblasts from
patients and pre-symptomatic carriers of mutations in PS1 and PS2 contain increased amounts
of the more amyloidogenic version of the Aß peptide, Aß1-42 or Aßx-42 (Scheuner et al., 1996).
The mean age of onset of AD in PS1-linked FAD families is approximately 45 years with a
range of 32 to 56 years. In contrast, the mean age of onset in the Volga German families with
the N141I PS2 mutation is 52 years and individual ages of onset in these kindred range from
40-85 years (Tanzi, 1996). Whether considered as a group or individually, the PS1 FAD
kindred exhibit a more narrow range in age of onset of AD than do the families with PS2
mutations. The known (>50) FAD mutations are distributed throughout the PS1 gene,
although almost half of all reported mutations in PS1 are in predicted TM domains.
Additionally, all FAD missense mutations occur in amino acids that are conserved between
PS1 and PS2 (Tanzi, 1996).
The cellular distributions of the PS1 and PS2 are similar with both localized to the nuclear
envelope, endoplasmic reticulum (ER) and the Golgi (Kovacs  et al.,  1996). Overall, the
cytoplasmic staining pattern observed for the presenilins is reticular and punctuate, suggestive
of vesicular staining. Plasma membrane staining is not found for either of the presenilins
(Kovacs et al., 1996; Cook et al., 1996). In comparison with the wild-type PS1 and PS2, no
gross abnormalities in the subcellular localization of mutant presenilins have been reported.
PS1 was also found in dendrites (but not axons) of human neuronal cell lines expressing PS1.
Haass and colleagues have reported the phosphorylation of the N-terminus of PS2 but not of
PS1 (Haass et al.,   1996), further supporting the related, but differential roles for these
proteins.
While the biological functions and physiological roles of the presenilins are not yet known,
both have been proposed to possibly act as receptors, ion channels, or molecules involved in
protein processing or trafficking (Sherrington et al., 1995; Levy-Lahad et al., 1995; Kovacs et
al., 1996). The most valuable clues regarding possible functions of the presenilins have
emerged from the recent findings that PS1 and PS2 are homologues of two C.elegans genesINTRODUCTION
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known as sel-12 (50% identity; Levitan and Greenwald, 1995) and  spe-4 (25% identity,
L'Hernault and Arduengo, 1992). It is worth noting that greater than 80% of the FAD
mutations identified in the PS1 and PS2 gene occur in amino acids that are perfectly
conserved in sel-12, which encodes a member of the Notch family of receptors involved in
intercellular signaling and the determination of cell fate (Levitan and Greenwald, 1995). The
latter role is indirectly supported by our previous findings that PS1 and PS2 are localized to
the ER and Golgi where they could conceivably participate in the processing and/or cellular
trafficking of plasma membrane-bound and secretory proteins. PS1 has been reported to be
processed into two fragments: a 27 kDa N-terminal 18 kDa C-terminal fragments (Thinakaran
et al., 1996).
These data suggest a common pathogenic pathway for the early-onset FAD gene defects in
APP and the presenilin genes revolving around the increased production of Aß42.
ApoE polymorphism
In humans, apoe (apoe = gene; ApoE = protein) is a single gene located on chromosome
19q13.2 with three major allelic variants (e2, e3, e4) encoding three protein isoforms ApoE2,
ApoE3, and ApoE4 (Bales et al.,  2000). ApoE has been widely documented to play a role in
sporadic late onset AD. ApoE first came to light in AD as a susceptibility gene (Strittmatter et
al., 1993). Whereas the apoe2 and apoe3 alleles have no effect or a even beneficial effect,
possession of the apoe4 allele, especially homozygosity for apoe4, appears to shorten the date
of AD onset by some 5-10 years (see Figure 4). In a recent assessment of the impact of
ApoE4 on AD as a function of age of onset in over 300 families and affected sib-pairs with
FAD (Blacker et al., 1997), ApoE4 was found to be strongly associated with AD, however,
the risk for AD due to inheritance of ApoE4 was most significant in FAD families with mean
age of onset between 61 and 65 years. In addition, two copies of ApoE4 was associated with a
lower age of onset in this study (Blacker et al., 1997). AD and Down’s syndrome patients
who are apoe4-positive exhibit increased amyloid burden in the brain presumably due to
increased aggregation or decreased clearance of Aß (Hyman et al.,  1995). AD patients who
are heterozygous, and especially those who are homozygous for apoe4 tend to have more
congophilic angiopathy (Lue  et al., 1999), perhaps suggesting a connection with current
vascular/ cholesterol hypotheses of AD (Sparks, 1997). Still other alternatives may follow
from the finding that ApoE can influence microglial expression of several inflammatory
indicators (Laskowitz et al., 1998), and this effect seems to be isoform-dependent (Barger andINTRODUCTION
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Harmon, 1997). In addition, ApoE promotes axonal growth and synaptogenesis, probably
because it regulates the transcellular transport of cholesterol and phopholipids (Mesulam et
al.,  2000). The ApoE/lipoprotein complex seems to act as scavenger of normally secreted
extracellular lipophilic/non-aggregated Ab in vivo (Poirier et al.,  2000). In brief, the ApoE
initially binds to the lipophilic region (amino acids 18-42) of soluble A b,  via the LDL
receptor the lipoprotein with the bound A b is internalized into the cell and directed  via
chlathrin-coated pits to endosomal compartments, where it is processed through the usual
endosomal/lysosomal pathway.
Figure 4. Onset of AD pathology and loss of neural substance in relation to the ApoE
genotype.
Apoptosis in AD
Recent data in cell culture have shown that brain neurons are particularly vulnerable towards
degeneration by apoptosis. Further the inducers that activate the program (e.g. A b, oxidative
damage, low energy metabolism) correspond to conditions present in the AD  (Cotman and
Anderson, 1995) and DS brain (Seidl et al., 2001). Furthermore, some neurons in vulnerable
regions of the AD brain show evidence of DNA damage, nuclear apoptotic bodies, chromatin
condensation (Dragunow et al.,  1995), and the induction of selected genes characteristic of
apoptosis (Giannakopoulos et al., 1999; Sawa, 1999; Tortosa et al., 1998; de la Monte et al.,
1997; Nishimura et al., 1995) in cell culture and animal models. This suggests the possibility
that apoptosis may be one of the mechanisms contributing to neuronal loss in this disease. On
the other hand, DNA damage is present in the majority of neurons in vulnerable regions in
early and mild cases. In most tissues, cells in fully activated apoptosis degenerate and areINTRODUCTION
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removed within hours to days and thus it seems all DNA damage is unlikely to signify
terminal apoptosis. The presence of extensive DNA damage suggests an acceleration of
damage, faulty repair process, loss of protective mechanisms, or an activation and arrest of
parts of the apoptotic program. DNA damage is unlikely to be an artifact of post mortem delay
or agonal state. The existence of protective mechanisms for neurons may exist as these cells
are nondividing and essential. In this context it is interesting that Bcl-2 is upregulated in most
neurons with DNA damage (Satou  et al., 1995; Su et al., 1996). Further, apoptosis-related
gene expression is altered (Su  et al.,  1997). Recently, a close involvement of caspases,
executor molecules of apoptosis, in A b toxicity and in AD brain was found (Eckert  et al.,
2001a; Lu et al., 2000; Gervais et al., 1999; Weidemann et al., 1999; Pellegrini et al., 1999).
Thus it appears as if neurons are in a struggle between degeneration and repair. As research
advances it is critical to reduce the stimuli that cause the neuronal damage and discover the
key intervention points to assist neurons in the repair processes (Cotman and Su, 1996).
Figure 5. Loss of cholinergic neurons in neurodegenerative disorders (y-axsis: number
of neurons in Nucleus basalis Meynert) correlates with the cognitive decline measured as
Mini Mental State Score (figure taken from Arendt, 1999; x-axsis; l, adult controls; n,
AD patients).
The cognitive decline of patients with neurodegerative dementias correlates significantly with
neuronal cell loss (see  Figure  5). One current hypothesis is that at least some human
degenerative disorders are caused by ecotopic programmed cell death, that are
mechanistically similar to those that occur in normal development but that are for some
reason, however, being expressed by the wrong cells or at the wrong time (Arendt, 1999)INTRODUCTION
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It has long been recognized that there is a loss of neurotransmitters in the AD brain. New
findings have extended these observations to evaluate localized fiber loss. In particular, axon
length in the area of A b deposits has been reported to be reduced in comparison with the
neighboring neurophil, a result that has been hypothesized to reflect local axotomy and to
explain the mechanism for synaptic loss (Cotman and Anderson, 2000).
Oxidative stress in AD
Dysfunction of mitochondrial chain activity may predipose for neurodegenerative disorders,
since most of these diseases are associated with elevated levels and byproducts of oxidative
stress (Ojaimi et al, 1999). Immunohistochemical data have demonstrated many of the
hallmark modifications of oxidative damage in AD brain, including the presence of proteins
modified with advanced glycation end products (AGE; Takeda  et al., 1998),
malondialdehyde, 8-hydroxy-deoxyguonosine, 4-hydroxynonenal (Markesberry and Carney,
1999) and nitrotyrosine (Good  et al., 1996), along with increased amounts of lipid
peroxidation (Markesberry and Carney, 1999). Oxygen free radical stress not only leads to
direct cellular injury, it may also influence neuronal integrity by triggering redox-sensitive,
NF-kB-mediated transcription of various pro-inflammatory and apoptosis-related genes in
surrounding cells (Kaltschmidt et al., 1997). Although the majority of research on AD
oxidative stress had focused on the possibility of free radical generation by affected neurons
(Behl, 1997; Mattson and Pederson, 1998) as a result of impaired electron transport chain
function during mitochondrial oxidative metabolism, the concept of free radical toxicity
actually has its roots in inflammation processes, where the secretion of ROS and nitrogen
radicals by inflammatory cells is a major mechanism for attacking opsonized target.
Alternative sources of free radicals in the AD brain are therefore likely to induce activated
microglia (see: Cellular mediators of inflammation in the AD brain), which have the potential
to produce large amounts of ROS as a result of activation of the NADPH complex  (Della-
Bianca et al., 1999).INTRODUCTION
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Neuroinflammation in AD
A virtual textbook of inflammatory mediators has been observed in the Alzheimer’s disease
brain over the last 15 years. These mediators are typically undetectable or background levels
in samples from non-demented elderly persons, and have been investigated at
immunohistochemical, biochemical, and molecular levels. As with all new developments in
science, perception of these findings has evolved over time. Initially, resistance was high.
Many of the early results were dismissed as artifact, an impossibility given in the
'‘immunologic privilege'’ of the brain (Hickey and Kamura, 1988; Weckerle  et al., 1986,
1987; Aisen and Davis, 1994; McGeer and McGeer, 1995). It is now clear that the brain may
have many unique immunologic properties, but it is by no means an immunologicalyy
isolated organ.
With this understanding, new challenges have arisen. Are inflammatory mechanisms actually
causing damage in AD or they present merely to remove the detritus from other, more
primarily pathologic processes? Are anti-inflammatory drugs a viable therapeutic option for
AD?
Cellular mediators of inflammation in the AD brain
Microglia
Activated microglia clusters at sites of aggregated A b deposits and deeply interdigitate
neuritic plaques. Since microglial cells are related to peripheral macrophages (Ling et al.,
1993), they are one of the most obvious targets for research in AD inflammation. Although in
the normal brain microglia also play neurotrophic roles (Streit et al., 1999), their potential
neurotoxic action have been emphasized in AD research. Once activated in vitro, microglia
are capable producing a variety of pro-inlammatory molecules (McGeer et al., 1989) and
potentially neurotoxic substances (Banati et al., 1993) that could contribute to localized or
more widespread CNS injury. These include complement, cytokines, ROS, secreted proteases,
glutamate and NO (Banati et al., 1993). Moreover, Ab stimulates microglial production of IL-
1, IL-6, TNF-a, MIP-1a, MCP-1, and ROS (Cotman and Tenner, 1996; Giulian et al., 1996).
In addition, activated microglia release the excitotoxins glutamate (Piani et al., 1992) and
quinolinic acid (Espey et al., 1997). Exposure to those substances may not necessarily kill the
entire cell, however, could result in a disastrous degree of dentritic pruning (Mattson and
Barger, 1993), thereby leading to cognitive impairment that is not unavoidably related toINTRODUCTION
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neuronal loss. Moreover, AD patients show elevated levels of glutamate in CSF (Jiménez-
Jiménez et al.,  1998).
AD microglia reportedly upregulate their expression of the macrophage scavenger receptor
(MSR; El Khoury et al., 1998) and RAGE (receptor for AGE; Yan  et al., 1996), both of
which may have Ab as ligands. It has also been shown that adhesion of microglia to A b
fibrills via scavenger receptors lead to immobilization of the cells and induces them to
produce ROS (El Khoury et al., 1998). Moreover, there are findings that support a role for
microglia in transforming diffuse plaques into neuritic plaques (Cotman and Tenner, 1996;
Mackenzie et al., 1995), probably a key process in AD pathology.
Astrocytes
Like microglia, astrocytes are found at sites of Ab deposition, but in contrast the positioning
of astrocytes in plaques differs from that of microglia. Astrocyte somas form a corona at the
perimeter of the neuritic halo that, in turn surround a dense core A b deposit (Mrak et al.,
1996). Astrocytes may impair the natural ability of microglia to clear plaques (Snow et al.,
1988). In addition, astroglial cells are capable to produce complement factors (Gasque et al.,
1998), an ApoJ/ApoE complex (LaDu et al., 1998), IL-1 (Del Bo et al., 1995), IL-6 (Van
Wagoner et al., 1999), S100-b (Van Eldik et al., 1994), TGF-bs (Kriegelstein et al., 1995),
a1-ACT (Das et al., 1995), ICAM-1 (Akiyama  et al., 1993), prostaglandins and COX-2
(Bauer et al., 1997), and iNOS (Lee et al., 1993) upon activation.
Neurons
Perhaps surprisingly, neurons themselves have been consistently identified as a cell type
capable of producing inflammatory molecules mediators, including complement (Shen et al.,
1997), COX (Oka and Takashima, 1997), the cytokines IL-1, IL-6 and TNF-a as well as their
receptors (Yan  et al., 1995) and M-CSF (Yan  et al., 1997). It is therefore possible that
neurons themselves may exacerbate inflammatory reactions in their vicinity and thus
contribute to their own destruction in AD.
Inflammatory pathways in the AD brain
Just as damaged tissue and the chronic presence of highly inert abnormal materials are
classical stimulants of inflammation in the periphery, thus Ab, tangles, and neurodegenerationINTRODUCTION
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are the most likely sources for inflammation in the AD brain. From there, as in the periphery,
a nearly bewildering number of inflammatory subsystems are involved, each characterized by
an abundance of amplifying and dampening loops, as well as multiple interactions with the
other subsystems.
Complement
The classical component pathway is made up of some 20 or more components, many of them
serine proteases that can be sequentially activated as an amplifying cascade.
Some complement factors (C5b, C6, C7, C8 together with multiple C9 components) may
form the membrane attack complex (MAC). When assembled on a cell membrane, this
macromolecular terminal reaction complex forms a ring-like structure. The transmembrane
channel caused by MAC assembly at the cell surface permits the free diffusion of ions and
small molecules into and out of the cell, disrupting cellular homeostasis, particularly Ca
2+
homeostasis, and ultimately resulting in cell lysis in case a sufficient number of MAC
complexes have assembeled on the cell. Notably, the MAC can also induce bystander lysis of
healthy adjacent tissue (Neuroinflammation Working Group, 2000).
b-pleated, fibrillar Ab (Webster et al., 1997) and, more recently, t-containing neurofibrillary
tangles (Rogers et al., 1998) have been shown to directly activate the classical complement
pathway fully in vitro, and to do so in the absence of antibody. For Ab the details of binding
and activation are relatively clear. A 13-15 amino acid sequence on the human C1q A-chain
collagen-like tail contains five cationic side chains that bind in a charge-based fashion to
anionic side chains along the N-terminus of human Ab (Jiang et al., 1994). Notably, rodent
Ab differs from human Ab by three amino acids in the N-terminal region (Velazquez et al.,
1997) and mouse C1q lacks two of the positively charged residues in the A-chain site critical
for A b/C1q binding (Jiang  et al., 1994). The latter finding may have implications for
transgenic mouse models of AD that express human A b but do not express human C1q.
Human Ab activates human C1 more efficiently than mouse C1 (Webster et al., 1999).
By binding multiple Ab molecules or by stabilizing already-formed oligomeres of A b, C1q
appears to nucleate the formation of A b fibrills (Webster et al., 1999). In addition to A b
aggregates and neurofibrillary tangles, other potential sources for classical pathway activation
exist in the AD brain. Neurodegeneration, for example, may ultimately expose DNA andINTRODUCTION
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neurofilaments to the extracellular environment, thereby activating complement cascades
(Linder et al., 1979).
Initiation of the complement induces chemotactic and activating signals to inflammatory cells
bearing appropriate receptors, and so do microglia and astrocytes (Gasque  et al., 1998).
Therefore, reactive astrocytes and activated microglia are all highly co-localized with plaque
containing aggregated Ab (McGeer et al., 1989). Neurons also reportedly express receptors
for C3a and C5a (Davoust et al., 1999), but the functional significance of the finding has not
been conclusively determined.
Upregulation of complement defense proteins, including C4 binding protein (C4bp),
vitronectin, and clusterin (apolipoprotein J; ApoJ), also occurs in the AD brain. ApoJ has been
shown to bind A b, potentially facilitaing A b transport across the cerebrovasculature
(Zlokovic et al., 1996). Although the receptors for ApoJ transport are not well understood at
this time, they may include an endocytosing member of the low density lipoprotein (LDL)
receptor family (Chun et al., 1999).
Cytokine and chemokine pathways
IL-1 is an immunoregulatory cytokine that is overexpressed within affected cerebral cortical
regions of the AD brain (Griffin et al., 1998). IL-1 overexpression seems to occur early in
plaque evolution, suggesting that it plays a orchestrating role in plaque formation. It is already
evident in diffuse, non-neuritic Ab deposits, and can be observed in autopsied brain samples
from fetuses and young children with Down’s syndrome (Griffin et al., 1995). In particular,
IL-1 promotes the synthesis (Mackenzie, 2000) and the processing (Buxbaum et al., 1992) of
APP and may therefore promote further amyloid production and deposition in plaques. A
reciprocal relationship also seems to exits wherein the secreted form of APP (sAPP) activates
microglia and induces excessive production of IL-1 (Barger and Harmon, 1997). Moreover,
IL-1 activates astrocytes to express several acute phase and/or Ab-binding proteins, including
a1-antichymotrypsin (a1-ACT; Das et al., 1995), ApoE (Das et al., 1995) and complement
factors (Barnum et al., 1994). One of the most important trophic actions of IL-1, however, is
induction of S100b overexpression, a neurite growth promoting cytokine, by reactive
astrocytes (Sheng  et al., 1996). A significant correlation between cross-sectional area of
dystrophic neurites in A b plaques and the number of plaque associated S100b
immunoreactive astrocytes, suggesting that its neurite growth-promoting action is directly
reponsible for dystrophic neurite growth near Ab deposits (Mrak et al., 1996). Finally, IL-1INTRODUCTION
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may also influence AD patho-pharmacology by its ability to induce expression and activity of
acetylcholineesterase (AChE). Presumably such an effect would exacerbate cholinergic
decline and dysfunction in AD.
IL-6 is a pleitropic cytokine that mediates immune response and inflammatory reactions
affecting CNS cell growth and differentiation (Hirano  et al., 1997). Normally at barely
detectable levels in the adult CNS, it is strongly induced under pathological conditions
(Vallieres and Rivest, 1997) and induces acute phase reactants, act as a major pyrogen,
increases vascular permeability, lymphocyte activation and antibody synthesis (Strauss et al.,
1992). IL-6 seems to modulate APP synthesis and may also act on neurons, inducing the
expression of acute phase proteins a2-macroglobulin (a2-MAC) and metallothionine (Bauer
et al., 1993). It has been suggested that IL-6 may appear before neuritic changes rather than
neuritic degeneration. In the CSF, AD patients exhibit significantly decreased concentrations
of soluble IL-6 receptors compared to healthy, age-matched controls, whereas IL-6 protein
levels are unaltered (Hampel et al., 1998). Interestingly, patients with multiple sclerosis, like
AD patients, show decreased CSF soluble receptor levels (Padberg et al., 1999).
Elevated TNF-a levels in AD serum (Fillit et al., 1991), CSF, cortex, and glial cell cultures
after exposure to Ab (Tarkowski et al., 1999) were found. The pathophysiologic action of
TNF-a in AD are controversial given its role as a potent pro-inflammatory, cytotoxic
polypeptide in the periphery and in such other CNS disorders as brain trauma (Mullberg et al.,
1995), multiple sclerosis (De Vos et al., 1998), and Parkinson’s disease (Hsu et al., 1996).
Low levels of TNF-a can act neuro-protective (Bruce et al., 1996), however, excess of TNF-
a is able to kill human cortical neurons (Good et al., 1996; McKee et al., 1998). Activation of
neurons by TNF-a induces the expression of protective molecules, including manganese
superoxide dismutase (SOD). In contrast, TNF-a is a potent stimulator of NF-kB, that
elevates the expression of pro-inflammatory factors such as complement and cyclooxygenase
(COX; Cardinaux et al., 2000), as well as survival factors such as Bcl-2 (Tamatani  et al.,
1999).
TGF-bs are multifunctional peptide growth factors that play pivotal roles in tissue
development, homeostasis and repair (Kriegelstein et al., 1995). TGF-bs have been shown to
modulate a wide range process that are implicated in AD, including brain injury, brainINTRODUCTION
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inflammatory response and microglial activation, extracellular matrix production,
accumulation and regional distribution of amyloid, regulation of known and potential AD risk
factors (e.g., APP (Monning et al., 1994), a2-MAC (Webb et al., 1994), and COX-2 (Luo et
al., 1998)), and inhibition of cell death (Böttner et al., 1996; Unsicker et al, 1991). TGF-b1
has been detected in plaques, and higher TGF-b1 levels were found in cerebrospinal fluid
(Chao et al., 1994a) and serum (Chao  et al., 1994b) of AD cases than in nondemented
controls.
Although well known as an anti-inflammatory cytokine, TGF-b also exerts pro-inflammatory
effects in certain pathological conditions. In addition, TGF-b1 is a potent chemo-attractant for
microglia, stimulates prostaglandin-E2 (PGE2) synthesis, increases COX-1 expression in
astrocytes and COX-2 expression in both astrocytes and neurons (Luo et al., 1998). Altered
levels of TGF-b could be responsible for the elevated levels of COX observed in AD (Ho et
al., 1999). Experiments with transgenic mice identified TGF-b1 as an inducer of vascular
amyloid deposition and modulator of A b accumulation in the neuropil (Wyss-Corey  et al.,
1997). TGF-b protected against Ab and glutamate neurotoxicity in cell culture possibly by
upregulating antiapoptotic or calcium-stabilizing factors such as Bcl-2, Bcl-XL, and calbindin.
Alternatively, TGF-b protection against A b toxicity may be limited to paradigms involving
only short term Ab exposure, as long term exposure has the opposite effect (Prehn  et al.,
1996).
Blood coagulation and fibrinolysis systems
Originally discovered as mechanisms that regulate the flow and coagulation of blood in the
vasculature and sites of vascular injury, the blood coagulation and fibrinolysis system have
recently been recognized as playing important roles in inflammatory and tissue repair
processes in extravascular tissues. Like tissue factor and thrombin, tissue plasminogen
activator (tPA), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor
type I (PAI-I) are present in senile plaques (Rebeck et al., 1995). Interestingly, a secreted
form of APP with a Kunitz-type inhibitor domain is identical to protease nexin-2, a potent
inhibitor of factor IX and XI. Factor XIIIa found in reactive microglia in AD brains may
function as a transglutaminase to cross-link cytoplasmic proteins upon apoptotic cell death
(Greenberg et al., 1991).INTRODUCTION
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Acute phase proteins
The acute phase proteins are a diverse set of molecules that arise early in inflammation as the
acute phase response. Like many other inflammatory mediators, a wide range of acute phase
reactants has been found in association with senile plaques and extracellular neurofibrillary
tangles. a1-ACT is consistently co-localized with Ab deposits in the AD brain, and has been
suggested to play a role in their formation by enhancing the conversion of nonfibrillar forms
of the molecule to A b fibrills (Eriksson  et al., 1995). Polymorphisms in a1-ACT, the most
common of which is located in the signal peptide, have been investigated as risk factors for
AD in several studies; most of them found a weak association (Kamboh et al., 1995).
a2-MAC is a potent, broad spectrum protease inhibitor, probably evolved as primitive host
defense systems. The formed protease/a2-MAC complex is removed by endocytosis
following binding of this domain to the a2-MAC receptor/LDL receptor-related protein (a2-
MACR/LRP). This systems was shown to serve as a clearance system for inflammatory
proteins, including  a2-MAC itself, ApoE, APP, IL-1b, TGF-b and several others (Borth,
1992). a2-MAC and its receptor have been implicated in several AD pathophysiological
processes and was detected in neuritic plaques and neurofibrillary tangles (Strauss  et al.,
1992). Ab also reportedly forms a complex with a2-MAC that is subsequently removed by
a2-MACR/LRP endocytotic clearance mechanisms (Narita  et al., 1997). Recently, a new
locus for familial Alzheimer’s disease (FAD) had been proposed on chromosome 12, where
both a2-MAC and a2-MAC/LRP genes are located (Pericak-Vance et al., 1997).
sAPP bears a number of properties in common with acute phase proteins. It is elevated at sites
of tissue damage, and its synthesis and release are at least partly mediated by pro-
inflammatory stimuli as IL-1b (Buxbaum  et al., 1998). When applied to microglia at
subnanomolar concentrations, sAPP stimulates NF-kB activity, IL-1 and inducible nitric
oxide synthase (iNOS) expression, and neurotoxicity (Barger and Harmon, 1997). This pro-
inflammatory activity of sAPP is inhibited by binding to ApoE, with ApoE3 being more
effective than ApoE4.
A short graphical summary of the main neuroinflammatory events taking place in AD
pathology shows Figure 82 at the end of thesis.INTRODUCTION
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Anti-inflammatory drug studies in AD
Anti-inflammatory therapy should be beneficial in delaying the onset or slowing the
progression of AD, assuming the neuroinflammation in the neurodegenerative disorder.
Epidemologic retrospective analysis showed a clear association between the use of
nonsteroidal anti-inflammatory drugs (NSAIDs) and relative risk for AD. However, all recent
intervention trials have only been able to slower the progression of AD by about one year  and
failed to indicate a relevant therapeutic benefit after the clinical onset of AD
(Neuroinflammation Working Group, 2000). AD inflammation is chronic but weak,
accumulating significant damage only over many years duration. Interestingly, anti-
inflammatory drugs like NSAIDs, including COX-2 inhibitors, cyclosporin and FK-506
reduce not only glial activation but do also reduce the levels of A b (Lee and Wurtmann,
2000).
The major epidemiological studies concerning anti-inflammatory treatment are summarized in
the following table.INTRODUCTION
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study criteria relative risk/ results/
outcome
Inferred anti-inflammatory treatment
Case control studies. No differentiation between osteoarthritis  and rheumatoid arthritis
Heyman et al., 1984 40 AD patients 1.19 for arthritis
French et al., 1985 78 AD patients in Minneapolis/ USA 0.62 for arthritis
Broe et al., 1990 178 AD patients in Australia 0.56 for arthritis
Li et al., 1992 70 AD patients and 140 control from the same neighborhood in China 0.16 for arthritis
The Canadian Study of Health and
Aging, 1994 201 AD patients matched with 468 controls in Canada 0.54 for arthritis
Breitner et al., 1994 26 elderly twin pairs in whom one twin developed AD 3 or more years before the
other 0.64 for arthritis
Breitner et al., 1995 sibships with differential onset of AD 0.45 for arthritis
Case control studies focused on rheumatoid arthrits
Graves et al., 1990 130 AD patients and 130 matched controls from Seatlle/ USA 1.18 for arthritis
Jenkinson et al., 1989 92 AD patients and 92 non-AD patients 0.17 for arthritis
population based reports
Beard et al., 1991
McGeer et al., 1996
rheumatoid arthritis patients, no age specified
Only low potent salicylates were used for the treatment
4.4% higher prevalence
for dementia
McGeer et al., 1990 973 established rheumatoid arthritis patients age over 65 in the US only four cases of
dementia
McGeer et al., 1990 7490 patients over 65 with diagnosis of rheumatoid arthritis in Canada/ USA 0.39% with co-diagnosis
of dementiaINTRODUCTION
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Myllykangas-Luosujarvi
and Isomaki, 1994
government statistics from Finland on causes of death
rheumatoid arthritis
general population 0.12%
0.54%
NSAIDs
case control epidemiological surveys
McGeer et al., 1996
Four case control studies (The Canadian Study of Health and Aging, 1994;
Breitner et al., 1994; 1995; Stewart et al., 1997). Risk for AD under NSAID
users.
0.475 for AD
In’t Veld et al., 1998 and Stewart
et al., 1997
Risk for AD under NSAID users
prolonged use of
NSAIDs further reduces
th risk for AD
population based studies
Lucca et al., 1994
Review of the data from two clinical AD trials in Italy.
Percentage of NSAID user among
AD patients
general elderly patients
0.8%; 0.0%
22.8%, 20.3%,18.5%
 Andersen et al., 1995
NSAID users age 55 or over suffering from AD in a total cohort of 5893 in
Rotterdam:
NSAID users
non-NSAID users
1.4%
2.5%
Rich et al., 1995 Comparsion of 32 AD patients who used NSAIDs with 177 non-NSAID users
with AD in Baltimore/ USA over one year
NSAID user exhibited
significantly slower
disease progressionINTRODUCTION
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post mortem evaluations
Mackenzie and Munoz, 1998
brain pathology of NSAID users was compared
with age matched controls
Similar degree of senile plaque and neurofibrillary tangle
pathology,
NSAID use was associated with a significant reduction in
the number of senile plaques-associated, activated
microglia.
Steroid anti-inflammatory agents
epidemiological studies
The Canadian Study of Health and
Aging 1994, Breitner  et al., 1995,
Graves et al., 1990
risk of steroid users was compared with controls failed to obtain a significant odds ratio indicative of a
preventive action against AD
Breitner et al., 1994 risk of steroid users was compared with controls odds ratio 0.25 for AD
post mortem evaluation
Mackenzie and Munoz, 1998 evaluation of activated, plaque-associated microglia in non-demented elderly
humans
no effect of steroids
Table 1. Summary of epidemiological studies about the involvemnt of NSAIDs use and deceased risk for AD.INTRODUCTION
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A summary of the major neuroinflammatory events taking part in AD pathology is found in
Figure 82. After all, it seems that AD is not associated to only one of the above mentioned
conditions, but a multi-factoral disorder where all of thses risk factors and/ or familail
predispositions are involved. However, the major risk for getting AD is increasing age.
Figure 6. Scheme of AD pathology. Several factors like age or associated genes induces
neurodegeneration mainly via apoptosis contributing to dementia (according to Haass,
1997).INTRODUCTION
30
Peripheral immuno-competent cells
The immune system can be divided into the innate and the adaptive immunity. Cells of the
innate immunity are granulocytes, natural-killer (NK) lymphocytes and monocytes.
Monocytes can differentiate into macrophages upon stimulation and infiltrate various tissues.
Monocytes and microglia origin from the same progenitor cells. Moreover, the complement
belongs to innate immune system. The adaptive immunity involves the T- and B-
lymphocytes, whereas the T cells trigger mostly of the cellular immunity while the humoral
immunity is mainly carried out by B cells.
Density centrifugation of whole blood enriches a fraction of the leukocytes, the so-called
peripheral blood mononuclear cells (PBMC) that consists of T lymphocytes, mainly, and to a
lesser content of NK- and B-lymphocytes and some monocytes.
T lymphocytes (CD3
+) gained their name as they developed in the microenviroment of the
thymus, an organ located in the mediastinum anterior to the heart. T cells can be divided into
two subsets: the T helper/ inducer or according to their antigen CD4
+ cells and T cytotoxic/
suppressor or CD8
+ cells. CD4
+ T lymphocytes are stimulated by MHC-II positive e.g.
professional antigen presenting cells for example macrophages that phagocytize non-self
particles and presents them via MHC class II. In addition, CD4
+ T cells induce humoral
immunity by binding to appropiate B cells (CD19
+). In contrast, CD8
+ T lymphocytes
recognize antigens which are presented on MHC-I, therefore playing an important role in
natural anti-viral and tumor defense. Subsequently to binding to a non-self ‘foreign’ antigen
presenting cell, the cell is killed or apoptosis is induced by the cytotoxic T lymphocyte
(Janeway and Travers, 1997). Under certain condition, CD8
+ lymphocytes are capable of
inhibiting immune response in an antigen-specific manner (Niijkamp and Parnham, 1999).
Binding of naive T cells to their specific MHC-I or MHC-II presented antigen via the T cell
receptor (TCR) and in combination with some costimulatory receptors forms the
immunological synapse. Here, the two cells are getting in very close and tight contact.
Simillar to a neurological synapse, information is transmitted via secreted molecules
(cytokine). Subsequently, the TCR autophosphorylates its intracellular domain, and the signal
is further mediated by the Ras/Raf-kinase cascade, protein kinase C and phospholipase
activation (see Figure 54). The naive T lymphocyte differentiate into an effector cell, that
execute its immunological function. Most T cells are eleminated by apoptosis after theINTRODUCTION
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infection in order to terminate the i mmune response, however, some T cells survive as
memory T cells (Janeway and Travers, 1997).
B cells are capable to produce different classes of immunoglobins and are MHC-II positive. B
lymphocyte activation is initiated by specific-recognition of antigen receptor, i.e. membrane-
bound immunoglobins or via interaction with CD4
+ T cells. Similar to memory T cells, some
B cells resist as plasma cells (Janeway and Travers, 1997).
NK cells are lymphocytes with cytotoxic potential against virus-infected and certain tumor-
transformed cells. NK cells differ from cytotoxic T lymphocytes in their human lymphocytte
antigen (HLA)-independent manner of target-cell recognition. However, both NK and
cytotoxic T lymphocytes carry the CD8 antigen (Janeway and Travers, 1997).
Apoptosis of peripheral immune-competent cells
The immune system is an example of a system in which programmed cell death (PCD) is a
major mechanism of regulation. In the lymph nodes, PCD is a basic mechanism that allows
the termination of the normal immune response and the prevention of the formation of
activated autoimmune B and T cells. The mechanism whereby apoptotic cells are efficiently
identified, removed, and degraded by phagocytes in mammalian cell are not well understood,
scavenger receptors, CD14 or the receptor for oxidized LDL are supposed to be involved
(Mevorach, 1999). Phospahtidyserine appears on the outer membrane upon the initiation of
apoptosis, and seem to be a part of recognition of apoptotic cells and their fragments.
Although cell death by apoptosis is measured in hours, the removal of apoptotic fragments is
normally so rapid that apoptotic cells are rarely seen, even in tissues such as thymus where up
to 95% of cells undergo apoptosis (Surh and Sprent, 1994). It is thought that uptake of these
cells by specific receptors in phagocytes results in disposal of cellular contents without
induction of inflammation (Savill et al., 1993).
Immunogerontology
Gerontology, especially immunogerontology, is becoming a more and more important
discipline in medicine, since more people are getting older in the industrialized countries. A
decline of some immune function, termed immunosenescence, is known since decades (Guidi
et al., 1998), mainly involving specific immunity. The content of autoreactive antibodies
raises with increasing age and thereby enhances the risk for immuneregulatory dysfunctionINTRODUCTION
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(Hijmans et al., 1984). Other immune functions (e.g. CD25
+ T cells, CD50
+ T cells, density of
CD45RA or CD45RO on T cells, CD4/CD8-ratio) remain unmodified with aging (Ginaldi et
al., 2000; Yen et al., 2000). However, the causes for the immunosenescence remain unclear.
Membrane changes taking place in the aging process are involved in altered binding of
hormones, antigens, and cytokines (Woda et al., 1979) as well as in defective transmission
through ion channels (Griffith et al., 2000). Moreover, other theories explain declined cellular
activity within aging by increased oxidative stress (Guyton et al., 1998). Previous studies in
lymphocytes revealed elevated byproducts caused by ROS (e.g. lipidperoxidation (Hendricks
and Heidrick, 1998), oxidized proteins  (Berlett and Stadtman, 1997; Stadtman, 1992), and
DNA-damage (Wei et al., 1998)). Altered and impaired signal transduction in general seems
to be a major cause for impaired cellular function in all aged tissues (Müller et al., 1996;
Eckert et al., 1994). The performance of the immune system is closely related to the health
situation of the individual. Longevity is associated with appropriate immune function
(Sansoni et al., 1997; 1992; Franceschi et al., 1995). Moreover, recent research indicates that
the immune system is not autonomously. It interacts with the whole organism in bi-directional
ways (Guidi et al., 1998). Close interaction of the central nervous system (CNS) and immune
cells become more evident in the recent years. Immune cell function is modulated by
neuroendocrines and as well by neurotransmitters and vice a versa  (Carson and Sutcliffe,
1999; Hanisch  et al., 1996). In addition, neurodegenerative diseases like dementia of
Alzheimer type (DAT (Eckert et al., 2001; 1998)), Down’s Syndrome (DS (Park et al., 2000))
and the dymyelating disease multiple sclerosis (MS (Crucian et al., 1995a)) are accompanied
by altered lymphocyte function and apoptosis. Chronic psychosocial and emotional stress is
associated with declined and/ or impaired immune function (Berkenbosch et al., 1991).
The clinical relevance of immunosenescence is quite high, since impaired function of the
immune network contribute to pathologies like cancer, increased susceptibility to infectious
diseases and autoimmune disorders, cardiovascular diseases and the not clearly defined
general multimorbidity  (Bruunsgaard  et al., 2000a). Moreover, a prospective study
emphasized the close relation between decreased T cell proliferation after mitogenic
activation and increased mortality (Murasko et al., 1987).
The relevance of physiological immune aging is, in addition, of great interest with respect to
determine disorders with pathologic immune function in aging individuals. However, there
are growing evidences that neurological disorders are often associated with changed immuneINTRODUCTION
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properties. Immune cells provide a good accessibility and are therefore a useful tool to
explore the mechanism taking place within this disorders
AD and peripheral immune cells
Peripheral blood cells provide a good accesibility and are therefore used as cell model in
several studies determing molecular mechanism of AD pathology (Monning  et al., 1990,
1992; Bauer et al., 1991; Eckert et al, 1998). Moreover, as lymphocytes are detected in AD
brain and are undetectable in healthy aging brains, they seem to be an interesting target for
further research (Itagaki et al., 1988; Rogers et al., 1988).
There are some studies that show altered muscarinic receptor signal transduction  in AD
lymphocytes: Density (Bmax), affinity (Kd), and norepinephrine-stimulated cyclic adenosine
monophosphate (cAMP) generation of the b-adrenergic receptor on lymphocytes in patients
with dementia of the Alzheimer type and in normal aged controls showed no differences
(Gietzen  et al., 1989). However,  the B max of 
3H-N-methyl-scopolamine (
3H-NMS) was
significantly decreased both in early and late onset AD groups as compared with age-matched
controls, whereas the Kd was the same in AD and control group. In addition, the average B max
in early AD was significantly lower than in late AD. The density of the binding of 
3H-NMS
was also significantly lower in a subgroup of old subjects with Down's syndrome, whereas no
changes were found in younger individuals with DS or in patients with multi-infarct dementia.
In the AD group, the difference in binding sites was unrelated either to the severity of
dementia or disease duration. Treatment of the patients with cholinergic agents did not alter
the binding values in any of the examined group (Ferrero et al., 1991).
Moreover, A b is detectable on peripheral circulating monocytes, is upregulated upon
activation with pyrogen (lipopolysaccharide, LPS) and its expression is increased in AD (Jung
et. al., 1999).
Levels of APP in PBMC are increased in aging, AD and in Down’s syndrome (Pallister et al,
1997). Lymphocyte APP was non significantly higher in AD vs. aged controls. In addition,
the ratio of lymphocyte APP751:APP770 mRNA levels was significantly lower in AD
subjects compared to a healthy old cohort. This decreased ratio is most likely due to an
average 31% increase in the lymphocyte APP770 isoform in AD patients compared to 12% in
the old cognitively intact group (Ebstein et al, 1996).INTRODUCTION
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Soluble A b induces IL-2 receptor expression and proliferation in peripheral T cells from
healthy individuals, but not from patients with AD (Trieb et al, 1996). Moreover, human
dendritic cells (DC), propagated from the peripheral blood of healthy individuals, were
incubated with Ab25-35 and no apoptosis or necrosis, production of TNF-a was induced. DC
pulsed with Ab aggregates were unable to stimulate T cells in an autologous coculture system.
The results demonstrate that amyloid may escape immune recognition by its failure to activate
antigen-presenting cells and by inhibiting MHC class II surface expression (Schmitt et al,
1997).
Consistent with observations of reduced depolarization-induced Ca
2+ rises in dissociated
neurons of aged mice, corresponding age-related changes of reduced mitogen-induced Ca
2+
responses were observed both in mouse lymphocytes and, more importantly, in circulating
human lymphocytes (Eckert et al., 1994). Beta-amyloid or its fragment, 25-35, interacts with
neuronal calcium regulation. Moreover, exposure of Ab to peripheral lymphocytes elevated
the phytohemagglutinin (PHA)-induced Ca
2+ mobilization (Eckert  et al., 1993).  This
amplifying effect of  Ab on the mitogen-induced rise of free i ntracellular calcium in
circulating lymphocytes was strongly reduced in AD patients. Moreover, low  Ab responses
were significantly correlated with the presence of the ApoE4 (Eckert et al., 1995).
Neither the basal [Ca
2+]i, nor the activation-induced Ca
2+ responses differed among
neutrophils or lymphocytes from aged controls and AD patients. However, a delayed Ca
2+
response was found in AD lymphocytes after PHA-stimulation (Eckert et al., 1997).
Apoptosis contributes to neuronal death in AD. Particularly in lymphocytes, apoptosis plays
an important physiological role, as explained above. The susceptibility to apoptosis seems to
altered in PBMC from AD patients compared to non-demented controls (Eckert et al., 1998a;
Eckert et al., 1998b; Eckert et al, 2001a). Interestingly, lymphocytes of AD patients are more
vulnerable to oxidative-stress induced apoptosis.AIM OF THE THESIS
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Aim of the thesis
The research concerning Alzheimer's disease is one of the most dynamically changing and
controversy fields within medical science in the last decades. Still little final data are known
about the molecular mechanisms of this disorder. Moreover, AD occurs only in aging
humans, so that no animal model is available. For long time, the only possible material for
research was post-mortem brain tissue of AD patients. However, no functional studies are
possible in dead tissue, only the status-quo of just prior to death situation could be assessed.
Brain cells of alive AD patients are inaccessible for biochemical studies. Thus newer
developments of transgenic animals bearing AD-associated mutations seem to be promising.
In addition, another focus in AD investigations was cell culture with neuronal cell lines or
primary cell transfected with AD risk genes. Most neural cell lines derive from neoplastic
origin, while most primary neuronal cells are made from embryonic/ fetal tissue. Both models
have intrinsic problems for AD research. It is not associated with a neoplastic situation and is
definitely a disorder restricted to the aging process. Embryonic brain cells may not harbor the
gene constellation that is required for AD. Thus the AD patient appears to be the best model
for investigating this disorder. Therefore, our laboratory used peripheral blood cells of AD
patients as model to investigate membrane changes, impaired Ca
2+ homeostasis (Eckert et al.,
1993), Ab toxicity in AD and apoptosis in peripheral cells from AD patients.
The aim of this thesis is based on previous findings indicating an enhanced apoptosis of
peripheral blood cells in patients suffering from sporadic AD (Eckert et al., 1998). These
changes should be investigated in more detail and characterized more firmly with new assays,
and should again be compared with aged lymphocytes from non-demented control persons. A
major focus is to find the cellular target and the mechanisms for altered apoptotic regulation
in AD.MATERIAL
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Material
Apparatus:
Agitator, type REAX 2000, Heidolph, Merck Eurolab GmbH, D-60487 Frankfurt
Biomax
TM TranScreen-LE, Eastman Kodak, Rochester, New York, USA
CO2-incubators Heraeus, Typ BB 6220, Heraeus Instruments GmbH, D-63450 Hanau
Coverslips for haemacytometer (Neubauer chamber), Superior, Merck Eurolab GmbH, 60487
Frankfurt
Culture dishes and flasks, Corning
® 25 cm
2, Polystyren (tissue culture treated), Dunn
Labortechnik GmbH, D-53567 Asbach
Developer, Replenisher, GBX reagents, Eastman Kodak, Rochester, New York, USA
Distillery for aquadd , type Destamat Bi 18E, Heraeus Quarzglas, D-63801 Kleinostheim
FACSCalibur￿ (E1034), Becton Dickinson, D-69126 Heidelberg
Horizontal slab gel electrophoresis apparatus 10 x 15 cm, PeqLab Biotechnologies GmbH, D-
91058 Erlangen
Incubator for bacteria, Kelvitron kl. Heraeus Instruments GmbH, D-63450 Hanau
Inverse microscope, Modell TMS, type I04, Nikon, Japan
Laminar flow hood, Heraeus InstrumentsGmbH, D-63450 Hanau
Latex examination gloves, Ansell GmbH, D-81829 München
Liquid scintilattion counter, Wallac 1409 Berthold, Turku, Finland
Magnetic agitator, type Poly 15, H + P Labortechnik, Merck Eurolab GmbH, 60487 Frankfurt
Microtiter plates IWAKI, 96 well with flat bottom, Dunn Labortechnik GmbH, D-53567
Asbach
Microtiter plate, U-shaped botttom, sterile, Greiner Labortechnik, D-72636 Frickenhausen
Microcentrifuge, type GS-6R Centrifuge, Beckman, D-47807 Krefeld
Monovette
® (blood collection systems), NH4-Heparin 9 ml, Sarstedt, D-51588 Nümbrecht
Multifly
® cannula-Set 21G, 0,8 mm, 30 cm tube, Sarstedt, D-51588 Nümbrecht
Multipette
® plus 4981, Eppendorf, Merck Eurolab GmbH, D-60487 Frankfurt
Neubauer chamber Superior, Merck Eurolab GmbH, D-60487 Frankfurt
Parafilm
® M, Merck Eurolab GmbH, D-60487 Frankfurt
pH-meter, type CG 825, Schott, D-65719 Hofheim
Pipetus
®-akku, Hirschmann, Merck Eurolab GmbH, D-60487 Frankfurt
Plastibrand
® Tip-Rack, 5 – 300 µl, Brand, Merck Eurolab GmbH, D-60487 FrankfurtMATERIAL
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Pipettes model Pipetman 10, 20, 200, 1000 und 5000 µl, Abimed, D-40764 Langenfeld
Pipettes sterile packed 5, 10 and 25 ml, Greiner Labortechnik, D-72636 Frickenhausen
Power supplies for gel electrophoresis, PowerPac 300; 1000, respectively, Bio-Rad,D-80939
München
PP-tubes 15 ml and 50 ml, Cellstar
®, Greiner Labortechnik, D-72636 Frickenhausen
Transferpette
®-8, 10 - 100 µl, Brand, Merck Eurolab GmbH, D-60487 Frankfurt
Transferpette
®-8, 30 - 300 µl, Brand, Merck Eurolab GmbH, D-60487 Frankfurt
UV/VIS-photometer, type U-2000 Spectrophotometer, Hitachi, D-40547 Düsseldorf
Vertical slab gel electrophoresis apparatus, Bio-Rad, D-80939 München
Scale, type Mettler AT 261 DeltaRange
®, Mettler-Toledo, Greifensee, Schweiz
Water bath, type Thermomix 1441, B.Braun-Melsungen, D-40595 Düsseldorf
Water bath, type 1003, GFL, Merck Eurolab GmbH, D-60487 Frankfurt
X-ray films, Biomax
TM MR films for gels with 
33P or 
35S samples, Biomax
TM MS films for
gels with 
35S samples in combination with screen, Eastman Kodak, Rochester, New York,
USAMATERIAL
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Chemicals:
7-Aminoactinomycin D (7-AAD), Moleculare Probes, Leiden, The Netherlands
Ammonium persulfate (APS), Merck Eurolab GmbH, D-60487 Frankfurt
Aqua bidest
CellWash
®, Becton Dickinson, D-69126 Heidelberg
Citric acid-monohydrat, pro analysi , Merck Eurolab GmbH, D-60487 Frankfurt
Dimethylsulfoxide (DMSO), pro analysi, Merck Eurolab GmbH, D-60487 Frankfurt
Ficoll separating solution Seromed
®, Biochrom KG, D-12247 Berlin
Dithiothreitol (DTT), Merck Eurolab GmbH, D-60487 Frankfurt
Fetal calf serum (FCS), GibcoBRL, Life Technologies GmbH, D-76131 Karlsruhe
Hydrochloric acid, HCl 37%, Merck Eurolab GmbH, D-60487 Frankfurt
Isopropanol, LiChrosolv
® Gradient Grade, Merck Eurolab GmbH, D-60487 Frankfurt
KHCO3, pro analysi, Merck Eurolab GmbH, D-60487 Frankfurt
methanol, Rotisolv
® HPLC gradient grade, Roth, D-76185 Karlsruhe
L-(
35S)-methionine, Amersham Buchler; D-39528 Braunschweig
Ortho-phosphoric acid 85%, pro analysi, Merck Eurolab GmbH, D-60487 Frankfurt
PBS, Dulbeccos´s Phosphate Buffered Saline, GibcoBRL, Life Technologies GmbH, D-
76131 Karlsruhe
Propidium iodide, Sigma Aldrich Chemie GmbH, 89552 Steinheim
RPMI 1640 medium with Glutamax-1, with 25MM HEPES, GibcoBRL, Life Technologies
GmbH, D-76131 Karlsruhe
Sodium-monohydrogenphosphate-dihydrat, pro analysi, Merck Eurolab GmbH, D-60487
Frankfurt
N,N,N’,N’,-Tetramethylethylendiamin (TEMED), Bio-Rad,D-80939 München
Triton X-100, Merck Eurolab GmbH, D-60487 Frankfurt
Trypan-blue dye 0,4%, GibcoBRL, Life Technologies GmbH, D-76131 Karlsruhe
Urea, Sigma, St.Luois, MO, USAMETHODS
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Methods:
Unless otherwise noted, all preparation, extractions and incubations were proceeded in
microcentrifuge tubes (0,2 ml; 1,5 ml; 2 ml). Small volumes were pipetted with automatical
pipettes (Gilson/ Abimed: P2, P10, P20, P200, P1000, and P5000). All buffers and solutions
were made from commercially available chemicals of analytical grade and purified (Millipore
MilliQ-Plus) or double distilled water and were autoclaved or sterile filtered prior to use.
Human volunteers and animals:
Human blood samples:
All experiments regarding human subjects have the approval of an ethical commission
(approval date: 11/ 1997; Dept. of Psychiatry, Univ. of Frankfurt, PD Dr. L. Fröhlich, Prof.
Dr. K. Maurer). All venous blood samples were collected between 8.00 am and 11.00 am in 9
ml NH4-heparin monovettes in order to prevent fluctuations due to circadian rhythmic.
Samples were stored in the blood collection system with slight agitation until isolation. To
prevent bursting of red blood cells, which elevates the extracelluar K
+ levels, blood samples
were collected slowly.
Blood collection system:
Monovettes (NH4-heparin) Sarstedt
Adapters Sarstedt
Butterflies (Wing-Flo) Braun
Non-demented control blood donors:
Blood samples were taken from healthy subjects less than 35 years old, termed young, and
healthy persons over 60 years, termed old group.  Subjects with psychiatric and
neurodegenerative disorders or acute infections were excluded. In addition, subjects with
pathological distribution of lymphocyte subpopulations in flow cytometric analysis according
to the SENIEUR protocol (Ligthardt et al., 1984) were rejected from the study. Most of the
elderly patients were taking drugs against cardiovascular disorders. None of the volunteers
received psychotropic medication, drugs with known effects on the immune system, or
antioxidative agents.METHODS
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AD-patients:
Blood samples were taken from patients diagnosed with possible DAT or probable DAT.
Patients were randomized, blinded and blood samples collected by the clinicians of the
Gedächtnis Ambulanz of University Frankfurt. Patients were rated by Mini Mental State
Examination Scores (MMSS), Syndrom-Kurz Test (SKT) and Brief Cognitive Rating Scale
(BRCS). Patients with acute infections were rejected from the study. Some of the AD-patients
received anti-dementia drugs mainly nootropics or acetylcholine esterase inhibitors. None of
the patients received drugs with known effects on the immune system or antioxidative agents.
Animals
All animals were housed in cages with a maximum of 10 animals per cage. Food and water
were free accessible, room temperature and humidity was kept constantly. A light/ dark cycle
of 12 hours is installed in the animal housing. All experiments described in this thesis are in
concordance with the German law and had been approved by the Regierungspräsidium
Darmstadt (committee regarding experimental animals, approval date 01/1998).
Cages Altromin
Standardized diet for mice and rat Altromin
NMRI mice
Young (3-4 months) and old (23-25 months) female NMRI mice used in this thesis were from
Harlan Winkelmann or kind gifts from Aventis Pharma (Frankfurt, Germany). The latter were
obtained at an age of 12 months and maintained at the Biocenter’s animal care facility until
use. All animals were housed in plastic cages with water and food ad libitum and were
maintained on a 12-hour light/dark cycle. Mice with skin lesions, spleenomegaly and
macroscopically visible tumors were excluded. For ex vivo studies, mice were treated daily
with 100 mg/kg EGb761 per os in 0.2% agarose or with vehicle alone for 14 days. All
experiments were performed in accordance with the German animal right regulations.
Transgenic mice:
For experiments with transgenic mice, C57BL/6J mice of both sexes were used. Three
different types of transgenic mice were generated by N. Touchet and C. Czech (RhoneMETHODS
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Poullenc/ Aventis Pharma, Vitry-Sur-Seine, France) in cooperation with IFFA Credo,
Transgenic Alliance (France) and kindly donated to our laboratory.
Figure 7. Generation of transgenic mice (taken from http://www.accessexcellence.org/
AB/GG/transgenic.html).
Genetic engineered mice were expressing a human wildtype Presenilin-1 (PS1 wt) transgene
or a PS1 transgene expressing either a single pathogenic mutation at codon M146 (PS1
M146L) or multiple FAD-specific mutations M146L + H163R + A246E + L286V + C410Y
(PS1 M5), since the combination of different PS1 mutations shows additive effects on Ab1-42
secretion (Citron et al., 1998), or mutant human APP (APP695SDL; described by Moussaoui et
al., 2000). Transgene expression is under the control of the human HMG-CR-promotor which
represents a housekeeping-type promotor that shows a strong and ubiquitous expression
pattern with high expression in neurons (Czech  et al., 1997; Czech  et al., 1998). APP
expression was under the control of bPDGF promotor (Czech et al., 2000). APP transgenic
and non-transgenic animals were littermates or subsequent generation siblings and are
therefore strain matched. PS1 transgenic mice showed normal growth and development, and
revealed no apparent behavioral changes compared to littermate controls. At an age of 18, 6
months, respectively, plaque formation is observed in brains of APP695SDL or
APP695SDLxPS1 M146L transgenic mice. In later experiments, mice from our own breeding
facilities were used. Genotyping had been investigated by genomic PCR (see molecular
biology section of this chapter). Moreover, double transgenic were generated by crossing PS1
M146L with APP695SDL mice.METHODS
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Female NMRI mice Harlan Winkelmann
Transgenic BL/6 mice gift from C.Czech Aventis, France
Cellbiological methods:
General cell culture:
All here described experiments with primary cells and cell lines were conducted under sterile
conditions in a laminar flow box. Cells were kept at 37°C, 94% humidity and 5% CO2 in
sterile culture vessels.
For short-term culture, human, murine PBMC, murine spleenocytes or Jurkat leucimic T cells
were seeded at 5 x 10
5 cells/ml in culture medium. Cell suspension was maintained in RPMI
supplemented with 10% fetal calf serum (FCS), 1% antibiotics (Penicillin (10.000 IU/ml),
Streptomycin (10.000 IU/ml) and 2 mM GlutaMax) as culture medium. Cells were washed
with phosphate buffered saline (PBS).
RPMI-culture medium:
-10% FCS (2 hours heat inactivated at 56°C) Gibco BRL Life Tech.
- Penicillin/ Streptomycin Gibco BRL Life Tech.
￿ in RPMI Gibco BRL Life Tech.
10 x PBS Gibco BRL Life Tech.
Culture vessels and -flasks Iwaki/ Corning/ Greiner
Sterile filters 0,2 mm pores Iwaki
Cells were investigated directly (native cells/ PBMC) or after short-term culture (activated
cells = lymphoblasts) as indicated. For short-term culture cells were seeded at density of 0.5 x
10
6 cells/ml in complete medium supplemented with 5 µg/ml PHA-L. After 48 h of
incubation at 37 °C and 5% CO2, cells were washed once in PBS, seeded in complete medium
containing 50 U/ ml of human recombinant IL-2 and incubated for 72 h to predispose to
apoptosis according to the method of Zheng et al (1995). Activated lymphocytes consisted to
nearly 100% of CD3
+ cells and expressed CD95 to over 96% as determined in FACS analysis.
Leucoagglutinin (PHA-L; source: Phaseolus vulgaris, red kidney bean) Sigma
Interleukin-2 (IL-2) Boehringer Mannheim/ RocheMETHODS
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Determination of cell number and vitality
To resolve the cell number, cells were resuspended with care and mixed with trypan dye
solution (10:1). An aliquot of the stained cell suspension is subjected to a Neubauer chamber.
The arithmetical mean from different counting sections is determined and the cell number
calculated in respect to the chamber factor and the dilution.
Neubauer-chamber Merck
Trypan blue dye Gibco BRL LifeTech
Cryoconservation of cells
Cells were washed with PBS, collected by centrifugation and all supernatant removed. Cells
were resuspended in freezing medium, containing DMSO, in order to prevent harm by ice
crystal formation during storage under freezing conditions. Cells were subjected quickly on
ice for several minutes and than stored overnight in a freezer (-20°C). The following day, the
cells were subjected in an –80°C freezer overnight and can than stored for an independent
time in liquid nitrogen.
To thaw cells, cryotubes containing the desired cells were rapidly subjected from the freezer
or the nitrogen tank to a prewarmed (37°C) water bath for one or two minutes, until the
solution is thawed. The cells were immediately diluted in a large amount of prewarmed
complete culture medium, and washed several times by gentle centrifugation. Finally the cells
are seeded in a culture vessel.
Freezing medium:
-50% FCS Gibco BRL Life Tech
-10% DMSO (dimethylsulfoxide) Sigma
￿ in RPMI
Cryotubes Greiner
Isolation of human PBMC
Freshly collected, heparinized venous whole blood was diluted with the same amount of PBS
and carefully layered on 2 parts of Ficoll Hypaque in a 15 or 50 ml centrifuge tube. PBMC
were separated from red blood cells, granulocates and platelets by gradient centrifugation at
2000 rpm (400 x g) for 20 minutes at room temperature. The Ficoll Hypaque solution consists
of polymerized sugars with an exact density of 1.07 g/cm
3 that is identical with that of vital
lymphocytes and monocytes (constituents of the PBMC). Therefore, PBMC collect at theMETHODS
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interphase between the Ficoll solution and the blood serum (see Figure 8). The more dense
cellular blood components are collected at the bottom of the tube, the less dense parts like
platelets remain in the supernatant. The PBMC from the interphase is carefully collected with
a sterile pipette, washed twice in PBS, counted with trypan staining and resuspended in
culture medium.
Figure 8. Separation of cellular blood components by gradient centrifugation on Ficoll-
Hypaque.
Tubes Greiner
Ficoll-Hypaque Biochrom
PBS GibcoLifeTech
Culture medium:
RPMI 1640
1% penicillin/ streptomycin
10% fetal calf serum (FCS) all GibcoLifeTech
Isolation of CD4
+ or CD8
+ lymphocytes
PBMC were isolated as described above. Cells were resuspended in cold PBS supplemented
with 10 mM EDTA at concentration of 10
7 cells/ml. Appropriate magnetic-coupled antibody
is added and the mixture incubated for 15 minutes at 4°C. Separation columns are placed in
the magnetic field and washed twice with PBS/EDTA. Labeled cells were loaded onto the
 plasma, platelets
 PBMC: lymphocytes,
             monocytes
 Ficoll
®
 granulocytes
 red blood cellsMETHODS
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column and eluted by gravity flow. Isolated T cell subsets were cultured under standard
conditions.
PBS/EDTA:
10 mM EDTA Merck
￿ in PBS Gibco BRL LifeTech
Magnetic-labeled antibodies (anti CD4/ anti CD8)
Midi MACS separation columns
Magnetic device (Midi) all MACS Miltenyi Biotec
Isolation and preparation of murine PBMC and spleen lymphocytes:
Mice were killed by cervical dislocation, venous blood was collected and anticoagulated with
heparin. PBMC were isolated by centrifugation on Ficoll hypaque as described for human cell
preparation (see there). T cells were isolated from the spleen with magnetic beads according
to the manufacturer’s instructions (Dynal, Sweden). In brief, spleen cell suspensions were
prepared by mechanical dissociation of individual spleens in PBS supplemented with 10%
FCS, penicillin (10.000 IU/ml) and streptomycin (100 µg/ml; PBS-FCS). Red blood cells
were lysed in hypotonic buffer for 2 minutes. Cells were washed twice, mixed with magnetic
beads specific for B cells and incubated with shaking for 20 minutes at 4°C. T cell content of
spleen cells was determined by CD3-staining to be over 80%.
Pan B magnetic beads Dynal (Sweden)
Magnetic stand for 15 ml tubes and microcentrifuge tubes Dynal (Sweden)
Tubes Greiner
Anti-murine CD3 Pharmingen
PBS-FCS:
1 x PBS GibcoLifeTech
Penicillin/ Streptomycin GibcoLifeTech
10% fetal calf serum (FCS) GibcoLifeTech
Hypotonic lysis buffer:
155 mM NH4Cl Merck
10 mM KHCO3 Merck
Whole blood cultures:
Blood was collected in NH4-Heparin vacuum syringes. One volume of blood was diluted in 9
volumes of RPMI (1:10) supplemented with penicillin (100 U/ ml) and streptomycin (100 µg/METHODS
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ml). The cell suspension was cultured in 96-well plates. Cells were stimulated with either
PHA-L (10 µg/ml) or 12-O-tetradecanoyl 12-phorbol 13-acetate (PMA) and Ionomycin (50
ng/ml, 200 ng/ ml, respectively) or remained untreated (basal) as indicated.
Whole blood culture medium:
100 U/ml penicillin
100  µg/ml streptomycin
￿ in RPMI all Gico BRL LifeTech
Leucoagglutinin (PHA-L; source: Phaseolus vulgaris, red kidney bean) Sigma
12-O-tetradecanoyl 12-phorbol 13-acetate (PMA) Sigma
Figure 9. In vivo activation of T cells by TCR-MHC/peptide ligation. This event can be
mimicked in vitro by TCR binding with mitogens (e.g. PHA) or phorbolester (PMA) and
Ca
2+ ionophore (Ionomycin).
Induction of apoptotic cell death:
Lymphocyte death was induced with the following stimuli for up to 24 hours: 10
-7 M
dexamethasone, 10 mM 2’-deoxy-D-ribose, 100 or 500 nM staurosporine or 0.4 ng/ ml
agonistic CD95-antibody (clone 2R2) or 50 ng/ml Fas-ligand. As control, spontaneous in vitro
apoptosis, that occurs when primary cells are removed from the organism, was always
determined, as well. Withdrawal of the growth factor IL-2 leads lymphoblasts into the so-
called activation induced cell death (AICD).
Jurkat cells were incubated with Fas-ligand (0-100 ng/ml) for 3 or 24 hours as indicated.
When announced, murine spleen cells were incubated with EGb761 or other antioxidants 1 to
2 hours prior to apoptosis induction.METHODS
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dexamethasone (dissolved in DMSO) Sigma
2‘-deoxy-D-ribose Sigma
staurosporine (dissolved in DMSO) Sigma
DMSO Merck
CD95 antibody Boehringer Mannheim/ Roche
Fas-ligand and potentiator kit Upstate Biotechnology (Biozol)
Gingko biloba extract (EGb761, dissolved in PBS) Schwabe AG, Karlsruhe
Analytical cellbiological methods:
Flow cytometry with a fluorescence-activated cell-sorter (FACS)
Flow Cytometry involves the use of a beam of laser light projected through a liquid stream
that contains cells, or other particles, which when struck by the focussed light give out
signals, which are picked up by detectors. These signals are then converted for computer
storage and data analysis, and can provide information about various cellular properties. The
term "flow cytometry" derives from the measurement (meter) of single cells (cyto) as they
flow past a series of detectors. The fundamental concept is that cells flow one at a time
through a region of interogation where multiple biophysical properties of each cell can be
measured at rates of over 1000 cells per second. These biophysical properties are then
correlated with biological and biochemical properties of interest. The high through-put of
cells allows for rare cells, which may have inherent or inducible differences, to be easily
detected and identified from the remainder of the cell population.
In order to make the measurement of biological/biochemical properties of interest easier, the
cells are usually stained with fluorescent dyes which bind specifically to cellular constituents.
The dyes are excited by the laser beam, and emit light at longer wavelengths. Detectors pick
up this emitted light, and these analogue signals are converted to digital so that they may be
stored, for later display and analysis.METHODS
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Figure 10. All used fluorochromes and dyes can be excited by light of 488 nm.
Many larger flow cytometers are also "cell sorters", instruments which have the ability to
selectively deposit cells from particular populations into tubes, or other collection vessels.
These selected cells can then be used for further experiments, cultured, or stained with
another dye/antibody and reanalysed. In order to sort cells, the instrument’s electronic
interprets the signals collected for each cell as it is interogated by the laser beam, compares
the signal with sorting criteria set on the computer. If the cell meets the required criteria, an
electrical charge is applied to the liquid stream which is being accurately broken into droplets
containing the cells. This charge is applied to the stream at the precise moment the cell of
interest is about to break off from the stream, then removed when the charged droplet has
broken from the stream. As the droplets fall, they pass between two metal plates, which are
strongly positively or negatively charged. Charged droplets get drawn towards the metal plate
of the opposite polarity, and deposited in the collection vessel, or onto a microscope slide, for
further examination.METHODS
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Figure 11. A single laser flow cytometer with five parameters of detection. Two detectors
detect the light scatter, and three photomultiplier tubes (PMTs) detect the fluorescent
signals. The bandpass filters are set up for optimal detection with the fluorochrome:
FITC (Fluoresceinisothiocyanate in FL-1), PE (R-phycoerythrin in FL-2) and PerCp
(Peridin chlorophyll protein) or CyChrome (both in FL-3).
Following acquisition of data on the flow cytometer, analysis is undertaken to find out how
many cells from the sampled population meet a criteria of interest. For example, does a
population of cells express one molecule, but not another. The data can be displayed in a
number of different formats, each having advantages and disadvantages. The common
methods are histogram, or dot plots. Once excited, the emitted light is directed to one of three
fluorescent detectors (FL1, FL2 and FL3). There are a series of fixed (i.e. can't be changed)
light filters that direct a particular wavelength light to a designated detector. All FITC (green)
emissions go to FL1, all red to FL2 and all far red to FL3. In addition to these fluorescent
emissions the FACS can also collect information on reflected laser light. There are two
additional detectors the measure forward and right angle light scatter. Forward light scatter
(FSC) measures that ability of a particle (cell) to deflect light from its path. Small cells deflect
little light while large cells will deflect more. Consequently this parameter is a rough
approximation of size. Side scatter (SSC) measures the ability of a particle to redirect light at
a 90° angle. Cells with a lot of cellular structure (i.e. granulocytes) will redirect more light
than a cell with little intracellular structure (red blood cells).METHODS
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Figure 12. A representative histogram, displaying relative fluorescence intensity in
relation to the number of events, and a representative dot plot, plotting one parameter
e.g. FSC against another like SSC, for instance. The right figure represents a typical dot
plot of lysed whole blood. Smallest cells low in SSC are lymphocytes (e.g. T-, B-, and
NK-cells). The cell population in the right lower corner are the monocytes, the cells with
the approximately same size and high in granulate are the granulocytes.
The simplest way of displaying flow cytometry data is the frequency histogram. Frequency
histograms display relative fluorescence or scattered light signals plotted against the number
of events. The simplicity of this type of display is the main attraction. To see the relative
levels of other parameters which were collected at the same time , one needs to use one of the
forms of bivariate displays namely dot, density or contour plots. In these type of displays, one
parameter is plotted against another in an X versus Y axis display.
Fluorescence activated cell sorter (FACS, flow cytometer) FACSCalibur
TM
CellQuest
TM analysis software
FACSComp
TM software
SimulTest
TM software all Becton Dickinson
Analysis computer Power Macintosh 7600/132 Apple MacintoshMETHODS
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Fluorochromes:
Fluoresceinisothiocyanate (FITC):
FITC is a fluorochrome with a molecular weight of 389 kDa and an absorption maximum at
495 nm (Figure 13). Its excitation by 488 nm light leads to a fluorescence emission around
520 nm. Using a 530 ± 15 nm bandpass filter will give optimum detection for this
fluorochrome. The isothiocyanate derivative is the most widely used for conjugation with
antibodies. FITC has a high quantum yield (efficiency of energy transfer from absorption to
emission fluorescence) and approximately half of the absorbed photons are emitted as
fluorescent light. The number of FITC molecules per conjugate partner (antibody) is usually
in the range of three to five molecules (Pharmingen, 1999).
Figure 13. Spectra and formula of fluorescein-isothiocyanate (FITC)
R-phycoerythrin (PE):
PE is an accessory photosynthetic pigment found in red algae.  In vivo, its functions is to
transfer light energy to chlorophyll during photosynthesis. In vitro, it is a 240 kDa protein
with 34 phycoerythrobilin fluorochromes per molecule. The large number of fluorochromes
per PE molecule make R-phycoerythrin an ideal pigment for flow cytometry applications. Its
absorption maximum is 564 nm (Figure 14). When excited by 488 nm light, its fluorescence
emission maximum is approximately 576 nm. In average, one molecule PE is conjugated with
one antibody molecule (Pharmingen, 1999).METHODS
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Figure 14. Absorption and emission spectra of PE.
Peridin chlorophyll protein (PerCp):
PerCp is a component of the photosynthetic apparatus found in the dinoflagellate,
Glenodinium sp. PerCp is a protein complex with a molecular weight of approximately 35
kDa. When excited by light at 488 nm from an argon-ion laser, PerCp has a excitation
maximum around 490 nm, with an emission spectrum, which peaks at 677 nm. The emitted
light is collected in the fluorescence-3 (FL-3) channel (Pharmingen, 1999).
Cy-Chrome
TM:
CyChrome is a tandem conjugate system, with an absorption maximum of approximately 650
nm, which combines PE and a cyanine dye (MW 1.5 kDa). When excited by 488 nm light, the
excited fluorochrome PE is able to transfer its fluorescence energy to the cyanine molecule,
which than fluoresces at a longer wavelength. The resulting fluorescent maximum is
approximately 650 nm. Using a 650 longpass filter will give optimum detection for this
fluorochrome. The efficiency of the light energy transfer between the two fluorochromes is
rather high, as less than 5% of the absorbed light is lost as fluorescence by PE. An average of
one CyChrome molecule is coupled per molecule antibody (Pharmingen, 1999).
Electronic compensation for multi-color immunofluorescence staining:
Monoclonal antibodies conjugated to FITC, PE, PerCp, or CyChrome and DNA dyes (PI, 7-
AAD) are used in combination to analyze multiple antigenic determinants within a cell
population. FITC emission is detected as green signal by the FL-1 detector, PE and PI
measured as an orange signal by the FL-2 detector and PerCp, CyChrome or 7-AAD is
measured as a violet signal by the FL-3 detector. However, a significant amount of orange
fluorescence is present in the FITC emission, some green fluorescence is present in the PEMETHODS
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emission, and similar for the other fluorochrome and dyes, Especially PI has a broad emission
and can be detected in all fluorescence channels. This spectral overlap, if uncorrected, will
lead to a fluorochrome signal picked up by an inappropriate detector. Compensation is the
process of correction for this overlap; it is the electronic subtraction of unwanted signal to
remove the effects of spectral spillover. Through compensation, the fluorescence
measurement of a cell sample stained with one fluorochrome is electronically forced to be
identical to unstained cells, with regard to the two remaining, inappropriate detectors.
Calibrite
TM Kit Becton Dickinson
Cell preparation and staining for Flow Cytometry:
Staining of whole blood or whole blood cultures:
Whole blood cultures were transferred into an 1.2 ml 96-well plate, centrifuged at 300 x g,
and the supernatants were discarded. Whole blood was stained with the appropriate antibodies
following the manufacture’s manual. In brief, 1 µl of each antibody was added to blood cell
pellets and incubated for 10 minutes at room temperature. Adding 500 µl of hypotonic buffer
for 15 minutes lysed red blood cells. Since PMA/ Ionomycin treatment stabilizes the red
blood cell membrane, 1 ml CellLyse was needed to completely lyse the erythrocytes. Cells
were pelleted by 300 x g and additionally washed with 500 µl CellWash
®.
Anti-human antibodies:
FITC-conjugated
isotype control IgG1 (clone X40)
anti-CD3 (clone SK7)
anti-CD8 (clone SK1)
anti-CD69 (clone L78)
anti-HLA-DR (clone )
anti-IL-2 (clone 25723.11)
anti-TNF-a (clone 5344.111)
anti-BrdU (clone B44) all Becton Dickinson
isotype control IgG2b (clone 27-35)
isotype control IgG1
anti-Bcl-2 all Pharmingen/ BD
anti-phospho-tyrosine (clone 4G10) Santa Cruz biotechnology, USA
PE-conjugated
isotype control IgG1METHODS
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anti-CD4 (clone SK3)
anti-CD8 (clone SK1)
anti-CD19 (clone 4G7)
anti-CD16+ anti-CD56 (clones B73.1;  MY31,respectively)
anti-CD25
anti-CD95
anti-IL-2 (clone 25723.11)
anti-IFN-g (clone 6401.1111) all Becton Dickinson
anti-TNF-a Sigma
PerCp-conjugated
isotype control IgG1
anti-CD3 (clone SK7)
anti-CD8
anti-murine antibodies:
FITC-conjugated
k isotype control IgG1 (clone R3-34)
anti-CD3e (clone 145-2C11)
anti-CD4 (clone RM4-5)
PE-conjugated
rat isotype control IgG1
anti-CD8 (clone 53-6.7)
CyChrome-conjugated
anti-CD3 (clone 17A2) all Pharmingen/ BD
TrueCount
TM beads all Becton Dickinson
DNA-dyes
propidium iodide Sigma
7-AAD (dissolved in DMF) Molecular Probes
CellWash
TM
10 x CellLyse
TM
10 x CellPerm
TM
10 x CellFix
TM all Becton Dickinson
10 x PermWash
TM
PermFix
TM
Brefeldin A (Golgi Plug
TM) all Pharmingen/ BD
Samples were assayed with FACSCalibur using Simulset software (all Becton Dickinson).
Forward (FSC) and side (SSC) angle scattered light gating excluded dead cells, granulocytes
and monocytes. For each sample, 10,000 cells were acquired.METHODS
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The lymphocyte subset were quantified by staining with anti-CD3-FITC, anti-CD19-PE, and
anti-CD16-PE + anti-CD56-PE in order to explore the percentage of T-, B-, and NK-
lymphocytes, respectively. Staining with anti-CD4-FITC and anti-CD8-PE determined T
lymphocyte subsets. Early T cell activation was resolved by staining with anti-CD69-FITC or
IgG1-isotype control.
All activated cells were stained with CD3-PerCp and CD8-PE in order to gate all CD3
+ T
cells and to differentiate between the subsets. Findings of Rostaing et al. (Rostaing et al.,
1999) and unpublished data of our group revealed that the CD4 antigen is down regulated
after PHA activation while the CD8 surface density remains unchanged. Therefore we
electronically gated the CD3
+CD8
+ cells (T cytotoxic/ suppressor cells) and the CD3
+CD8
-
cells (CD3
+CD4
+ or T helper cells) and assumed that all CD8
- cells are CD4
+.
Quantification of lymphocyte number:
Absolute numbers of lymphocytes were determined with TrueCount
® beads and CD3-PerCp,
CD8-PE, and CD4-FITC according to the manufacture’s manual. In brief, 50 µl of whole
blood and 1µl antibody reagent containing fluorochrome conjugated antibodies against anti-
CD3, anti-CD8, and anti-CD4 (TriTest
®) were pipetted into an TrueCount
® tube containing a
specific amount of beads and incubated for 15 minutes at room temperature. 250 µl CellLyse
®
were added for additional 15 minutes in order to lyse red blood cells. Samples were measured
by flow cytometry with settings appropriate for suspension containing lysed red blood cells
without wash. For each sample, 100,000 events were acquired. Cell population and beads
were gated and cell count calculated in relation to the bead’s number.
Detection of cytokine expressing cells:
Whole blood cultures were placed in an incubator for 22 hours at 37°C. For cytokine
detection, cells were incubated with Brefeldin A at a concentration 10 µg/ml for the last 16
hours of stimulation, to inhibit cytokine secretion. Cultures were surface stained as described
above, followed by fixation and permeabilization with FACSPerm
®. Intracellular cytokine
staining was performed with anti-cytokine mAbs specific for IL2, IFN-g, and TNF-a or an
isotype control antibody (1 µl of each mAb per 30 µl whole blood) in FACSPerm
® for 30
minutes at room temperature.METHODS
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Determination of proliferation:
Whole blood cultures were incubated for 72 hours with or without stimulation at 37°C. 24
hours before harvest, Brom-3’desoxy-uridine (BrdU) was added at a final concentration of 20
µM to the cultures. Cells were stained according to the method of Gaines et al. (1996) using
an anti-BrdU-antibody or isotype control. In brief, surface receptors were stained as described
above. After red blood cell lysis and an additional washing-step, leukocytes were transferred
into a 96-microtiter roundbottom plate and fixed with 100 µl 1% paraformaldehyde (CellFix
®)
overnight at 4°C. Cells were permalized by washing with saponin-containing buffer
(PermWash
®). Cells were resuspended in PBS containing 10 mM MgCl 2 and 50 U DNase-I
and incubated at 37°C for 45 minutes. DNA digest was stopped by centrifugation at 4°C, cells
washed and resuspended in 50 µl PermWash
®. Blood cells were stained with 1 µl of an anti-
BrdU-antibody or IgG1-isotype control for 30 minutes at room temperature in the dark. After
washing out excessive antibodies, cells were resuspended in CellWash
® and analyzed by flow
cytometry.
Brom-3’desoxy-uridine (BrdU) Sigma
DNase-I Boehringer Mannheim/ Roche
MgCl2 Sigma
Determination of phosphorylated tyrosine residues:
T cells were stimulated and samples prepared according to the method of Hubert et al. (1997).
In brief, 500 µl diluted whole blood was transferred into microcentrifuge tubes and at brought
to 37°C in a heatblock with gentle agitation. Cells were activated by addition of PHA-L (10
µg/ml) for 3 minutes, rapidly chilled on ice, and centrifuged at 500 x g. Pellets were
resuspended in freezing medium, containing 10% DMSO and 50% FCS in RPMI medium.
Samples were stored at –20°C until analysis. For sample preparation, cells were rapidly
thawed at 37°C, transferred into an 1.2 ml 96-well plate and washed two times with
CellWash
®. Red cell lysis was not necessary since freezing the cells already destroyed red
blood cells’ membranes. After surface staining, cells were fixed with 4% paraformaldehyde
(CellFix
®) for 20 minutes on ice, permeabilized with 1% saponine (PermWash
®), stained with
1 µl of anti-phosphotyrosine antibody or isotype control (IgG2b), and analyzed by flow
cytometry. The ratio between mean fluorescence intensity of the stimulated and unstimulated
cells was calculated.METHODS
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Analysis of intracellular Bcl-2
For intracellular staining, wholeblood was surfaced stained with each 1 µl of PE- and PerCp-
conjugated antibodies for 15 minutes, lysed with CellLyse
TM for 10 minutes, washed with
CellWASH
TM, and fixed with PermFix overnight at 4°C. After fixation cells were washed and
resuspended in PermWash to permeabilize the leukocytes. Staining of Bcl2 was done with 1
µl of the corresponding antibody or isotype control for 45 minutes at room temperature.
Finally, cells were washed with PermWash and resuspended in 200 µl CellWASH.
CD3+
CD19+
lymphocytes
Figure 15. Gating strategy for determining intracellular Bcl-2. Lymphocytes were gated
by FSC/SSC and CD3-PerCp/SSC or CD19-PE/SSC and double positive cells displayed
in a FL-1 (Bcl-2-FITC) histogram. NK lymphocytes (dark gray) remain after
subtracting CD3 (light gray) and CD19 (black) cells.
Detection of apoptotic cell death
Staining with propidium iodide
Propidium iodide as well as its analogous ethidium bromide intercalates between the bases in
double stranded DNA. When stacked between the bases, interactions between the p-electrons
of the dye and the DNA bases occur, resulting in an altered emission maximum (Figure 16).METHODS
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The emitted fluorescence intensity is dependent on the length of the DNA molecule; the more
basepairs the molecule consists of, the stronger is the fluorescence intensity subsequent to
appropriate excitation.
According to Nicoletti and coworkers (Nicoletti et al., 1991) apoptosis can be detected by
lysing the cells in hypotonic buffer and staining of the DNA content. Sub-G0-DNA content,
indicative for apoptotic nuclei, is determined by flow cytometry in FL-2.
Figure 16. Molecular structure of propidium iodide. It posses the common planar
conformation with conjugated bindings as the most DNA intercalating substances.
Absorbance and emission spectra of propidium iodide. In contrast to ethidium bromide,
propidium iodide can be excited by an argon laser (488 nm) and detected in FL-2.
Lymphocytes were harvested by centrifugation at various time points and the pellets were
resuspended in lysis buffer containing propidium iodide. Samples were stored at 4°C for 1-2
hours before flow cytometry analysis using Cell Quest software. In order to avoid to detect
RNAs that are smaller than chromosomal DNA and occur in the very low sub-G0-DNA
content, events with very low fluorescence intensity are excluded by electronically gating.
Lysis buffer:
0.1% sodium citrate Merck
0.1% Triton X-1000 Sigma
50 µg/ml propidium iodide Sigma
Vital cell populations displaying a very small percentage of apoptotic subG0 nuclei (PBMC
derived from healthy controls, for instance) exhibits a huge G 0/G1-peak and smaller G 2-peak
when subjected in a histogram plot (Figure 17). The G0/G1-peak represents the cells in the G0-
/G1-phase, respectively. Doubled DNA contents owned by cells in the G2-phase are displayedMETHODS
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as G2-peak. In between those two peaks, there is a population, displaying cells that are in the
DNA-synthesis (S) phase. Usually, primary cells from healthy volunteers provide a
representative large G 0/G1-peak and a relatively small though well detectable G 2-peak. In
contrast, immortalized cell lines or tumor cell lines (Jurkat leucimic lymphoblasts, for
instance) are permanently entering the cell cycle, therefore display a relatively increased G 2-
peak.
A)      B)
Figure 17. representative histogram of PI-stained (according to Nicoletti et al., 1991)
PBMC of young individual. A) Basal apoptotic levels of freshly isolated PBMC; B) dRib-
induced apoptosis in human PBMC after 24 hours incubation.
Staining with 7-aminoactinomycin (7-AAD)
Experiments, exploring the apoptotic behavior of lymphocyte subsets, were performed with
the DNA dye 7-Aminoactinomycin (7-AAD; described by Schmid et al., 1994), that can be
detected in FL-3; Figure 18), since 7-AAD posses a very distinct emission profile in contrast
to PI, that provides no conflict with the other cytometer channels and permits the detection of
two other fluorochrome (FITC and PE, for instance) within the same sample. In order to
explore the apoptotic levels of different lymphoycte subsets, the isolated PBMC samples were
stained with 7AAD, diluted in DMF, and monoclonal antibodies coupled with FITC, and
another coupled with PE.METHODS
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Figure 18. Molecular formula and absorption and emission spectra of 7-AAD.
An additional advantage of 7-AAD compared to PI-staining is that 7-AAD can not only detect
apoptotic cells, but also necrotic/ dead cells (Figure 19).
For 7-AAD-staining, the dye was dissolved at a concentration of 1.5 mM in N,N-
dimethylformamide (DMF) and added at a concentration of 6 µM to the cell suspension for 15
minutes at room temperature. Cells were washed by centrifugation, resuspended in PBS, and
immediately analyzed by flow cytometry. 7-AAD fluorescence intensity was plotted against
forward scatter (FSC) and cells in the area between autofluorescence and full G 0/G1-DNA
content were termed apoptotic.
7-AAD dye:
7-Aminoactinomycin (7-AAD; dissolved in DMF) Molecular Probes
N, N-dimethylformamide (DMF) Merck
live
apoptotic
dead
live
dead
apoptotic
CD4
CD8
Figure 19. To determine apoptosis of single subsets cells were gated in a dot plot (left
panel) displaying FL-1 (CD4-FITC) against FL-2 (CD8-PE) and CD4
+ (middle) and
CD8
+ (right panel) gated cells were plotted against 7-AAD fluorescence intensityMETHODS
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PBMC were triple stained with FITC-conjugated anti-CD3 or anti CD4 and PE-conjugated
anti-CD19, anti-CD16+56, anti-CD8 or anti-CD14, and the nuclear dye 7-AAD. 1 µl of each
antibody and 20µg/ml 7-AAD were used. Staining was performed in 96-well-MTP for 20
minutes at room temperature in culture medium. Cells were washed and resuspended in
CellWASH
TM.
DNA ladder
Cells were harvested by centrifugation (200 x g, 5 minutes) and washed with PBS. Cell pellets
were incubated in 50 mM TRIS (pH 7.5) containing 100 mM NaCl, 1 mM EDTA, 1% SDS
and 20 µg/ml proteinase K at 55°C overnight. After digestion of RNA with RNase A (10
µg/ml) nucleic acids were extracted with phenol/chloroform and precipitated with 70%
ethanol as standard procedure. Genomic DNA was electrophoresed in a 1% agarose gel and
stained with ethidium bromide.
Lysis buffer for DNA-ladder:
50 mM TRIS (pH 7.5)
100 mM NaCl
1 mM EDTA
1% SDS
20 µg/ml proteinase K all Merck
RNase A Roche/Boehringer Mannheim
phenol (equilibrated with TRIS buffer pH 7.4) Sigma
chloroform
ethanol
agarose all Merck
ethidium bromide solution (10 mg/ml) Gibco BRL LifeTechMETHODS
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Genetic engineering:
DNA sources:
Oligonucleotidprimer were purchased from MWG Biotech (Ebersberg, Germany) or ARK
Scientific (Darmstadt, Germany). For sequences of the numbered oligonucleotides described
under genetic engineering, see appendix.
Human PS1 in pcDNA3 was a kind gift from C.Haass (München, Germany) to H. Hartmann
of our laboratory.
cDNA constructs were generated using standard molecular biology techniques (Sambrook,
Fritsch, and Manitais, 1989). Enzymes for genetic engineering of plasmid or genomic DNA
were purchased from New England Biolabs (Frankfurt, Germany) and utilized as
recommended by the supplier. DNA fragments were extracted from agarose gel using
GlassMax DNA isolation Kit or CONCERT
TM Rapid Gel Extraction System (both GibcoBRL
LifeTech).
For cDNA cloning, the constructs were transformed into competent cells of the bacterial
strain Top 10 (Invitrogen, Groningen, The Netherlands) prepared by the CaCl 2 method
(according to Sambrook, Fritsch, and Maniatis, 1989).
Plasmid DNA was purified from bacterial cultures by using the QIAprep
® Spin Miniprep Kit
(Qiagen, Hilden, Germany). Large-scale preparations of plasmid DNA were prepared with the
Qiagen Plasmid Maxi Kit (Qiagen, Hilden, Germany). Total RNA was isolated from human
PBMC or human brain with the RNAgents Kit (Promega, Heidelberg, Germany).
Oligonucleotides and genomic or plasmid DNA were stored in sterile H 2O at 4°C or –20°C.
RNA was stored in DEPC-H2O at –80°C.
RT-PCR cloning of human Presenilin-2 (PS-2) and alg-3
Human brain samples from the frontal lobe of a non-demented person were obtained from the
Institue of Psychiatry (London/ UK; Eckert et al., 2000). The brain sample was frozen in
liquid nitrogen immediately after autopsy with a post-mortem delay of 8-33 hours and stored
at –80°C. All vessels and instruments were rinsed thoroughly with RNaseAWAY
® (Merck,
Frankfurt, Germany). About 200 mg tissue from one human brain was homogenized (Potter:
B.Braun Biotech Int., Melsungen, Germany) with 1ml Denaturating Solution (Promega,METHODS
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Heidelberg, Germany) in a glass teflon homogenizer and total RNA was extracted according
to RNAgents protocol. For first strand synthesis, 1 µg of total RNA and either 1 µg of oligo
dT15 primer (oligonucleotide # 1) were annealed and than incubated with reverse transcriptase
(M-MuLV Reverse Transcriptase, MBI Fermentas, Heidelberg, Germany) according to the
supplier protocol.
PS-2 cDNA comprising the complete coding sequence of PS-2 and alg-3, a shorter fragment
of PS-2 (Vito et al., 1996) were amplified from the obtained single stranded cDNA. Reactions
were performed with 0.5 U PfuI-polymerase (NatuTec, Frankfurt, Germany), 0.25 µM of each
dNTP and 3 µM of each PCR primer in a final volume of 50 µl of 1 x PfuI reaction buffer per
reaction (standard procedure).
sense primer (PS-2: oligonucleotide # 2; alg-3: oligonucleotide # 3) MWG Biotech AG
antisense primer (oligonucleotide # 4) MWG Biotech AG
deoxynucleotides (dNTPs; 10 mM each) GibcoBRL LifeTech
PfuI polymerase (5 U/µl) NatuTec
10 x reaction buffer NatuTec
cycling parameters (Perkin Elmer Gene Amp PCR System 9700; standard procedure):
segment cycles temperature time
1 1 94°C 3 minutes
2 20 94°C 30 seconds
55°C 30 seconds
68°C 45 seconds
3 1 68°C 10 minutes
The primers were designed to give defined cohesive termini upon digest with KpnI and XbaI
(New England Biolabs, Frankfurt, Germany). Furthermore, a Kozak consensus sequence
(CCACC) and a startcodon (ATG), where necessary, was initiated in sense oligonucleotides
prior to the first coding base triplett. Subsequent to a digest with KpnI and XbaI, the cohesive
fragment was ligated into a linearized pcDNA3 vector (Invitrogene)according to standard
procedures. PS-2-pcDNA3 and alg-3-pcDNA3 were sequenced by the dideoxynucleotide
method.
KpnI + 10 x reaction buffer 2 New England Biolabs
XbaI + 10 x reaction buffer 2 New England Biolabs
Ligase + reaction buffer (containing ATP) New England Biolabs
pcDNA3 vector InvitrogeneMETHODS
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Figure 20. PS-2-pcDNA3 vector. The cloned PS-2 cDNA is under the control of the CMV
promotor, subsequent to a stop codon there is a polyA site. The vector contains a
neomycin resistance for selection in eukaryotic cells, and an ampicillin resistance for
selection in prokaryotes. All other vectors generated here are analogously.
RT-PCR cloning of human Presenilin-1s (PS-1s) and Presenilin-1Cas (PS-1Cas)
PS-1s and PS-1Cas were amplified from PS-1-pcDNA3 using appropriate primers (PS-1s:
oligonucleotide # 5 and oligonucleotide # 6; PS-1Cas: oligonucleotide # 7 and oligonucleotide
# 6). The annealing temperature was 54°C (PS-1s) and 50.7°C (PS-1Cas), respectively.
For cloning strategy, see above generation of PS-2 and alg-3.METHODS
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ApoE-genotyping
e2
CfoI CfoI
21 16
112 158
CfoI CfoI
18 91 81
e3
CfoI CfoI
21 16
112 158
CfoI CfoI
18 91 33
e4
CfoI CfoI
21 16
112 158
CfoI CfoI
18 72
CfoI
48
CfoI
33 48
CfoI
19
Figure 21. Restriction map of three principal alleles e2, e3, and e4 of apoE gene. Codons
112 and 158 contain polymorphic nucleotides 3745 and 3883. Cutting sites for CfoI are
arrowed. Numbers between cutting sizes indicate fragment sites in base pairs.
Genomic DNA from whole blood of AD-patients was isolated, and 10 µl of obtained DNA
subjected to PCR using standard procedures ( oligonucleotide # 8 ;  oligonucleotide # 9 ),
according to Wenham et al., 1991). The amplificate was digested overnight with 25 U CfoI at
37°C and analyzed in 20% polyacrylamide gel.
High pure PCR template preparation kit Boehringer Mannheim/ Roche
HotStarTaq Polymerase Qiagen
CfoI and 10 x buffer Boehringer Mannheim/ Roche
10 bp ladder PromegaMETHODS
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Figure 22. Polyacrylamide gel stained with ethidium bromide and viewed through UV
light. CfoI restriction fragments from five possible apoe genotypes: apoe3/3, 16 bp, 18
bp, 21 bp, 33 bp, 48 bp, 91 bp; apoe2/3, 16 bp, 18 bp, 21 bp, 33 bp, 48 bp, 81 bp, 91 bp;
apoe3/4, 16 bp, 18 bp, 21 bp, 33 bp, 48 bp, 72 bp, 91 bp; apoe4/4, 16 bp, 18 bp, 21 bp, 33
bp, 48 bp, 72 bp; apoe2/4, 16 bp, 18 bp, 21 bp, 33 bp, 48 bp, 72 bp, 81 bp, 91 bp. 10 bp
step ladder. Sizes in basepairs.
Genotyping of the offspring from transgenic mice
Genomic DNA from suspected transgenic mice was isolated from about 1 cm ends of mouse
tails. PCR was performed using standard procedures and primers for human ps-1
(oligonucleotide # 10;  oligonucleotide # 11), human app ( oligonucleotide # 12;
oligonucleotide # 13), and MFH (murine fetal hemoglobin;  oligonucleotide # 14;
oligonucleotide # 15; annealing temperature for all reactions 53°C) as an internal control for
genomic DNA. PCR was analyzed in an 1% agarose gel.
DNeasy Tissue Kit  QiagenMETHODS
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Taq Polymerase + 10 x reaction buffer Gibco BRL LifeTech
Figure 23. Ethidium bromide stained agarose gel viewed through UV light. 1
st and 2
nd
lane, mouse transgene for human PS-1 (PCR with Primers for human PS1 and MFH,
respectively); 3
rd and 4
th lane, non-transgenic littermate mouse (no amplificate with PS-1
primers but PCR product with MFH control primers).
Sequences of oligonucleotides
oligonucleotide # 1: TTTTTTTTTTTTTTT
oligonucleotide # 2: CGGGGTACCCCGATGCTCACATTCATGG
oligonucleotide # 3: CGGGGTACCCCGATGGTGTGGACGG
oligonucleotide # 4  TGCTCTAGAGCATCAGATGTAGAGCT
oligonucleotide # 5: CGGGGTACCCCGATGAATATGGCAGAAGG
oligonucleotide # 6: TGCTCTAGAGCACTAGATATAAAAT
oligonucleotide # 7: CGGGGTACCCCGATGCCTCATCGC TCT
oligonucleotide # 8: TCCAAGGAGCTGCAGGCGGCGCAMETHODS
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oligonucleotide # 9. ACAGAATTCGCCCCGGCCTGGTACACTGCCA
oligonucleotide # 10: TAATTGGTCCATAAAAGGC
oligonucleotide # 11: GCACAGAAAGGGAGTCACAAG
oligonucleotide # 12: GTAGCAGAGGAGGAAGAAGTG
oligonucleotide # 13: CATGACCTGGGACATTCTC
oligonucleotide # 14: GATCATGACCGCCGTAGG
oligonucleotide # 15: CATGAACTTGTCCCAGGCTT
Proteinchemical methods:
Western blotting procedure:
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE)
For SDS-PAGE, protein samples were supplemented with 2 x SDS-sample buffer. For PS1
detection, samples were run under reducing conditions, but without boiling the sample since
aggregation of presenilins is likely to occur under heat. Usually 10-30 µl samples were
electrophoresed in parallel with a rainbow molecular mass marker on vertical slab SDS-
polyacrylamide gels. Homogenous gels (0.5 mm) were cast as indicated, according to the
protocol of Biorad Bulletin 1156 (1984).
Electrophoresis was started at 100 V until the buffer front entered the separating gel; voltage
was than set up to 200 V. The running time was about 4 hours.
1 x SDS-sample buffer
62.5 mM Tris-HCl, pH 6.8 at RT
2% w/v SDS
10% glycerol
50 mM DTT
Running buffer:
25 mM Tris-HCl, pH 8.3 at RT,
192 mM glycine
0.1% (w/v) SDS.
Stacking gel :METHODS
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40% acrylamide
2% bis-acrylamide
Tris-HCl, pH 6.8
10% SDS
H2O
TEMED
APS
Running gel:
40% acrylamide
2% bis-acrylamide
Tris-HCl, pH 8.8
10% SDS
H2O
TEMED
APS all Merck
For analysis of human PS1 transiently expressed in Jurkats or in transgenic mice, Western
blotting was performed with 16% polyacrylamide gels as described elsewhere (Sych et al.,
2000). R27 is a polyclonal antibody that was raised in rabbit and reacts with several epitopes
(N- and C- terminal) in the loop region. 231 reacts with the N-terminus. Both antibodies were
a kindly gift of B. Yankner (Children Hospital, Havard Medical School, Boston, USA) .
The transfer cassette is assembled according to the manufacturer's instructions and the transfer
was run at 120V and 350 mA for 1.5 hours. The blotting apparatus is chilled in an ice bath.
After transfer, the membrane is placed in blocking solution on a rocker platform for at least 60
min at RT and subsequently incubated with primary antibody diluted in Blocking Solution on
a rocker plate 1 h at RT or overnight at 2-8°C. After extensive washing with PBS-Tween, the
membrane is incubated with the secondary antibody for 60 minutes. Chemiluminescent
detection was performed with ECL according the supplier instructions.
Transfer buffer:
12 mM Tris-HCl, pH 8.3 at RT,
96 mM glycine,
20% (v/v) methanol.  Merck
Chill to 2-8°C prior to use.
PBS-Tween:
0.01% (v/v) Tween 20 in Dulbecco's PBS
Blocking Solution:
2% (w/v) nonfat dry milk in PBS-TweenMETHODS
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 Quantitfication of Bcl-2
The content of Bcl-2 was determined from peripheral lymphocytes (1x10
6 cells) with an
ELISA assay (Oncogene, USA) according to the manufacture’s manual.
Statistical evaluation of the data:
Statistical analysis was performed by Student’s paired/ unpaired t-test, correlation or one-way
or two-way ANOVA followed by post-hoc tests (Tukey, Bonferroni) calculations (Prism 2.01,
GraphPad Software, Inc, San Diego, USA). All data presented are means – S.E.M. Results
were termed significant if p<0.05.RESULTS
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Age-related changes in apoptotic cell death of human peripheral blood cells
Basal and spontaneous apoptosis are increased in lymphocytes from elderly subjects
Using PI staining, the sub-G1-DNA content in lymphocytes from ‘healthy’ elderly and young
controls was quantified. Figure 27 shows the histogram plots of PI-stained lymphocytes of
two representative subjects. Student’s t-test revealed that the percentage of basal apoptotic
nuclei in freshly isolated lymphocytes was significantly elevated in aged subjects compared to
young controls (means ± S.E.M.: old: 1.35 ± 0.196% vs. young 0.84 ± 0.113%; *p<0.05;
Figure 24a).
Figure 24. a) basal levels of apoptotic nuclei in freshly isolated PBMC. Apoptosis was
determined by propidium iodide staining as described in methods. Cells derived from
aged humans (over 60 years old) display significantly more basal apoptotic nuclei (1.35 –
0.196%, n = 34) than younger controls (up to 35 years old; 0.84 – 0.113%; n = 32,
*p<0.05, Student’s t-test). b) spontaneous apoptosis in PBMC of young and old humans:
cells were cultured for 24 hours in absence of stimuli. In aging, significantly more
apoptotic cells accumulate under this condition. PBMC from old subjects displayed 8.06
– 0.85% apoptotic cells while young subjects showed only 5.52 – 0.43% apoptotic nuclei
**p<0.01.
 In addition, we found a significant higher content of cells undergoing spontaneous in vitro
apoptosis after 24 hours in the group of old subjects in relation to young ones (Figure 24b,
**p<0.01; old 8.06 ± 0.85%; young: 5.52 ± 0.43%). Moreover, when all investigated subjects
were pooled for regression analysis, increasing age positively correlated with percentage ofRESULTS
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apoptotic cells by regression analysis. Spontaneous apoptosis after 24 hours increased 2.1-fold
(slope = 0.061 ± 0.02) between 15 and 93 years of age (Figure 25, dotted line (- - -)). There
was a significant (***p < 0.001, n = 85) correlation between age and the portion of apoptotic
cells.
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Figure  25. Spontaneous and CD95 induced apoptosis in PBMC after 24 hours
incubation: Lymphocyte apoptosis correlates with increasing age. PBL from subjects
ranging from 17 to 82 years of age were cultured 24 h in vitro and spontaneous
apoptosis (open circles = O) was determined by flow cytometry analysis. % apoptotic
cells was correlated with gender age (r= 0.34, ***p < 0.001, n = 85). The percent increase
per year is 0.06 – 0.03 %.  Black rhombs (u) symbolize apoptosis of cells cultured for 24
hours with an agonistic CD95-antibody. In addition, correlation with age is also highly
significant (r = 0.50, ***p < 0.001, n = 46). CD95 induced apoptosis increases even more
with age than the spontaneous in vitro apoptosis does (slopes of the linear regression
analysis: 0.122 – 0.04; 0.061 – 0.02, respectively).
To ascertain that these alterations in apoptotic cell death were not linked to alterations in the
distribution of PBMC subpopulations, the same experiments were performed with activated
lymphocytes consisting to over 95% of CD3
+ cells. Lymphocytes, which are undergoing
proliferation, can be triggered to programmed cell death by withdrawal of interleukin-2 (IL-
2). IL-2 is the most critical determinant in this process (21). Activated lymphocytes have been
shown to be more sensitive to apoptosis than non-treated native cells. Basal apoptotic levelsRESULTS
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of activated T-cells correlated significantly with the donor age (*p<0.05, n=52; Figure 26). In
addition, spontaneous in vitro apoptosis after 24 hours (under these conditions also called
AICD: activation-induced cell death, that is triggered by IL-2 treatment followed by
withdrawal) did as well significantly correlate with age (*p<0.05, n=45; Figure 26).
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Figure 26. Basal apoptotic levels and activation-induced cell death (AICD ) of activated
lymphoblasts correlate significantly with the age of the donor.  Open circles (O) show
basal apoptotic levels after lymphocyte activation as described in methods. Correlation
with subjects' age is significant (*p<0.02; n = 52). Closed circles (l) display AICD of
activated lymphoblasts after 24 hours withdrawal of IL-2 (*p<0.03; n = 45).RESULTS
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Figure 27. Histogram plots of propidiume-iodide stained and lysed PBMC from each an old (upper level) and a young (lower level)
individual. Percentage of sub-G1-DNA-content (% apoptotic cells) under different conditions is indicated. First column shows basal
apoptotic levels of freshly isolated PBMC, the second displays the spontaneous in vitro apoptosis after 24 hours in culture, and the last two
columns exhibit dRib- and CD95-induced apoptosis after 24 hours.RESULTS
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PBMC from aged donors are more vulnerable to induction of apoptosis by oxidative
stress
Oxidative stress was induced with 2-deoxy-D-ribose (dRib, (Barbieri et al., 1994)). Cells
were incubated for 24 hours at 37°C, harvested, propidium iodide stained and analyzed by
flow cytometry. In the presence of 10 mM dRib, the sub G 1-DNA content was elevated in
both groups compared to spontaneous apoptosis but PBMC of elderly subjects did react
significantly more sensitive to this apoptotic stimulus than the younger group.
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Figure 28. Spontaneous in vitro apoptosis was subtracted from CD95- and dRib-induced
apoptosis resulting in the percentage of apoptosis induced by the agent. This so called
induced apoptosis over control was correlated with age of subjects. Black stars ( *)
represent dRib- induced apoptosis, open rhombs (￿) symbolize CD95-induced apoptosis.
After subtraction of spontaneous apoptosis, a significant increase of vulnerability to ROS-
induced apoptosis was determined (Figure 28; correlation *p<0.05 and Figure 29: old: 7.92 –
1.8% vs. young: 3.0 – 1.2%, *p<0.05), indicating an age-related impairment to cope with
oxidative stress. In addition, higher concentrations of 2-deoxy-D-ribose (50 mM) could not
induce higher levels of apoptotic cells in old volunteers (old: 7.22 ± 1.20 vs. young: 6.85 ±
1.45; n = 37 per group; p = 0.42).RESULTS
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Figure 29. Induced apoptosis over control (spontaneous apoptosis) after 24 hours by
dRib (10 mM) and staurosporine (100 nM) in groups of young and old subjects (dRib:
young = 3.00 – 1.187% vs. old = 7.92 – 1.741%, n = 11; *p<0.05; staurosporine: 23.71 –
6.331% vs. 27.65 – 5.634%; n.s.; n = 11, respectively).
Functional CD95 expression is higher in lymphocytes of elderly subjects
Incubation for 24 hours with an agonistic monoclonal anti-CD95 antibody that acts like a Fas-
Ligand, showed significant changes in the induction of apoptosis in native cells between
young and old genders (6.19 ± 0.26%; 11.05 ± 1.78%, respectively, ***p<0.001). Apoptotic
cells correlated significant with donor age after incubation with a CD95 antibody
(***p<0.001, Figure 28, black line). However, in young donors the number of apoptotic cells
is not altered after CD95 treatment compared to spontaneous apoptosis (n.s.; paired t-test). In
contrast, PBMC from aged donors are far more sensitive to apoptosis with agonistic CD95
antibody (paired t-test gave: ***p<0.001). By subtracting the spontaneous apoptosis in each
subject the CD95 induced apoptosis is determined, that increases significantly with aging
(Figure 28).
Apoptosis induced by staurosporine does not correlate with aging
To examine whether the age-related increase in apoptosis is specifically associated with
oxidative stress or not, and/or with the higher expression of activation receptors, we also
induced programmed cell death in PBMC by staurosporine. Though, induction of cell death
with staurosporine is very common throughout literature, the mechanism are still not fullyRESULTS
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elucidated (Krohn  et al., 1998). However, it seems that ROS are not directly involved in
apoptosis initiation, possibly caspases are activated directly by staurosporine. Incubation of
PBMC with 100 nM staurosporine showed a dramatic increase in the percentage of apoptotic
cells compared with the untreated controls undergoing spontaneous apoptosis (***p<0.001).
However, no significant effect could be determined related to aging ( Figure  29).
Staurosporine induces apoptosis independently from the donor’s age. In summary, the data
indicate that there are differences in efficacy to induce age-related changes in apoptosis by
different stimuli.
Elevated expression of activation markers in aging
In order to explore the mechanism for the increased susceptibility to apoptosis in PBMC from
aged donors, we determined the expression of activation markers HLA-DR, CD95 (Apo, Fas)
and CD25 (Interleukin-2-receptor). Quantitation of T-lymphocytes expressing  HLA-DR,
CD95 and CD25 (IL2-Ra) was performed by direct immunofluorescence in wholeblood
followed by FACS analysis (Figure 30). CD3
+ T-cells from young donors (up to 35 years)
showed a significantly (***p<0.0001) smaller portion of HLA-DR-positive cells (5.9 ± 0.4%)
than CD3
+-T-lymphocytes from aged subjects (10.8 ± 0.97%). CD3
+ cells from young donors
expressed significantly less CD95 receptors than elderly subjects over the age of 60 years
(young: 34.2 ± 2.3% vs. old: 46.4 ± 2.6%). No significant changes with age concerning the
expression of CD25 could be detected (young: 13.3. ±0.7% vs. old: 14.8 ±1.3%).
The portion of cells displaying CD95 correlates, as expected, significantly with the percentage
of CD95-agonistic-antibody induced apoptosis (data not shown), confirming the age-related
increase in CD95-induced cell death.RESULTS
79
0
15
30
45
60
75
a) HLA-DR b) CD 95 c) CD 25
***
***
ns
old
young
Figure 30. Determination of surface expressed activation markers of CD3
+-lymphocytes
from young (n = 32) and old genders (n = 34). T-cells from young donors displayed a
significantly (***p<0.0001) smaller portion of HLA-DR-positive cells (5.9 ± 0.4%) than
T-lymphocytes from older subjects (10.8 ± 0.97%). CD3
+ cells from young donors
expressed significantly less CD95 receptors than elderly subjects (young: 34.2 ± 2.3% vs.
old: 46.4 ± 2.6%). No significant changes with age concerning the expression of CD25
could be determined (young: 13.3. ± 0.7% vs. old: 14.8 ± 1.3%).
The more the peripheral lymphocytes express CD95 and CD25 at basal levels, the higher is
the percentage of cells undergoing apoptosis initiated by glutathione depletion (10 mM and 50
mM dRib) as shown by correlation (Figure 31), indicating that these lymphocytes are more
susceptible to oxidative stress.
Figure 31.  Correlation of dRib-induced (50 mM) apoptosis and basal expression of
activation markers. Correlation with a) HLA-DR (n.s. p = 0.07, n= 33); b) with CD95
(***p<0.0001; n = 25); and c) with CD25 (**p<0.01, n = 41).RESULTS
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Elevated levels of Bcl-2 in lymphocytes from aged humans
Overexpression of Bcl-2 counteracts apoptotic processes  (6) probably by activating anti-
oxidative mechanism. To investigate the link between apoptosis and oxidative stress in
peripheral human lymphocytes we determined the basal content of Bcl-2 in freshly isolated
PBMC by ELISA. There was a positive correlation between the content of Bcl-2 and the
percentage of basal apoptotic cells (Figure 32; *p<0.05; n= 18). Moreover, the amount of Bcl-
2 seems to increase with aging (Figure 32 inset).
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Figure 32. Basal expression of Bcl-2 seems to increase with aging (inset) in human
PBMC. Peripheral cells of young subjects displayed 19.6 ± 5.66 U Bcl-2/ mg protein,
PBMC of aged volunteers expressed 25.8 ± 5.67 U Bcl-2/ mg (n = 9 per group). Content
of Bcl-2 correlates significantly (*p<0.03; n=18) with basal percentage of apoptotic cells
in freshly isolated PMBC from young and old donor.RESULTS
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Increased apoptosis in Alzheimer’s disease
Apoptosis in peripheral blood mononuclear cells of patient with DAT
Earlier results of our group indicate elevated basal levels in PBMC from patients suffering
from sporadic DAT (Eckert et al., 1998; 1999; 2001). Moreover, spontaneous and dRib-
induced apoptosis was similarly altered in this cohort of patients. Apoptotic cell death was
determined by an ELISA kit sensitive for histones which become apparent when nucleosomes
occur during apoptosis.
One aim of the present thesis was to reproduce and extend these results with flow cytometric
methods in a second cohort of sporadic AD patients. Furthermore, the mechanisms underlying
the altered apoptotic behavior of PBMC from AD-patients should be elucidated.
Heparinized blood samples of DAT-patients were collected by our clinical cooperation
partners from the  ‘Gedächtnis-Ambulanz des Universitätsklinikums Frankfurt am Main’. The
PBMC were isolated from the blood samples within 1 hour later as described. Staining of
apoptotic nuclei was performed with PI and analyzed by flow cytometry. Samples of matched
elderly non-demented controls were run in parallel.
Figure 33.  Representative PI-stained basal PBMC (immediately after isolation) from an
old non-demented control and an AD-patient.
A significant increase in the basal apoptotic levels was determined in PBMC from AD-
patients compared to age-matched controls (Figure 33). Demented patients showed about the
doubled amount of apoptotic cells after isolation of PBMC compared with cells from control
A) old non-demented control B) patient with DATRESULTS
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persons. Moreover, when all data of demented patients were pooled and plotted against the
Mini Mental State Examination Score (MMSS) there was a significant correlation with
increasing apoptotic nuclei (*p<0.05).
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Figure 34.  Whole freshly isolated PBMC were stained with Propidiume Iodide as
described by Nicoletti et al., 1993. Basal levels of apoptotic peripheral cells correlate
significantly with severity of disease (Mini Mental State Score; n = 34, *p<0.05).
Compared with old non-demented controls, AD-patients provide increased basal levels
of apoptotic cells (inset; control: 1.35 ± 0.196%vs. AD: 2.37 ± 0.287%; n = 34 per group;
**p<0.01).
Analysis of apoE genotype showed an increased percentage of basal apoptotic cells from AD
patients carrying APOE4 (Figure 35). However, due to the very small number of E4 positive
subjects these changes are not statistically significant. PBMC of AD-patients and elderly
controls were incubated for 24 hours in order to determine the spontaneous apoptosis. In
addition, samples were cultured in the presence of 10 mM or 50 mM dRib, 0.1 µM
dexamethasone, 50 ng/ml Fas-ligand or an agonistic CD95-antibody, respectively. Samples
were processed as described and apoptosis d etected by PI-staining. The results areRESULTS
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summarized in Figure 35. Treatment with 50 mM dRib showed elevated levels of apoptotic
nuclei in AD (AD: 13.86 ± 1.625% vs. control: 8.43 ± 1.554%; *p<0.05; n = 13 per group),
however, since massive necrosis did already occur at this dose of dRib, this treatment was
omitted in further experiments. In contrast, dRib at a concentration of 10 mM clearly induced
apoptosis. This concentration was the standard condition for the following experiments.
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Figure 35. Patients with apoE4 genotype show elevated levels of basal apoptotic cells
(3.72 ± 1.163%; n = 11) compared with patients that are not ApoE4-positive (2.87 ±
0.636%; n = 19). However, those changes are not significant, probably due to a too low
number of included subjects included.
Significant differences were detected in spontaneous and Fas-receptor mediated apoptosis.
Furthermore, ROS- (via dRib) and Fas-ligand induced apoptosis correlated significantly with
the MMSS of each individual, indicating an increased vulnerability to ROS and an enhanced
functional expression of Fas-receptor as the dementia proceeds.RESULTS
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AD-patients old controls PBMC
mean age; number
of patients; mean
MMSS
mean age; number
of volunteers
% apoptotic cells
from AD-patients
% apoptotic cells in
age-matched
controls
significance (AD
vs. controls)
correlation with
MMSS
basal
73.4±3.5 years;
n=34, 18.8±1.12
MMSS
71.5±4.6 years;
n=34
2.37 ± 0.287% 1.35 ± 0.196% **p<0.03 *p<0.05
spontaneous
72.2±3.1 years;
n=22, 19.1±1.48
MMSS
74.0±4.9 years;
n=25
8.10 ± 0.793% 5.01 ± % **p<0.01
not done.(n.d.): due
to too small
number to calculate
proper correlation
analysis
dRib (10 mM)
74.7±6.1 years;
n=10, 19.0±1.94
MMSS
73.2±3.1 years;
n=11
7.23 ± 1.964% 7.92 ± 1.740 n.s. n.d.
dexamethasone
74.1±4.8 years;
n=11, 18.9±1.34
MMSS
73.7±3.1 years;
n=15
5.32 ± 1.215% 6.57 ± 2.107% n.s. n.d.
Fas-L
77.6±5.8 years;
n=15, 19.3±1.78
MMSS
73.8±6.0 years;
n=16
13.64 ± 3.528% 7.40 ± 0.980% *p<0.05 n.d.
Table 2. Percentage of PI-stained PBMC from patient with DAT and elderly controls.RESULTS
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Changes in lymphocyte’s subsets in aging and AD
In order to explore, whether those changes in apoptotic cell death were due to, it is necessary
to determine if the constituents of the PBMC (T-, B-, and NK-lymphocytes) were changed in
AD-patients. Moreover, the lymphocyte subsets might have a different apoptotic behavior that
should be analyzed.
The PBMC consist mainly of T-cells (varying from 80 to 60% in relation to the volunteer’s
age). About two thirds of the T lymphocytes are T helper cells (CD4
+). Therefore, changes in
the percentage of T lymphocytes, and/ or their subsets T helper- or T suppressor cells, could
influence the number of apoptotic cells in the whole PBMC.
First, the changes of PBMC constituents were determined in ‘healthy aging’.
Absolute number of total T cells, as well as the number of CD4
+- and CD8
+-
lymphocytes decreases with aging
To determine the absolute amount of T lymphocytes with respect to their subsets, an aliquot
of heparinizied blood samples was quantified by flow cytometry using TrueCount
® beads and
antibodies against CD3, CD8, and CD4. Only CD3-PerCp-positive cells were electronically
gated and a minimum of 100,000 cells was acquired The number of CD3-positive cells
significantly decreases in aging (CD3, young: 1888 ± 147 cells/µl; old: 1236 ± 153 cells/µl; n
= 17-21; **p<0.005). The loss of cells observed in aged subjects seems to be distributed
among both subsets (CD4, young: 1109 ± 103 cells/ µl; old: 763 ± 84 cells/ µl; n = 17-21;
*p<0.012 and CD8, young: 601 ± 53 cells/µl; old: 353 ± 68 cells/µl; n = 17-21; **p<0.005;
Figure 36A). However, the number of CD8
+ cells seems to be more affected by aging than the
T helper lymphocytes (CD4
+).RESULTS
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Figure 36. (A) The absolute number of CD4 and CD8 lymphocyte is significantly
reduced in blood samples from aged donors. Cell counts were determined by using the
TrueCount
® kit, providing a defined number of beads in the staining tube. (B) The
density of the costimulatory receptors CD4 and CD8 on lymphocytes from young and
old subjects. Mean fluorescence intensity (MFI) determined, as the mean channel
number is proportional to the density of the measured receptor. No changes concerning
CD4-receptor density were observed between lymphocytes from young and old donors.
In contrast, a significant decrease of CD8-receptor was determined in lymphocytes from
aged donors when compared with young ones. Soluble CD8-receptor is known as an
activation marker.
In addition, the mean fluorescence intensity (MFI) that is proportional to receptor surface
density was measured. The density of the CD3- and CD4-receptor was not altered between the
group of young and old donors (CD3, young: 182 ± 17; old: 160 ± 7, CD4, young: 130 ± 10;RESULTS
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old: 122 ± 10; n = 11-14). Interestingly, the density of CD8-receptor on each single T
suppressor cell was significantly decreased in the aged group (CD8, young: 1300 ± 151; old:
1025 ± 81; n = 11-14; *p<0.05; Figure 36B).
To explore the changes of subsets within the whole lymphocyte population, the percentage of
T-, B-, and NK (natural killer)-lymphocytes were surveyed and plotted against the donors’
age. The percentage of CD3-positive cells within the gated lymphocyte population, as
determined by gating in FSC/ SSC, decreases with age (n = 54; **p<0.02; r
2 = 0.15; Figure
37A). Excitingly, the ratio of T helper to T suppressor-lymphocytes, termed CD4/CD8-ratio,
is not significantly changed in old individuals (young: 1.91 ± 0.18; old: 1.68 ± 0.21; n = 20-
22; figure 2B). The slight reduction of the CD4/CD8-ratio in the aged group becomes evident,
looking at the absolute number of CD4
+ and CD8
+ cells. The loss of CD8
+ cells is more
dominant than the loss of CD4
+ in aging (Figure 36A). However, there is no significant
correlation of CD4/CD8-ratio with donor’s age; n = 53; r
2 = 0.004. The percentage of B
lymphocytes was not significantly affected by the volunteer’s age (n = 53, r
2 = 0.006; data not
shown). Focusing on the NK subset, there was a significant increase of the percentage of
CD16
+ and CD56
+ cells within the lymphocyte gate (n = 53; ***p<0.001; r
2 = 0.19; Figure
37C). No changes concerning appearance of the forward-side scatter plot could be observed.
In both age groups, lymphocytes could be clearly identified and were sharply separated by
gating from monocytes and granulocytes.RESULTS
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Figure 37. Lymphocyte subset distribution in aging. The percentage of all FSC-SSC-
gated lymphocytes was determined and plotted against donor’s age. (A) The percentage
of CD3 positive cells significantly decreases with increasing age of the blood donor. (B)
However, the subset distribution of the CD3
+ T cells, expressed as CD4/CD8-ratio, did
not differ significantly between the two age groups. (C) The percentage of natural killer
(NK) lymphocytes significantly increases with increasing donor’s age.
In aging, the content of T lymphocytes (CD3
+) decreases and the percentage of NK cells
(CD16
+CD56
+) increases significantly with the donor’s age (Table 3). In addition, the ratio of
the T cell subsets (CD4
+, T helper/inducer and CD8
+, T cytotoxic/suppressor) remains
unchanged with aging.RESULTS
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young old
number of
volunteers
mean percentage
of positive cells
number of
volunteers
mean percentage
of positive cells
significance correlation with age r
2 number of
volunteers
lymphocyte subsets
CD3 n = 20 72.91 ± 1.543% n = 25 65.96 ± 2.162% **p<0.009 **p<0.003 0.1464 n = 54
     T lymphocyte subsets
CD4 41.38 ± 1.122 39.19 ± 2.801% n.s. n.s. -
CD8 23.65 ± 1.034% 25.76 ± 1.716% n.s. n.s. -
CD4/CD8-
ratio
n = 20
1.852 ± 0.130
n = 16
1.682 ± 0.214 n.s. n.s. -
n = 40
CD19 11.77 ± 0.862% 10.88 ± 1.175% n.s. n.s. -
CD16+
CD56
n = 22
16.55 ± 1.452%
n = 25
24.36 ± 1.895% **p<0.002 ***p<0.0006 0.1860
n = 53
activation markers on CD3
+ cells
HLA-DR n = 20 5.90 ± 0.435% n = 24 10.96 ± 0.995% ***p<0.0001 ***p<0.0001 0.3166 n = 50
CD95 34.24 ± 2.343% 46.36 ± 2.718% ***p<0.001 ***p<0.0006 0.2228 n = 44
CD25
n = 17
13.29 ± 0.690%
n = 22
15.05 ± 1.300% n.s. n.s. - n = 44
absolute determination of cell number
CD3/µl 1888 ± 147 1236 ± 153 **p<0.006 **p<0.005 0.1908
CD4/µl 1109 ± 103 763 ± 83.5 *p<0.02 *p<0.03 0.1158
CD8/µl
n = 17
601 ± 53
n = 21
353 ± 67.9 **p<0.005 **p<0006 0.1770
n = 35
mean fluorescence intensity of surfaced expressed receptor
CD3 181.6 ± 16.65 160.4 ± 7.32 n.s. n.s. -
CD4 130.3 ± 10.31 121.9 ± 9.90 n.s. n.s. -
CD8
n = 10
1300 ± 151
n = 14
1025 ± 80.90 *p<0.05 *p<0.04 0.1902
n = 18
Table 3. Determination of lymphocyte subset distribution and percentage of T cells expressing activation markers in aging.RESULTS
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The latter experiments showed that lymphocyte subsets change with aging: there is a decrease
of T lymphocytes and an incraese of NK cells. Interestingly, in AD patients we observed a
significant decrease in the absolute number of CD3
+ cells with increasing cognitive
impairment (*p<0.02;  Table  4). Therefore, a significant involvement of T cell mediated
immunity in more demented patients can be considered, since most of the patients displaying
quite high MMSS already showed this tendency.
The reduction of TCR associated CD3 in AD, though statistically insignificant, was analyzed
by back gating of the CD8
+ cells. When only CD8
+ gated cells of DAT-patients were
displayed in 2D plot, it became evident, that those cells that are low in CD8 display lower
number of CD3, as well (data not shown).
T cells
65%
B cells
10%
NK cells
25%
Figure 38. Average contents of the lymphocyte content in the PBMC in aged non-
demented persons.
No changes in the percentage of T-, B-, and NK-cells could be determined in whole blood
samples of AD-patients. In addition, the absolute number of T cell per µl whole blood did not
differ in demented persons (Table 4). However, one of these cell types must account for the
elevated of apoptosis found in PBMC in demented subjects. Therefore, apoptosis was
determined for each subset. First, the method was validated by determining changes in human
aging.RESULTS
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AD-patients elderly controls
mean age;
mean MMSS
mean percentage
of positive cells
mean age;
number of
volunteers
mean percentage
of positive cells
significance correlation with
MMSS
r
2 number of patients
lymphocyte subsets
CD3 n = 23 69.79 ± 1.865% n = 25 65.96 ± 2.162% n.s. n.d. - n = 23
     T lymphocyte subsets
CD4 60.06 ± 2.971% 50.95 ± 3.156% *p<0.05 n.s. -
CD8 24.31 ± 1.785% 33.51 ± 2.111% **p<0.003 n.s. -
CD4/CD8-
ratio
n = 39
2.31 ± 0.237
n = 16
1.68 ± 0.214 *p<0.03 **p<0.008 0.1477
n = 39
CD19 10.34 ± 0.832% 10.88 ± 1.175% n.s. n.d. - n = 23
CD16+
CD56
n = 23 23.32 ± 1.830% n = 25 24.36 ± 1.895% n.s. n.d. - n = 23
activation markers on CD3
+ cells
HLA-DR n = 10 9.83 ± 1.182% n = 24 10.96 ± 0.995% n.s. n.d. - n = 10
CD95 49.22 ± 5.443% 46.36 ± 2.718% n.s. n.d. -
CD25
n = 9
19.13 ± 3.712%
n = 22
15.05 ± 1.300% n.s. n.d. -
n = 9
absolute determination of cell number
CD3/µl 1285 ± 69.0 1236 ± 153 n.s. *p<0.02 0.2012
CD4/µl 796 ± 40.0 763 ± 83.5 n.s. *p<0.02 0.2317
CD8/µl
n = 26
365 ± 38.5
n = 21
353 ± 67.9 n.s. n.s. -
n = 21
mean fluorescence intensity of surfaced expressed receptor
CD3 135.80 ± 10.740 160.4 ± 7.32 n.s. n.d. -
CD4 119.40 ± 9.939 121.9 ± 9.90 n.s. n.d. -
CD8
n = 12
841.0 ± 87.45
n = 14
1025 ± 80.90 n.s. (p=0.067) n.d. -
n = 12
Table 4. Distribution of lymphocyte subsets, percentage of activated, absolute number and receptor expression of T cells in AD-patients and
elderly non-demented controls.RESULTS
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Apoptosis in lymphocytes’ subsets
Based on these data, the apoptotic behavior of lymphocyte subset from AD patients or aged
controls should be determined, in order to explore, whether the altered vulnerability to
apoptosis is all cells or specifically distributed in the different lymphocytes subsets.
To determine apoptotic levels of lymphocyte subsets, the detection method had to be adapted.
Propidiume iodide provides a too strong fluorescence that is detected not only in one
fluorescence channel (FL-2) of the flow cytometer but also partially overlaps with the two
other channels (FL-1 and FL-3). Therefore, the following experiments were performed with
the DNA dye 7-Aminoactinomycin (7-AAD; described by Schmit et al., 1994), that holds an
emission maximum at 650 nm and is purely detectable in FL-3. Moreover, 7-AAD posses a
very distinct emission profile, that provides no conflict with the other cytometer channels and
permits the co-detection of two other fluorochrome (FITC and PE, for instance) within the
same experiments. In order to explore the apoptotic levels of T-, B-, and NK-cells, the
isolated PBMC samples were stained with 7AAD and monoclonal antibodies against CD3 or
CD4, coupled with FITC, and against CD19, CD16+CD56, or CD8, coupled with PE.
In contrast to PI-staining according to Nicoletti  et al., 1993, 7-AAD staining allows the
differentiation between apoptotic and necrotic/ dead cells.
live
apoptotic
dead
live
dead
apoptotic
CD4
CD8
Figure  39. Determination of apoptotic cells with triple staining with 7-AAD and
monoclonal antibodies against CD4 and CD8. CD4 and CD8 positive cells, respectively,
were gated and displayed as dot plot showing 7-AAD fluorescence versus forward
scattered light. Photo multiplier detectors were set, that autofluorescence of 7-AAD of
live, intact cells were set in channel numbers between 10
0 and 10
1. A higher 7-AAD
fluorescence is evident in apoptotic cells, due to membrane damage. Cells that display
the whole DNA content, like permeabilized PI-stained nuclei, were termed dead.RESULTS
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7-AAD detects the same percentage of apoptotic cells as PI does.
To measure accurately the apoptotic population within the PBMC subsets, we used the
method of single-cell analysis by flow cytometry. In order to demonstrate that PI and 7-AAD
detect the same amount of apoptotic cells, the percentage of apoptotic cells detected with 7-
AAD was plotted against the amount of apoptosis determined with PI. Whole PBMC,
magnetic isolated CD4 and CD8 were single stained with 7-AAD or PI in two different tubes
and analyzed. The correlation is shown in Figure 40 (y = (0.88 ± 0.06)x + (2.65 ± 1.14); r
2 =
0.833; n = 51).
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Figure 40. Apoptotic cell death was induced in PBMC from healthy volunteers and
apoptosis detected in two separate experiments by PI- and CD4-FITC/7-AAD- or CD8-
PE/7-AAD-staining. The content of apoptotic cells found by PI-staining could be
reproduced by the new method using 7-AAD as DNA dye. Dotted line shows ideal
diagonal. Black line represent the linear regression of the experiment (n = 51, r
2 = 0.833;
p<0.0001).
Not only discrimination between CD4 and CD8-positive cells was made possible by the new
method, but also the remaining lymphocyte subsets (B- and NK-lymphocytes) could be
resolved.
To proove the reproducibility of this method, the comparison of apoptotic lymphocyte
behavior in aging was performed by using 7-AAD to determine the physiological apoptotic
changes in lymphocyte subsets in healthy aging.RESULTS
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Differences in apoptosis of human lymphocyte subsets in ‘healthy’ aging.
Basal levels of all lymphocyte subsets were elevated in samples derived from the aged group,
indicating that all types of lymphocytes are affected by aging. It is noteworthy that B
lymphocytes displayed large variances from both young and aged volunteers. Significant
changes in the B cell subsets are therefore unlikely to occur for this relatively small cohort.
Spontaneous apoptosis, in addition, was altered in all lymphocyte subsets with aging.
However, it seems that T cells are less vulnerable to spontaneous apoptosis than B cells.
ROS-induced cell death mediated by GSH depletion is increased in T and NK cells from aged
persons. Interestingly, B cells seem to be less vulnerable to dRib with increasing age, but this
was probably due to significantly increased levels of necrotic cells occurring in the aged
cohort, reducing apparently the amount of apoptotic cells (data not shown). Apoptotic cell
death by staurosporine-, dexamthasone- and Fas-ligand-treatment was not inducible in B and
NK lymphocytes. Induced levels of apoptotic cells calculated by subtracting the spontaneous
apoptosis gave differences near zero or negative results, therefore these data were omitted and
not displayed in the table.
Dexamethasone and staurosporine induced cell death is comparable with that found for the T
cell subsets (Table 8). There were no changes with aging.
The next table displays a summary of the percentage of apoptotic cells determined by triple
staining with 7-AAD, anti-CD3-FITC (T cells) and anti-CD19-PE (B cells) or anti-CD16+
anti-CD56-PE (NK cells), respectively (Table 6).
Bcl-2 content of lymphocyte subsets
In order to explore whether the antiapoptotic-acting proto-oncogene Bcl-2 is involved in the
apoptotic process observed with aging in lymphocyte’s subsets, the amount of Bcl-2 was
determined at a single cell level by flow cytometry.
In concordance with the findings, using an ELISA against Bcl-2 (see Figure 32), there were
no significant changes in Bcl-2 expression in the different lymphocyte’s subsets concerning
aging (CD3, young: 6.05 – 0.798; n = 9 vs. old: 5.71 – 0.503; n = 16; CD19, young: 6.00 –
0.908; n = 5 vs. old: 5.83 – 0.637; n = 9; CD56+16, young: 4.34 – 0.645, n = 5 vs. old: 4.36 –
0.434; n = 9; all data are mean fluorescence intensity (MFI); Figure 41).RESULTS
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Figure 41. Content of Bcl2 in human lymphocytes. No changes between cells from young
and aged volunteers could be detected.
When correlating the percentage of apoptotic cells of each individual with the content of Bcl2
in the corresponding subset, a significant correlation becomes evident for B cells. The more B
cells are apoptotic in a sample, the higher is the level of intracellular Bcl-2 of the same
sample. No significant correlation has been found in T and NK cells.
P value sig. n r
2
T cells 0.2392 n.s. 18 0.03189
B cells 0.0325 * 12 0.3003
NK cells 0.1289 n.s. 12 0.1289
Table 5. Correlation of apoptotic cells with Bcl-2 content in different lymphocyte
subsets.RESULTS
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young old T lymphocytes B lymphocytes NK lymphocytes
number
of volun-
teers
number
of volun-
teers
%
apoptotic
cells
from
young
persons
%
apoptotic
cells in
aged
persons
signifi-
cance
(young
vs.
aged)
corre-
lation
with age;
r
2
(number
of
subjects)
%
apoptotic
cells
from
young
persons
%
apoptotic
cells in
aged
persons
signifi-
cance
(young
vs.
aged)
corre-
lation
with age;
r
2
(number
of
subjects)
%
apoptotic
cells
from
young
persons
%
apoptotic
cells in
aged
persons
signifi-
cance
(young
vs.
aged)
corre-
lation
with age;
r
2
(number
of
subjects)
basal n = 9 n = 11
0.67 ±
0.114%
1.08 ±
0.208%
n.s. p =
0.07
*p<0.04;
0.0749
(22)
2.89 ±
0.850%
5.03 ±
1.607%
n.s. n.s. (13)
0.71 ±
0.223%
1.47 ±
0.273%
*p<0.04 n.s. (22)
spon-
taneous n = 9 n = 7
1.52 ±
0.292%
3.02 ±
0.467%
**p<0.00
6
**p<0.06
; 0.2230
(22)
11.33 ±
5.382%
13.96 ±
2.897%
n.s.
p=0.08
n.s. p =
0.06 (21)
9.43 ±
1.835%
11.74 ±
2.059% n.s. n.s. (20)
dRib n = 9 n = 11
8.57 ±
1.122%
17.56 ±
3.277% *p<0.02
*p<0.04;
0.1782
(20)
37.19 ±
8.999%
25.56 ±
7.176% n.s. n.s.
13.31 ±
2.997%
25.51 ±
4.205% *p<0.02
*p<0.02
(18)
Dex n = 9 n = 12 4.17 ±
0.805%
4.02 ±
0.508%
n.s. n.s. - -
Table 6. Apoptosis in different lymphocyte subsets in aging.RESULTS
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Apoptosis in lymphocyte subsets (T-, B-, and NK-cells) from AD patients
Apoptosis of lymphocyte subsets from AD patients were determined as described and
established above (see: Differences in apoptosis of human lymphocyte subsets in ‘healthy’
aging.). When correlated with the severity of the cognitive impairment, only basal apoptotic
levels of T lymphocyte correlated with the MMSS (*p<0.05; Table 9), but not B- and NK-
cells. Comparing the data with that of elderly non-demented controls, T cells showed elevated
levels of basal apoptotic cells, however due to the small number of included patients yet not
significant. Interestingly, natural killer cells show a clear increase in basal apoptosis (Figure
42).
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Figure 42. Comparison of all AD-patients with age-matched controls. Basal levels of
apoptotic T lymphocytes are increased in demented persons, though here not
significantly (possible due to the smaller number of included subjects compared with
Figure 34). B lymphocytes display quite high apoptotic levels, in general. There is no
difference between AD-patients and non-demented persons. In concordance with
findings of Solerte et al., 1998; 2000; Araga et al., 1991, NK lymphocytes seems to be
basely activated in AD-patients, since they show significantly increased levels of
apoptosis immediately after isolation (*p<0.05). All data are summarized in the
following table (Table 7).
Levels of spontaneous and agent-induced apoptosis determined after 24 hours in vitro is
summarized inTable 7. It becomes clearly evident, that only T cells from AD patients show
changes in cell death in correlation with the MMSS. B cell apoptosis is not effected by AD,
but basal apoptotic levels of natural killer lymphocytes are altered in demented persons.RESULTS
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AD-
patients
old
controls T lymphocytes B lymphocytes NK lymphocytes
number
of
patients;
mean
MMSS
number
of age-
matched
controls
% apop-
totic
cells
from AD-
patients
% apop-
totic
cells in
age-
matched
controls
signifi-
cance
(AD vs.
controls)
corre-
lation
with
MMSS;
r
2
% apop-
totic
cells
from AD-
patients
% apop-
totic
cells in
age-
matched
controls
signifi-
cance
(AD vs.
controls)
corre-
lation
with
MMSS
% apop-
totic
cells
from AD-
patients
% apop-
totic
cells in
age-
matched
controls
signifi-
cance
(AD vs.
controls)
corre-
lation
with
MMSS
basal
n=16;
19.3±1.5
MMSS
n = 11
1.54 ±
0.223%
1.08 ±
0.208%
n.s.
(p=0.08)
*p<0.03;
r
2 =
0.2762
4.89 ±
1.782%
5.03 ±
1.607% n.s. n.s.
2.78 ±
0.528%
1.47 ±
0.273% *p<0.023 n.s.
spon-
taneous
n=7;
17.7±2.5
MMSS
n = 7
3.77 ±
0.268%
3.02 ±
0.467% n.s. n.d.
24.80 ±
7.723%
13.96 ±
2.897% n.s. n.d.
8.60 ±
1.734%
11.74 ±
2.059% n.s. n.d.
dRib
n=7;
17.7±2.5
MMSS
n = 11
18.83 ±
5.039%
17.56 ±
3.277%
n.s. n.d.
33.55 ±
5.018%
25.56 ±
7.176%
n.s. n.d.
18.42 ±
5.402%
25.51 ±
4.205%
n.s. n.d.
Dex
n=7;
17.7±2.5
MMSS
n = 12
3.55 ±
0.776%
4.02 ±
0.508% n.s. n.d. - -
Table 7. Apoptosis in lymphocyte subsets from AD-patients and elderly controls.RESULTS
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Bcl-2 content in lymphocytes from AD patients
The amount of the anti-apoptotic protein Bcl2 was measured by flow cytometry in the
different subsets of AD patients by triple staining. Elevated, however insignificant,
intracellular expression of Bcl2 could be determined in T cells of AD patients when compared
with non-demented elderly controls.
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Figure 43. Amount of intracellular Bcl2 in T, B and NK cells of AD patients and elderly
controls. T cells of AD patients show a trend to increased levels (CD3: AD, 6.52 – 0.635;
n = 11; control, 5.71 – 0.503; n = 16). B and NK cells showed no changes in Bcl2 levels
(CD19: AD, 6.12 ± 0.554; n = 11; control, 5.83 ± 0.637 n = 9; CD16+56: AD, 4.63 ± 0.227;
n = 9; control, 4.36 ± 0.434; n = 9).
To explore whether changes of Bcl2 expression in lymphocytes are involved in the
progression of AD, the amount of Bcl2 of each cell type was correlated against the Mini
Mental State Score of each individual. Interestingly, only T cells (dotted line) show a
significant relation to the cognitive capacity of the patients (CD3: *p<0.03, r
2 = 0.346, n =
11). No changes were detectable in B and NK cells.RESULTS
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Increased CD4
+/CD8
+-ratio in AD that correlates with the severity of the
dementia
An additional subset within the PBMC are the T cell subsets, or CD4 and CD8. The following
diagramm shows a normal distribution pattern of an aged non-demented individual.
T helper CD4
43%
T suppressor CD8
22%
B cells
10%
NK cells
25%
Figure 44. Constituents of PBMC including the T Cell subsets CD4 and CD8 of an
average elderly human.
There was a significant difference in the ratio of the T cell subsets, the CD4/CD8-ratio, which
correlates significantly with the severity of the dementia (**p<0.008). These data are in
concordance with other findings (Robinson Agramonte et al., 2001; Lombardi et al., 1999;
Shalit et al., 1995; Hu et al., 1995; Pirttila et al., 1992; Leffell et al., 1985).RESULTS
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Figure 45. The percentage of CD4
+ and CD8
+ lymphocytes was determined in whole
blood samples of elderly controls and AD-patients. There is highly significant
correlation of the CD4/CD8-ratio with the MMSS of each individual patient (n = 39,
**p<0.01). Compared with old controls, the ratio is significantly increased in demented
patients (controls: 1.68± 0.214; n = 16 vs. AD: 2.31± 0.237; n = 39; *p<0.05).
The absolute number of determined T helper and T cytotoxic/ suppressor cells did not differ
in demented persons, but there was a positive correlation between the MMSS and the number
of CD3
+ and CD4
+ cells per aliquot whole blood (*p<0.02). The fluorescence intensity of
stained receptors determined by flow cytometry is proportional to the number of surface
expressed receptors per cell. Here, a tendency to a decreased number of CD8-receptors was
determined in T cells from persons with DAT. Based on these data, it can be speculated, that
in dependence to the progression of the cognitive decline (measured as MMSS) changes in the
T cell subsets occur. The ratio of the T helper to the T suppressor cells significantly increases
and so does the number of activated T cells (cells displaying HLA-DR and CD95). Moreover,
number of T cells and expression of the CD8 receptor is altered in more severe demented
persons. Therefore, it should be controlled whether the apoptotic changes in AD are due to by
determining the content of apoptotic cells for each single subset.
First, changes of T lymphocyte subset apoptosis were determined in ‘healthy’ aging.RESULTS
102
Changes of apoptosis in T cell subsets, CD4 and CD8.
In concordance with earlier findings (see  Age-related changes in apoptotic cell death of
human peripheral blood cells), increasing basal levels of apoptotic cells within the CD4 and
the CD8 subset were found in aging (Figure 46 and Table 8), indicating an involvement of
both subsets in the aging process. Here again, we could detect large variances in the cells
from the aged group, indicating that immunosenescence affects each person individually.
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Figure 46. 7-AAD positive cells plotted vs. the age of each blood donors resulted in
significant correlation.
Spontaneous and dRib-induced apoptosis were increased in T lymphocyte subsets from
elderly persons. However, some data are only close to statistical significance (p = 0.06 –
0.08). That might be due to the small number of volunteers included, since the aim of this
study was mainly to validate and establish the method and to reproduce the former data
obtained by PI-staining in healthy aging.
CD95 mediated cell death was increased in both subsets. It is evident from our data that T
helper are more susceptible to this apoptotic pathway since CD4
+ lymphocytes express more
CD95/Fas-receptor compared to CD8
+ (data not shown).
In concordance with earlier results we found no difference in cell death after staurosporine
(data not shown) and dexamethasone treatment (Table 8).RESULTS
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young old CD4
+ lymphocytes CD8
+ lymphocytes
number of
volunteers
number of
patients
% apoptotic
cells from
young
persons
% apoptotic
cells in aged
persons
significance
(young vs.
aged)
correlation
with age; r
2
(number of
subjects)
% apoptotic
cells from
young
persons
% apoptotic
cells in aged
persons
significance
(young vs.
aged)
correlation
with age; r
2
(number of
subjects)
basal n = 11 n = 21 0.93 ±
0.312%
1.43 ±
0.161 %
n.s. p=0.06 *p<0.05; r
2=
0.0871 (34)
0.78 ±
0.190%
1.45 ±
0.221 %
*p<0.03 *p<0.04; r
2=
0.1602 (34)
spontaneous n = 9 n = 10 3.07 ±
0.223%
5.98 ±
0.990%
*p<0.05 *p<0.02; r
2=
0.1190 (24)
2.20 ±
0.242%
3.50 ±
0.795%
n.s. p=0.08 **p<0.01; r
2=
0.2152 (24)
dRib n = 6 n = 23 7.64 ±
3.805%
15.64 ±
2.478 %
*p<0.05 *p<0.05; r
2=
0.1084 (28)
7.10 ±
2.425%
14.83 ±
2.974%
*p<0.04 n.s. p=0.06
Dex n = 9 n =24 3.33 ±
0.748%
3.70 ±
1.302%
n.s. n.s. 4.33 ±
1.718%
6.03 ±
2.309%
n.s. n.s.
Fas-L n = 5 n =6 7.03 ±
1.294%
12.16 ±
2.110%
n.s. p=0.08 n.d. 4.36 ±
0.708%
8.82 ±
2.933%
n.s. n.d.
Table 8. Apoptosis in T lymphocyte subsets in physiological aging.RESULTS
104
Density of Bcl-2 in human T cell subsets in aging
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Figure 47. There was a significant reduction of Bcl-2 levels in CD8
+ cells in the aged
cohort (CD8, young: 6.45 – 0.476, n = 11 vs. old: 5.37 – 0.298, n = 15), while there were
no changes detectable in the T helper subset (CD4, young: 5.93 – 0.423; n = 11 vs. old:
5.88 – 0.382, n = 15).
Only CD8
+ lymphocytes showed altered Bcl-2 expression in aging. CD4
+ lymphocytes are
not affected (Figure 47). Determining the amount of Bcl-2 in all CD3
+ cells, there was a slight
reduction, possibly due to diminished mean fluorescence intensity (MFI) of Bcl-2 observed
for the T suppressor cells. No changes with aging were determined in B and NK cells (Figure
41). Excitingly, when the number of apoptotic cells per subsets was plotted against the MFI of
Bcl-2 for each subset, there was a positive correlation for the T-helper subset (Figure 48;
*p<0.05; r
2 = 0.316; n = 10). It could be speculated, that there is no significant dependency of
CD8
+ lymphocyte’s apoptosis on the Bcl-2 content of the sample.
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Figure 48. Expression of Bcl-2 significantly correlated with the percentage of apoptotic
cells in CD4
+ lymphocytes. Interestingly, no association was seen in CD8
+ cells.RESULTS
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Altered apoptosis in T cell subsets of AD patients
Clues that T cells of AD patients show impaired apoptotic behavior and Bcl2 expression were
shown in earlier findings of this thesis. Moreover, since AD patients show an increased
CD4/CD8-ratio it seemed to be reasonable to further explore apoptosis in the CD4 and CD8
subsets of T cells.
A) old non-demented control
B) patient with DAT
Figure 49. Representative dot-plots from 7-AAD stained freshly isolated PBMC from an
old (A) and an AD-patient (B). Basal apoptosis is dramatically increased in the CD4
subset, but the CD8 lymphocytes are affected as well.RESULTS
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Basal apoptosis was determined in PBMC of AD patients triple stained with antibodies raised
against CD4 and CD8 and the DNA dye 7-AAD. Representative dot plots of CD4- and CD8-
positive T cells of an AD patient and an elderly control are shown above (Figure 49).
Basal percentage of apoptotic T cells were enhanced in demented patients (Inset Figure 50;
CD4: AD, 2.29 – 0.247%; control, 1.43 – 0.161%, **p<0.003; CD8: AD, 1.63 – 0.306%;
control, 1.45 – 0.221%; n = 21 in each group). A clear increase is evident in CD4
+ cells from
AD patients. Interestingly, when all analyzed patients were pooled and plotted against
decreasing MMSS, there was a significant correlation for the CD8 subset (black line),
indicating an enhanced vulnerability of CD8
+ T cells with increasing dementia.
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Figure 50. Percentage of basal apoptosis of T helper lymphocytes (CD4) and cytotoxic T
suppressor cells (CD8) from AD-patients. CD8 cells show an enhanced vulnerability
with increased severity of the disease (*p<0.05; n = 21). CD4 cells do not show a
significant correlation with MMSS. Compared with cells d erived from elderly non-
demented persons, the content of apoptotic cells is significantly increased in T helper
lymphocytes. In contrast, in this cohort of AD-patients the percentage was nor elevated
in CD8 cells, although this parameter increases with dementia’s severity. This seems to
be due to the relatively high distribution of patients with quite high Mini Mental State
Scores (mean MMSS: 19.38 ± 1.27).RESULTS
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In addition, patients that carry the apoE4 gene show increased basal apoptotic levels in both T
cell subsets (CD4: non-ApoE4, 1.87 – 0.437%, n = 12; ApoE4, 2.41 – 0.398%, n  = 9; CD8:
non-ApoE4, 1.39 – 0.340%, n = 12; ApoE4, 1.78 – 0.366%, n = 9).
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Figure 51. AD patients positive for ApoE4 display enhanced basal levels of apoptotic
cells in CD4 and CD8 T cells.
Spontaneous and agent-induced apoptosis of T cell subsets are summarized in the following
table. In AD, CD8
+ cells become more vulnerable against spontaneous and Fas-L induced
apoptosis as the diseases proceeds. T helper cell apoptosis, induced with oxidative stress or
Fas-L, correlates significantly with MMSS. Dexamethasone and staurosporine (data not
shown) showed no effects on cell from AD patients that are altered from that of aged controls.RESULTS
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AD-patients old controls CD4
+ lymphocytes CD8
+ lymphocytes
number of
patients;
mean MMSS
number of
volunteers
% apoptotic
cells from
AD-patients
% apoptotic
cells in age-
matched
controls
significance
(AD vs.
controls)
correlation
with MMSS
% apoptotic
cells from
AD-patients
% apoptotic
cells in age-
matched
controls
significance
(AD vs.
controls)
correlation
with MMSS
basal
n = 26;
18.9 ± 1.15
MMSS
n = 21 2.26 ±
0.264 %
1.43 ±
0.161 %
**p<0.003 n.s. 1.68 ±
0.285 %
1.45 ±
0.221 % n.s. *p<0.05
spontaneous
n = 10;
17.0 ± 2.2
MMSS
n = 10 8.78 ±
1.369 %
5.98 ±
0.990%
n.s.
(p=0.053)
n.d. 3.73 ±
0.975 %
3.50 ±
0.795%
n.s. n.d.
dRib
n = 12;
17.6 ± 1.86
MMSS
n = 23 12.84 ±
2.027 %
15.64 ±
2.478 %
n.s. n.d. 9.45 ±
2.359 %
14.83 ±
2.974%
n.s. n.d.
Dex
n = 10;
17.4 ± 2.02
MMSS
n = 24 5.99 ±
1.655%
3.70 ±
1.302%
n.s.
(p=0.15)
n.d. 4.37 ±
1.340 %
6.03 ±
2.309%
n.s. n.d.
Fas-L
n = 5;
17.0 ± 3.03
MMSS
n = 6 25.80 ±
7.043 %
12.16 ±
2.110% *p<0.04 n.d. 11.15 ±
2.902 %
8.82 ±
2.933% n.s. n.d.
Table 9. Summary of apoptotic cells determined by 7-AAD staining of PBMC from AD-Patients and age-matched controls.RESULTS
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Bcl-2 content in lymphocytes derived from AD patients
A clear reduction of Bcl-2 content can be observed in CD4 and CD8 T cells of AD patients
with increased severity of cognitive impairment. For CD8
+ lymphocytes, there is a significant
correlation with decreasing MMSS. Thus, when all examined AD patients where compared
with aged healthy volunteers, CD4
+ cells showed elevated Bcl-2 levels, while CD8
+ are not
altered. Possible explanation might be the high number of AD patients in this cohort with a
relatively high MMSS that show high Bcl-2 expression. In the progression of the diseases, the
Bcl-2 content is clearly reduced (CD4, p = 0.065, r
2 = 0.117; CD8, **p<0.01, r
2 = 0.258; n =
21).
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Figure 52. A) Comparison of Bcl-2 expression of AD patient with elderly controls. B)
Splitting of the AD patient group into two with the MMSS of 20 as cut-off reveals that
Bcl2 expressing is significantly incraesed only in mild AD cases. With increasing
dementia the Bcl2 content of T lymphocytes decreases.
Interestingly, when the percentage of apoptotic cells is plotted against the mean fluorescence
intensity a significant correlation occurs for CD4
+ lymphocytes (CD4, **p<0.008, r
2 = 0.262;
n = 22), a similar pattern as already seen in aging (see Figure 48).RESULTS
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Figure 53. Matching with the data derived young and aged non-demented volunteers,
the number of apoptotic cells in CD4 lymphocytes of AD patients correlates the Bcl-2
content with. No correlation can be observed in CD8
+ cells.RESULTS
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Is the observed increased basal apoptosis of T cells from AD patients due to
activation-induced cell-death, a result of T cell activation?
The results of the above part of this thesis show that the T lymphocytes are mainly
responsible for the enhanced cell death observed in AD peripheral leukocytes. In this part, the
underlying mechanism be determined.
As mentioned in the introduction, apoptosis is important for termination of T cell activation.
After immune response, great number of T lymphocytes will die by programmed cell death.
Some cells will survive as memory T lymphocyte, showing enhanced recall indelibility. This
is a physiologically occurring phenomenon. To test whether this mechanism is accountable
for T cell apoptosis in AD, an experimental model to analyze several events of T cell
apoptosis was established.
Establishment of in vitro T cell activation in aging
T cell activation can be mimicked in vitro by mitogens, e.g. PHA-L. Lectins like PHA-L bind
to glycolysated proteins, as the TCR. TCR engagement induces the normal cascades of
activation, summarized in the following figure (Figure 54). First event that was measured is
phosphorylation of tyrosine residues 3 minutes after PHA treatment to analyze the amount of
autophosphorylation of TCR associated proteins and members of subsequent kinase cascades.
4 hours after start of mitogen treatment, expression of the early activation marker CD69 was
assesed. Expression of some T cell relevant cytokines was determined after over night
incubation and finally proliferation of the leukocytes was explored after 3 days in culture.
Tyrosine phosphorylation subsequent to TCR engagement declines with the donor's age
After TCR engagement the number of phosphorylated tyrosines raises as a consequence of the
induction of kinase cascades. Whole blood cultures were stimulated with PHA-L (10 µg/ml)
or remained untreated for 3 minutes at 37°C with gentle agitation. Cells were transferred
rapidly on ice in order to stop the reactions. Intracellular staining was performed as described.
A ratio was calculated from the mean fluorescence intensity of PHA-L stimulated and the
untreated cells.RESULTS
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Figure 54.  T cell activation pathways and mechanism of action of PHA-L and PMA/ Ionomycin that simulate antigenic stimulation in vitro.RESULTS
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The ratio of tyrosine phosphorylation of CD4
+ lymphocytes correlated significantly with the
donor’s age (***p<0.001; n = 30; open circles in). However, no statistically significant
correlation was found for the amount of phosphorylated tyrosine residues with aging in the
CD8 subset (p = 0.083; n = 30; open triangles in Figure 55). A comparison of the two age
groups revealed a highly significant reduction of the phosphorylated tyrosine-ratio in T helper
lymphocytes (CD4, young: 1.473 ± 0.065; old: 1.180 ± 0.283; ***p<0.001; n = 13-14; inset).
In CD8
+ cells levels of phosphorylated tyrosine were reduced as well, though not statistically
significant (CD8, young: 1.319 ± 0.063; old 1.209 ± 0.035; p = 0.074; n = 13-14; inset Figure
55).
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Figure 55. Phosphorylation of tyrosine residues upon PHA-L activation in aging. Whole
blood cultures were stimulated with PHA-L for 3 minutes at 37°C and intracellulary
stained with an antibody that detects phosphorylated tyrosine residues or an isotype-
control. Data are expressed as ratio of PHA-stimulated and unstimulated cells. The ratio
of phosphorylated tyrosines correlates significantly with the donor’s age in CD4
+ cells.
When the groups of young and aged donors were compared there was a significant
decrease of phosphorylated tyrosine residues in the group of old volunteers (inset). In
CD8
+ lymphocytes a tendency towards reduced levels could be observed with aging,
however, those changes are not significant.RESULTS
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CD69 expression upon PHA-L and PMA/Ionomycin stimulation decreases with aging
Whole blood cultures were prepared as described above and stimulated with 10 µg/ ml PHA-
L or 50 ng/ ml PMA and 200 ng/ ml Ionomycin. After 4 hours incubation leukocytes were
stained with CD3-PerCp, CD8-PE and CD69-FITC and further processed as indicated. Figure
56 shows a representative set of density plots 4 hours without stimulation (Figure 56, upper
panel) and with stimulation (Figure 56: PHA-L, middle panel and PMA + Ionomycin, lower
panel) from a young and an old representative individual. Left quadrants represent CD8
- cells,
e.g. CD4
+ lymphocytes, right quadrants show CD8
+ T cells. The upper quadrants show CD69
+
lymphocytes, those in the left are CD4
+CD69
+, and the ones in the right upper quadrant are
CD8
+CD69
+. Only CD3-positive cells were gated.
Basal levels of CD69 were quite low and not different between young and old humans (CD4,
young: 1.16 ± 0.22%; old: 1.14 ± 0.17%; CD8, young: 1.91 ± 0.52%; old: 1.75 ± 0.38%; n =
19-20). A reduction of CD69 expression after T-cell activation with PHA-L was determined
for both T-cell subsets in aging (CD4, young: 49.64 ± 2.64%; old: 39.59 ± 3.56%; *p<0.014;
CD8, young: 53.09 ± 2.86%; old: 42.28 ± 4.30%; *p<0.02; n = 19-20; Figure 57A).
The phorbolester PMA and the calcium ionophore Ionomycin bypass the T-cell receptor by
directly activating protein kinase C and by elevating the intracellular levels of Ca
2+. Levels of
activated cells were significantly increased after PMA and Ionomycin treatment in both
subsets and in both age groups when compared with PHA-L treatment (***p<0.0001; paired
Student’s t-test). CD8-cells derived from young donors show maximal CD69 expression after
PMA and Ionomycin treatment. Interestingly, CD4-lymphocytes are not able to respond to
this with the maximal capacity within 4 hours. CD69 expression decreases highly
significantly on CD8
+ cells and significantly on CD4
+ lymphocytes in aging (CD4, young:
85.25 ± 2.40%; old: 75.84 ± 3.3%; *p<0.025; CD8, young: 96.94 ± 0.66%; old: 92.46 ±
0.91%; ***p<0.001; n = 19 in each group; Figure 57B).RESULTS
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Figure 56. Density plots of CD69 expression at basal condition (upper panel) and after
activation with PHA-L (middle panel) and PMA and Ionomycin (lower panel) for 4
hours of a young and an old representative donor. Only CD3-PerCp-positive gated
leukocytes are displayed in the plot.RESULTS
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Figure 57. Expression of the early activation marker CD69 is reduced in aging. Whole
blood cultures were activated with either PHA-L or PMA/ Ionomycin for 4 hours at
37°C. Subsequently, cells were surface stained for CD3, CD8 and CD69. Only CD3
positive gated cells were analyzed for CD69 expression. (A) TCR engagement triggered
by PHA treatment revealed significantly reduced levels of CD69 expressing cells in aged
donors in both T cell subsets. (B) This pattern remained when the TCR complex was
bypassed with PMA/ Ionomycin, though the differences were not that large anymore.RESULTS
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Cytokine expression is reduced in lymphocytes derived from aged donors:
Whole blood cultures were incubated for 22 hours at 37°C in the absence (basal) or presence
of mitogenic activation (PHA-L or PMA/ Ionomycin). 16 hours before the cells were
harvested and stained, Brefeldin A was added to the cultures, in order to block the secretion of
the cytokines. Thus, the cytokines were plugged in the Golgi and can, therefore, be stained
with appropriate antibodies (Figure 58).
The percentages of cytokine expressing cells of both age groups are summarized in table 1.
Lymphocytes derived from aged donors (n = 9) showed reduced levels of IL2 and Tumor
Necrosis Factor-a (TNF-a) expression even basal but as well upon activation, when
compared with young controls (n = 10). In contrast, production of Interferon-g (IFN-g) was
significantly elevated in PHA-L activated cells from aged persons. Basal Interleukin-2 (IL2)
expression was not altered in lymphocytes from aged volunteers. Subsequent to stimulation
with PHA-L or PMA/ Ionomycin cells from old persons tend to display reduced levels of IL2
expressing cells. As a T H1 cytokine IL2 is mainly expressed in CD4
+ T lymphocytes. In
addition, levels of IFN-g, were determined. Here, the percentage of basal IFN-g producing
lymphocytes was not altered in lymphocytes from aged donors. Upon stimulation with PHA
cells from old donors displayed significantly more IFN-g positive cells in both T cells subsets
when compared with old controls. Bypassing the TCR with PMA/ Ionomycin revealed the
largest amounts of IFN-g. However, changes between the age groups were not significant.
Finally, the percentage of TNF-a positive cells was determined. The T helper subset showed
age-related differences in the basal expression of TNF-a. In the CD8
+ population those
changes were not that evident. Mitogenic activation of the cells tends to effect age-related
changes more in the CD8 than in the CD4 subset.RESULTS
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Figure 58. Plots of cells intracellulary stained for IFN-g after stimulation with PHA for
22 hours. Secretion of cytokines was blocked by brefeldin A treatment for 16 hours.
Only CD3-PercP-positive gated leukocytes are displayed in the dot plot. Left quadrants
represent CD8
- cells, e.g. mainly CD4
+ lymphocytes, right quadrants show CD8
+ T cells.
The upper quadrants show IFN-g
+ lymphocytes, those in the left are CD8
- IFN-g
+, and
the ones in the right upper quadrant are CD8
+.RESULTS
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CD4
+ CD8
+
basal PHA-L PMA/ Ionomycin basal PHA-L PMA/ Ionomycin
young 1.43 ± 0.88 11.48 ± 5.95 30.80 ± 4.51 0.30 ± 0.20 4.95 ± 3.29 15.67 ± 7.21
IL-2
old 1.29 ± 0.64 5.17 ± 1.36 22.74 ± 4.33 0.41 ± 0.35 0.51 ± 0.90 10.13 ± 5.72
young 0.70 ± 0.34 0.89 ± 0.35 6.50 ± 1.35 1.40 ± 0.90 3.56 ± 1.24 16.38 ± 4.25
INF-g
old 0.25 ± 0.12 2.21 ± 0.35** 11.91 ± 5.31 0.47 ± 0.33 8.76 ± 1.30** 19.79 ± 3.04
young 3.22 ± 1.76 4.27 ± 1.68 31.91± 6.49 3.80 ± 1.91 8.05 ± 3.10 38.88 ± 12.20
TNF-a
old 0.14 ± 0.07* 5.52 ± 3.01 25.50 ± 14.21 1.15 ± 0.71 4.17 ± 1.52 19.42 ± 7.86
Table 10. IL2, IFN-g, and TNF-a cytokine expression in lymphocytes from young and old donors. Data is expressed in % cytokine
expressing cells (means ± S.E.M.). Whole blood cultures were stimulated either with PHA-L or PMA/ Ionomycin as described or remained
untreated (basal) for 22 hours. Brefeldin A was added 16 hours prior harvesting the cells. Leukocytes were surface stained for CD3 and
CD8, fixed and permeabilized. Staining with fluorochrome-coupled antibodies against IL2, IFN-g, TNF-a, or isotype-control identified
cytokine expressing cells. **indicates p<0.01 compared to young controls; *indicates p<0.05 compared to young controls.RESULTS
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Lymphocyte proliferation is significantly reduced in aging
72 hr after preparation of the whole blood cultures and stimulation, leukocytes were stained as
indicated above. Preliminary experiments showed that stimulation for 3 days and BrdU-pulse
for 24 hours are optimal conditions for this purpose. Figure 59 shows representative density
plots from a young and an old individual after PHA-L stimulation (10µg/ml).
young old
Figure 59. Dot plots of BrdU-incorporation upon stimulation with PHA-L taken from a
representative young and old subject. Cells were stained with an isotype antibody as
control or with an antibody raised against BrdU to explore the content of proliferating
cells. Only CD3-PercP-positive gated leukocytes are displayed in the dot plot. Left
quadrants represent CD8
- cells, e.g. CD4
+ lymphocytes, right quadrants show CD8
+ T
cells. The upper quadrants show BrdU
+ lymphocytes, those in the left are CD4
+BrdU
+,
and the ones in the right upper quadrant are CD8
+BrdU
+. After 72 hr PHA-L activation,
the T lymphocytes from the young individual clearly shows more cells positive for anti-
BrdU staining than the T cells from the old person does.
When proliferation was induced by activation with PHA-L via TCR ligation, T cells derived
from young donors incorporated significantly more BrdU within 24 hours than cells from
elderly persons did, indicating a higher proliferation (CD4, young: 24.75 ± 1.98%; old: 16.07
± 1.92%; **p<0.005; CD8, young: 42.21 ± 3.81%; old: 19.86 ± 1.76%; ***p<0.0001; n = 22-
25;  Figure  60A). By circumventing the TCR complex with PMA and Ionomycin the
significant decrease of BrdU-positive cells in aging was still evident, though not thatRESULTS
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obviously (CD4, young: 33.43 ± 2.84%; old: 24.35 ± 2.99%; *p<0.023; CD8, young: 50.70 ±
5.05%; old: 27.85 ± 2.86%; ***p<0.001; n = 22-25; Figure 60B). It is noteworthy that in both
age groups the proliferative activity of the T lymphocytes was mainly triggered by the CD8
subsets.
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Figure  60. Proliferation according to activation decreases in lymphocytes of aged
donors. (A) PHA-L stimulated cells show a markedly increased proliferation in the CD8
subset compared to CD4 positive lymphocytes. In aging the number of BrdU-
incorporating cells is significantly reduced in both subsets. (B) Activation subsequent to
PMA/ Ionomycin treatment showed as well a higher percentage of proliferating cells
within the CD8 subset. Moreover, lymphocytes from young donors revealed significantly
elevated levels of BrdU positive cells when compared with old controls.RESULTS
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Altered T cell activity in AD
To determine whether T cell activation of AD patients is comparable with that of elderly
persons in the sense of immunosenescence, the established methods were used to analyze T
cell reactivity in Alzheimer’s disease.
Increased ratio of phosphorylated tyrosine residues in AD in both T cell subsets
Whole blood cultures of AD patients and elderly non-demented controls were stimulated with
PHA-L or remained untreated for 3 minutes at 37°C as described above.
The ratio of tyrosine phosphorylation of CD4
+ and CD8
+ lymphocytes from patients with AD
was significantly increased compared to controls (CD4, AD: 1.362 – 0.0420, n = 6 vs. control
1.180 – 0.0283, n = 13; **p<0.01; CD8, AD: 1.435 – 0.1361, n = 6 vs. control: 1.209  –
0.0349, n = 13; *p<0.05; Figure 61).
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Figure  61. Ratio of phosphorylated tyrosine residues in AD-patients and elderly
controls. In demented patients the ratio is significantly higher for both T cell subsets,
indicating that mechanisms, like the uncoupling of the CD4-receptor that occurs in
aging, do not seem to be evident here.
CD69 expression is enhanced in AD upon TCR ligation and even when bypassing the TCR
Whole blood cultures were prepared as described above and stimulated with 10 µg/ ml PHA-
L or 50 ng/ ml PMA and 200 ng/ ml Ionomycin.
Basal levels of CD69 were unchanged in AD and elderly controls (CD4, AD: 0.87 – 0.284%,
n = 22 vs control: 1.196 – 0.282%, n = 18; CD8, AD: 2.33 – 0.537%, n = 22 vs. control : 4.64RESULTS
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– 2.810%, n = 18). A reduction of CD69 expression after T-cell activation with PHA-L was
determined for both T-cell subsets in healthy aged volunteers when compared with AD
patients (CD4, AD: 46.12 – 3.382%, n = 18 vs. control: 39.59 – 3.558%, n = 19; CD8, AD:
53.44 – 4.971%, n = 18 vs. control: 42.28 – 4.300%, n = 19; *p<0.05; Figure 62A).
When bypassing the T-cell receptor by directly activating protein kinase C with PMA and by
elevating the intracellular levels of Ca
2+ with ionomycin, levels of activated cells were
significantly increased in AD after PMA and Ionomycin treatment in both subsets. (CD4, AD:
83.13 – 2.764%, n = 19 vs. control: 75.84 – 3.300%, n = 14; *p<0.05; CD8, AD: 95.64 –
0.887%, n = 19 vs. control: 92.46 – 0.913%, n = 14; *p<0.05; Figure 62B).
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Figure 62. In concordance with the elevated phosphorylation-ratios observed above, the
percentage of T cells, expressing the activation marker CD69 after 4 hours of
stimulation, is significantly increased in AD-patients. The upper bar graph represents
the wholeblood cultures after stimulation with PHA-L, the lower one after activation
with PMA and Ionomycin.RESULTS
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Disproportionate lymphocyte proliferation in AD
When proliferation was induced by activation with PHA-L via TCR ligation, T cells derived
from AD patients incorporated significantly more BrdU within 24 hours than cells from
elderly healthy persons did, indicating a higher proliferation. In contrast, CD8
+ AD
lymphocyte show significantly decreased proliferation (CD4, AD: 25.98 – 2.288%, n = 18 vs.
control: 16.070 – 1.919%, n = 25; **p<0.01; CD8, AD: 16.66 – 1.523%, n = 20 vs. control:
23.59 – 3.066%, n = 25; *p<0.05; Figure 63A). By circumventing the TCR complex the
significant changes of BrdU-incorporation were not evident anymore, only a slight tendency
(CD4, AD: 30.94 – 3.421%, n = 18 vs. control: 24.35 – 2.991%, n = 22; CD8, AD: 26.21 –
2.501%, n = 19 vs. control: 38.82 – 5.375%, n = 22; Figure 63B).
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Figure 63. The percentage of proliferating cells within the T helper and T suppressor
subsets after stimulation with PHA-L (A) and PMA and Ionomycin (B) in AD and
elderly non-demented controls. Increased CD4 and decreased CD8 cell proliferation
might be a possible explanation for the altered CD4/CD8-ratio in AD.RESULTS
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Suitability of murine lymphocytes to study age-related changes and effects of
FAD-associated mutations on apoptosis
In this thesis, enhanced vulnerability to cell death in AD was found and, moreover, earlier
findings revealed perturbed calcium homeostasis in peripheral lymphocytes from AD patients
(Parshad et al., 1996; Eckert et al., 1997a, 1998, 2000a; Gasparini et al., 1998). In order to
close the gap between studies using neuronal cell lines transfected with PS1 mutations,
neurons from mutant PS1 transgenic animals and peripheral cells of AD patients, lymphocytes
from mice transgenic for FAD-specific PS1 mutations were investigated.
Accordingly to demonstrate that enhanced apoptosis in aged humans is related to the aging
process and not due to presymptomatic Alzheimer’s disease, the basal and oxidative stress-
induced apoptosis in lymphocytes from young and aged mice to exclude changes associated
with AD were investigated. To monitor the protective efficacy of potential therapeutic drugs
in preclinical studies, the effects of the Ginkgo biloba extract EGb761 on murine lymphocyte
apoptosis were studied in vitro and ex vivo in young and aged mice. The rationale for the
pharmacological intervention study is as follows: EGb761 is a potent antioxidant and has
already been shown to inhibit apoptosis in tissue culture experiments  (Ni et al., 1996;
Ahlemeyer et al., 1999; Bastianetto et al., 2000a) and oxidative stress in general (Kose et al.,
1997; Pietri et al., 1997). Its effectiveness in Alzheimer’s disease has been demonstrated by
recent trials (Kanowski et al., 1996;(Le Bars et al., 1997).
Age-related changes of apoptosis in murine lymphocytes: Similarities to
human aging
Basal levels of apoptotic nuclei
T cells were isolated from the spleens of young (3 months) and old (24 months) mice. To
reduce activation or cell death of T cells during the isolation procedure, B lymphocytes were
removed by magnetic beads in order to leave the T cells untouched. Basal DNA fragmentation
assessed immediately after isolation of the cells was analyzed by propidium iodide (PI)
staining. Fluorescence intensity was plotted against number of counts. Significantly increased
basal apoptotic levels could be determined in freshly isolated spleen cells from old mice (2.18
± 0.23% apoptotic cells; n = 13) compared to young mice (1.77 ± 0.26%; n = 9; *p<0.05;
Figure 65A).RESULTS
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Figure 64. 2-deoxy-D-ribose (dRib) induces DNA-fragmentation demonstrated by DNA-
ladder formation in murine spleen cells.  Apoptotic cell death pattern in murine
lymphocytes under basal conditions (immediately after isolation, 0 hours), levels of
apoptotic cells are too low, to give a detectable DNA ladder formation. After 24 and 48
hours incubation with dRib, a massive apoptotic endonuclease activity occurs, which is
evident by cleavage of chromosomal DNA between the nucleosomes producing oligomers
of 180 basepairs (typical “DNA ladder”).
Oxidative stress enhances the age-related differences in apoptotic cell death
2-deoxy-D-Ribose (dRib) depletes the intracellular pool of reduced glutathione thereby
promoting states of enhanced oxidative stress inside the cell (Ceruti et al., 1997; Barbieri et
al., 1994). Here it was demonstrated that dRib is able to induce apoptosis as well in murine
lymphocytes. To further confirm the apoptotic nature of cell death, DNA laddering of nuclear
fragmentation was assessed in murine T cells from individual mice.  Figure  64 shows a
representative experiment.
T cells of the spleen from young and old mice were incubated for 24 hours in the presence of
10 mM dRib. Spontaneous in vitro apoptosis (young: 25.15 ± 0.67% vs. old: 26.42 ± 1.65%)
of cells incubated over the same period with medium alone was subtracted in order to reveal
ROS/oxidative stress-induced apoptosis. Induction of oxidative stress revealed age-related
changes in programmed cell death. A significant increase towards higher apoptotic levels was
0 h   24 h  48 h
500 bp
200 bp
1000 bpRESULTS
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found in spleen cells of aged animals (old: 7.90 – 1.55%; young: 2.21 – 0.45%; **p<0.01; n =
9-13 in each group; Figure 65B).
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Figure 65. Basal (A) and dRib-induced (B) apoptosis in T cells of young and old mice.
Percent sub-G0 DNA content (termed as apoptotic cells) in freshly isolated lymphocytes
derived from young (3 months of age, white bars) and old (24 months of age, gray bars)
animals are shown. A) Apoptotic cell death was determined immediately after isolation,
B) cells were incubated for 24 hours at 37°C in the presence of dRib (10 mM). Data are
means ± S.E.M.; n = 9-13 per group, *p<0.05; **p<0.001.
Comparison from murine peripheral blood mononuclear cells (PBMC) with murine
spleenocytes
To compare these findings with results in studies from human PBMC (see:  Basal and
spontaneous apoptosis are increased in lymphocytes from elderly subjects), murine PBMC
were isolated according to standard procedures and basal, spontaneous and dRib-inducedRESULTS
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apoptosis was determined. dRib-induced apoptosis was calculated by subtracting the
spontaneous apoptosis. The results are summarized in the following table (Table 11).
young old significance
basal apoptotic levels 0.79 ± 0.21% 0.99 ± 0.31% n.s.
spontaneous in vitro
apoptosis
9.37 ± 1.58% 15.63 ± 2.91% *p<0.05
10 mM dRib-induced
apoptosis
7.17 ± 0.5% 17.8 ± 0.74% ***p<0.001
Table 11. Basal, spontaneous and dRib-induced apoptosis in murine PBMC, n = 10 per
group.
No differences in basal levels were found. In contrast, spontaneous and ROS-induced
apoptosis after 24 hours in vitro was clearly enhanced in cells from aged mice. Compared
with lymphocytes from the spleen, murine PBMC are less vulnerable to apoptotic cell death
In vitro effects of EGb761 on ROS-induced apoptosis in spleen cells from young and
old mice
To determine the protective potential of Ginkgo biloba extract on ROS-induced apoptosis in
vitro, freshly isolated spleen cells from young and old mice were co-incubated with various
doses of EGb761 and 10 mM dRib for 24 hours. The level of ROS-induced apoptosis (dRib
alone) occurring after 24 hours of any individual animal was taken as 100% (full apoptotic
effect). The percentage of basal apoptosis from freshly isolated lymphocytes was set as 0%
(Figure 66). Ginkgo biloba extract decreased dRib-induced apoptosis at concentrations above
10 µg/ml. Interestingly, EGb761 provides greater protective properties in cells from aged
animals. 250 µg/ml and 500 µg/ml revealed a significant reduction of apoptosis in aged mice
compared to young mice. Since absolute levels of dRib-induced apoptosis are higher in
lymphocytes from old animals (Figure 65B), these findings demonstrate that cells from old
mice specifically benefit from EGb761 treatment. In lymphocytes from young mice the
reduction was less pronounced than in elderly animals. Two-way ANOVA revealed
significant differences between mice groups and treatment with EGb761 (10-500 µg/ml;
p<0.05).RESULTS
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Figure  66. Prevention of ROS-induced apoptosis by increasing doses of EGb761.
Percentage of apoptotic lymphocytes after 24 hours without EGb761 treatment were set
100%. Basal apoptosis of freshly isolated spleen cells was defined as 0%. The anti-
apoptotic effects of EGb761 concentrations over 250 µg/ml differ significantly between
the to age groups (n = 3 per group, **p<0.01; *p<0.05).
Ex vivo effects of EGb761 on ROS-induced apoptosis in young and old mice
In order to explore the effect of  Ginkgo biloba extract on chronically treated cells and to
determine its ex vivo anti-apoptotic function, we treated young and old mice with EGb761 in
0.2% agarose or with agarose alone as placebo over a period of 2 weeks. The dose used (100
mg/kg) has been previously shown to improve learning deficits in aged mice  (Stoll et al.,
1996). After 14 days of treatment, mice were killed by cervical dislocation and spleens were
prepared as described above. No effect of EGb761 on basal apoptosis could be seen in both
groups (young: placebo; 1.77 ± 0.26%; EGb761, 1.76 ± 0.28%, n = 9 per group; old: placebo,
2.18 ± 0.23%; EGb761, 2.19 ± 0.31%, n = 13 per group), indicating no direct in vivo effect of
EGb761 on physiological apoptosis. In contrast, ex vivo ROS-induced apoptosis triggered by
treatment with dRib was significantly reduced in the placebo group of young animals
(placebo: 100.0 ± 3.10%; EGb761: 79.80 ± 3.58%; n = 9 in each group; ***p<0.001; Figure
67A). Interestingly, as already shown by our  in vitro experiments, lymphocytes from old
animals r evealed a significant (EGb761old: 55.55 ± 10.65% vs. EGb761young: 79.80 ±
3.58%; *p<0.05) greater protection by the plant extract than cells from younger mice did (old,RESULTS
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placebo: 100.0 ± 23.51%; EGb761group 55.55 ± 10.65%; n = 13 per group; 
+p<0.05; Figure
67B).
0
25
50
75
100
125
A)  young B)  old
*p<0.05
***p<0.001
placebo    EGb761 placebo   EGb761
%
 
f
u
l
l
 
a
p
o
p
t
o
t
i
c
 
e
f
f
e
c
t
Figure 67. Effect of oral EGb761-treatment on ROS-induced apoptosis in spleenic T
cells from young and old mice. Young A) and old B) female NMRI mice were treated
with 100 mg/kg EGb761 or vehicle (placebo) orally for 2 weeks. T cells were isolated
from the spleens and incubated with 10 mM dRib for 24 hours. Mean levels of dRib-
induced apoptosis of the placebo group were set 100% (100% full apoptotic effect).
Basal apoptosis of freshly isolated spleen cells was defined as 0%. A) In spleen cells from
young animals, ROS-induced apoptosis was diminished by EGb761 by about 20% when
compared with placebo treated mice (n = 9 per group, ***p<0.001). B) In cells derived
from old mice this effect was even more amplified. Apoptosis was reduced by about 45%
in the EGb761-treated group, though levels fluctuated more in aged animals, that results
in a lower significance (n = 13 per group, *p<0.05). However, cells from aged mice
revealed a significant greater benefit from EGb761-treatment than lymphocytes of
young animals did (placebo old (B) vs. placebo young (A): 
+p<0.05).RESULTS
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Transgenic animal models for AD
Impact of mutant PS1 to apoptosis of peripheral lymphocytes
Three different types of trangsgenic mice were generated by N. Touchet and C. Czech (Rhone
Poullenc/ Aventis Pharma, Vitry-Sur-Seine, France) and kindly donated to our labaratory.
Genetic engineered mice were either expressing a human wildtype Presenilin-1 (PS1 wt)
transgene or a PS1 transgene expressing either a single pathogenic mutation at codon M146
(PS1 M146L) or multiple FAD-specific mutations M146L + H163R + A246E + L286V +
C410Y (PS1 M5), since the combination of different PS1 mutations shows additive effects on
Ab1-42 secretion (Citron  et al., 1998). Transgene expression is under the control of the
human HMG-CR-promotor which represents a housekeeping-type promotor that shows a
strong and ubiquotious expression  pattern with high expression in neurons (Czech et al.,
1997; 1998). Transgenic and non-transgenic animals were littermates or subsequent
generation siblings and are therefore strain matched. PS1 transgenic mice showed normal
growth and development, and revealed no apperenet behavioural changes compared to
littermate controls. As shown by other studies, transgenic mice overexpressing mutant PS1
show an elevation in Ab42, however they do not develop amyloid deposits by 24 months of
age (Chui et al., 1999; Czech et al., 1998). In order to assess whether human PS1 is expressed
in peripheral cells of transgenic mice, a Western Blot analysis of spleenocytes homogenates
from transgenic and nontransgenic animals was performed. The blot was probed with a
monoclonal antibody against the N-terminal part of human PS1. The proteolytic expression
against of transgenic PS1 is different between the constructs. The characteristic N-terminal
fragment of PS1 is detectable in cells of mice expressing PS1 wt and PS1 M146L with the
appearance of small amounts of full-length PS1 M146L most likely due to saturation of
processing events as d escribed previously in transgenic mice and rats expressing high
amounts  of PS1 (Czech et al., 1998; Thinakaran et al., 1996). However, multiple mutations in
PS1 M5 resulted in a clear reduction in the N-terminal fragment and accumulation of full-
length PS1. This is most likely due to saturation of processing since the levels of PS1 M5
expression are lower than the levels of PS1 wt or PS1 M146L. Instead, the accumulation of
full-length protein suggests that PS1 M5 has severe structural alterations which make it no
longer a substrate for the PS-cleaving protesases.RESULTS
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Figure 68. Western Blot analysis of PS1 expression in spleenocytes (left blot) and
homogenated brains (right blot) from transgenic mice (lane 1, PS1 M5; 2, PS1 M146L;
3, PS1 wt) and non-transgenic littermate controls (lane 4).
control PS1 wt PS1 M146L PS1 M5
female 10 4 2 2
male 8 7 8 6
S 18 11 10 8
Table 12. Number and sex of transgenic and control mice included in the study.
Basal, spontaneous and agent-induced apoptosis was determined in enriched T lymphocytes
from the spleen (CD3
+ cells approximately 85%) from transgenic mice and littermate
controls.RESULTS
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Figure 69. Basal apoptotic cells of spleenic T cells from different PS1 transgenes. Cells
derived from mice with single and multiple mutations of PS1 show an elevated
percentage of apoptotic cells compared with PS1 wt and littermate control.
Freshly isolated lymphocytes from mice expressing mutant PS1 (PS1 M146L and PS1 M5)
stained with PI showed significantly enhanced basal levels of apoptotic cells compared to T
cells from PS1 wt transgenic (tg) and non-transgenic (non-tg) littermate controls (Figure 69).
Mutant tg mice exhibited a twofold increase in basal apoptosis. These findings could be
confirmed by our laboratory in an additional assay detecting cytosolic nucleosomes built
during apoptotic cell death (Eckert et al., 2001b).
Next, in vitro apoptosis after 2.5 and 24 hours incubation was determined. Lymphocytes from
PS1 M5 tg mice showed significantly enhanced vulnerability to spontaneous  in vitro
apoptosis when compared with that of T cells from PS1 wt tg and non-tg control mice,
whereas the vulnerability of the single mutation PS1 M146L was not markedly increased.
(Figure 70). The difference in vulnerability of T cells from PS1 M5 tg mice to apoptotic cell
death was not salient anymore 24 h after ex vivo conditions (data not shown; Eckert et al.,
2001b). Again, multiple mutations in PS1 showed much more apoptotic cells than cells from
PS1 wt tg and control mice did.RESULTS
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Figure 70. Spontaneous apoptosis after 2.5 hours in vitro. PS1 M146L displays elevated
levels of apoptosis, though not significantly compared with PS1 wt. Cells with PS1 M5
transgene are significantly elevated compared with wildtype protein. Interestingly, cells
derived from non-tg control mice display significantly increased levels compared with
PS1 wt, indicating a possible protective effect of overexpressed wildtype PS1.
APP/PS1 double transgenic mice
Mice bearing a triple mutation in the human APP gene were kindly donated by C. Czech and
mated in our breeding facility with PS1 M146L tg mice, in order to generate mice that show
AD like brain pathology at an age of 6 months (Moussaoui  et al., 2000). The offspring
consisted of tg mice with human mutated PS1 (PS1 M146L), human APP695SDL alone,
double transgenes (PS1 M146L x APP695SDL) or non-tg littermates, as confirmed by genomic
PCR (see methods, Figure 23). Those four different constructs were compared with PS1 wt
mice. Apoptosis was determined by 7-AAD-staining, to distinguish between apoptosis in CD4
and CD8 cells.RESULTS
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controls PS1 wt PS1 M146L APP695SDL
PS1 M146L x
APP695SDL
female 0 0 3 3 0
male 6 6 3 3 6
Table  13. Number and sex of transgenic animals and non-transgenic littermates
included in the study. All mice were at an age of 3 to 4 months.
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Figure 71. Basal apoptosis in T cell-enriched spleenocytes derived from transgenic mice
with either a mutated APP or PS1 transgene, or both, PS1 wt and non-transgenic
controls. White bars on the left represent CD4
+ cells, dotted bars on the right are CD8
+
cells. In concordance with the data from human T lymphocytes derived AD patients, the
FAD-associated pathogenic mutation display significantly elevated levels of basal
apoptotic cells. The increase of apoptosis is more evident in T helper cells (compare with
Figure 50 and Table 9).
Moreover, spontaneous, ROS- and dexamethasone induced apoptosis was assessed by 7-
AAD-staining after 24 hours in vitro.RESULTS
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Figure 72. Spontaneous apoptosis of transgenic mice after 24 hours culture in vitro.
White bars on the left hand represent CD4 cells, dotted on the right are CD8.
Pathogenic FAD-associated mutations display dramatically increased levels of apoptotic cells,
especially in CD4
+ cells, in concordance with findings from PBMC of AD-patients (see Table
9).
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Figure 73. ROS-induced apoptosis in spleenocytes from transgenic mice. Only T hepler
lymphocytes (white bars) display significantly elevated levels compared with controls.
CD8
+ cells from FAD-associated mutations (dotted bars) transgenes are increased,RESULTS
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though changes are not significantly altered. These data are in concordance with
findings in PBMC from AD-patients (see Table 9).
Enhanced vulnerability to ROS-induced apoptosis seems to be mainly restricted to mutant
PS1. Mice carrying the mutant APP do not show increased apoptotic values upon dRib
treatment.
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Figure  74. Dexamethason-induced apoptosis in spleenocytes from transgenic mice.
Pathogenic FAD-mutation are more vulnerable against cell death induced by
glucocorticoids. T
 helper cells (white bars) are more involved than CD8
+ lymphocytes
(dotted bars).
It is noteworthy that PS1 wt tg mice show decreased apoptotic features compared to littermate
controls (see Figure 71- Figure 74), indicating a probably anti-apoptotic role of overexpressed
PS1. This finding will be further explored in the subsequent experiments (see next chapter).
Antiapoptotic action of PS1 C-terminal fragments
Familial Alzheimer’s disease is predominantly connected with mutations in the Presenilin
family. Presenilin (PS) 1 and 2 have been shown to be involved in apoptosis. Recently, it was
found that ALG-3, a truncated form of PS2 rescued T-cells from Fas-induced cell death (Vito
et al., 1996), whereas overexpression of the full-length not proteolytic processed PS1 and PS2
enhances apoptosis. Presenilins are substrates of caspases. Caspase mediated cleavage of PS1
occurs between aspartate 345 and serine 346 (Grünberg et al., 1998).RESULTS
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In previous experiments (see APP/PS1 double transgenic mice) reduced apoptosis of spleen T
lymphocytes derived from PS1-transgenic mice compared to their non-transgenic littermate
controls was found. The transgenes carry their endogenous murine PS1 and additionally under
the control of the HMG promotor the human PS1. Therefore, tg PS1 wt mice express higher
amounts of total PS1 compared with non-tg controls. However, Western blot analysis
revealed that PS1 is processed normally in tg mice (Figure 76), whereas overexpression under
a strong promotor in cell lines often limits proteolytic capacity thereby leading to enhanced
apoptosis due to full-length PS1 (Kim et al., 2001). To further analysis the molecular basis of
this observed anti-apoptotic behavior in T cells from PS1 wt tg mice, a construct that encodes
a 531 bp fragment of PS1 and is analogously to ALG-3, named PS1short (PS1s, Met
292 -
Ile
467) and a construct, that encodes the C-terminal fragment processed by caspase cleavage,
named PS1Cas (Figure 78), were generated and transfected into Jurkat T cells and compared
with cells transfected with PS1 wt, PS2 wt and ALG-3 . Apoptosis was induced by Fas-ligand
engagement.
Figure 75. Membrane topology of PS1. Arrows indicate constructs of PS1 and C-
terminal fragments.RESULTS
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In lymphocytes from PS1-transgenic mice, it was observed that that spontaneous apoptosis is
significantly reduced in CD4
+ T-cells from PS1-transgenic mice compared to non-transgenic
littermate controls (Figure 77), the basal apoptotic levels showed clear tendency, but were not
significantly altered (data not shown).
Figure 76. Western blot analysis of spleenocytes derived from PS1-transgenic (PS1) mice
and littermates (lt) controls. By blotting with an N-terminal-specific antibody it is
obvious, that cells from PS1-tg express much more PS1 than lt, which only express their
endogenous PS1.
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Figure 77. Spontaneous apoptosis after 24 hr ex vivo is significantly decreased in CD4
+-
spleenocytes of PS1-transgenic mice when compared with littermates controls,
indicating a protective effect of additional PS1 during apoptosis.
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Protein analysis by western blotting revealed the existence of short PS1 fragments (~13 kDa)
when cells undergo apoptotic cell death (Figure 78). We hypothesized that this fragment
derived from casapse cleavage of PS1 during apoptosis. This fragment, termed PS1Cas, is
much more prominent in PS1 wt-transgenic animals than in littermate controls, though it is
produced in detectable amounts.
Figure 78. Western blot analysis of spleenocytes derived from PS1-transgenic (PS1) mice
and littermates (lt) controls. Blotting with a C-terminal-specific antibody small fragment
can be detected after induction of apoptosis. In wt-tg more fragments can be detected.
In order to investigate this fragment and its effects on apoptosis, several constructs encoding
full-length PS2, ALG-3, full-length PS1, and PS1s (a PS1-analoug to ALG-3; see Figure 75)
were generated and transfected into Jurkat T-cells. Apoptosis was induced with Fas-ligand for
4 and 24 hours. An additional construct was designed encoding the C-terminal fragment of
PS1 up to the considered caspase-cleavage site, named PS1Cas. Transfection and induction of
apoptosis in Jurkat cells showed that this fragment provides the same antiapoptotic action like
PS1s and ALG-3 (Figure 79). Fas-L induced apoptosis can be clearly diminished by C-
terminal fragments of PS2 (ALG-3) and PS1 (PS1s and PS1Cas) by about 40%.
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Figure 79. Apoptosis 4 hours after Fas-ligand treatment in Jurkat cells transfected with
PS1, PS2, PS1s, and ALG-3. PS1 and PS2 show slight protective effects against apoptosis
while the C-terminal fragments diminish significantly apoptosis by 40% when compared
with vector transfected cells. Basal levels are not significantly changed. After 24 hours
Fas-ligand treatment, changes between the different transfected constructs are not
significant (data not shown).
Figure 80. Transfection of Jurkat cells with PS1Cas and induction of apoptosis by Fas-
ligand. Apoptosis was measured after 4 hours by PI-staining and FACS analysis.
PS1Cas provides the same anti-apoptotic properties as PS1s.RESULTS
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The proteolytic cleavage of the presenilins and the generation of the C-terminal fragment
seems to play an important anti-apoptotic feedback mechanism in programmed cell death.
Several mutants interacting with the proteolytic processing are known to be involved in
familiar to Alzheimer’s disease.
Analysis of Presenilin-1 carrying a mutation at site D345A (D = aspartate was mutated to A =
alanine by site-directed-mutagenesis) are currently under investigation. Aspartate is needed as
recognition motif for most caspases. If cleavage of aspartate 345 by caspases is essential to
form this anti-apoptotic fragment (PS1Cas), cells carrying that mutation should not show any
decrease in apoptotic level.
Presenilins are involved in the Notch-cascade, playing an important role in fetal development.
However, the biological relevance of this antiapoptotic feedback for developmental processes
and in AD remains to be elucidated.DISCUSSION
143
DiscussionDISCUSSION
144
The present thesis demonstrates that Alzheimer’s disease and familiar Alzheimer’s disease-
related mutations have a significant impact on apoptosis of peripheral lymphocytes in patients
and transonic mice. To determine these changes from those present in ‘healthy’ aging,
programmed cell death was assessed in PBMC from young and elderly volunteers.
Previous results of our and other group reported an increased content of basal and dRib-
induced apoptotic cells in PBMC from patients with Alzheimer's disease relative to age-
matched controls (Eckert et al., 1998; 2001a; Lombardi et al., 1999). This effect is probably
not related to the physiological process of immunosenescence. In addition, apoptosis is a
hallmark in brains derived from Alzheimer's patients, possibly associated with states of
increased oxidative stress (Cotman et al., 1995; Simonian and Coyle, 1996; Tritschler et al.,
1994; Yamatsuji et al., 1996). Similar alterations could also be detected in peripheral cells of
AD patients (Mecocci et al., 1997; Parshad et al., 1996). In order to understand the specific
contribution of AD to the enhanced susceptibility of lymphocytes to apoptosis it is of
particular importance to know first the role of normal aging without dementia. Therefore, in
this thesis the age-related apoptotic behavior of peripheral human lymphocytes and the role of
oxidative stress were explored.
Altered apoptosis of peripheral lymphocytes in aging
Age-related differences in the vulnerability to cell death were clearly shown. Basal levels of
apoptotic nuclei in freshly isolated PBMC are significantly elevated in the group of aged
donors compared to younger ones. In parallel, basal levels of reactive oxygen species are
similarly increased in aging (Leutner, 2001). PBMC and activated CD3
+ lymphoblasts from
elderly subjects have an enhanced susceptibility to spontaneous and activation-induced  in
vitro apoptosis. This enhanced vulnerability is probably not related to a decline in IL2
production (Phelouzat et al., 1997) but must be correlated with an increased basal expression
of activation markers (e.g. CD95, CD25, CD69, HLA-DR) and higher levels of ROS. Usually,
apoptotic cells are eliminated quite fast after generation. A higher percentage of basal
apoptotic levels in aged human PBMC could indicate an impaired phagocytosis of these cells
in the aging organism. Thus even basal apoptotic levels might reflect a mild stimulation of the
cells due to the isolation procedure. The content of Bcl-2 slightly raises in peripheral cells
with aging. Moreover, other investigators and our laboratory could show that resting
peripheral blood cells do not express large amounts of Bcl-2 at all, but the content of Bcl-2DISCUSSION
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increases significantly after activation with PHA-L and IL-2  (Reed  et al., 1992). Basal
amounts of Bcl-2 correlate with the content of basal apoptotic cells in aging. Since Bcl-2 is a
physiological apoptosis inhibitor, it could be possible that cells prone to undergo apoptosis
express higher amounts of Bcl-2 as a defending mechanism. Therefore, it appears not to be
surprising that apoptotic cells display more Bcl-2 at basal levels. Activated lymphoblasts
displayed the more Bcl-2 the younger the donor was. These data implicate a strong correlation
between lymphocyte's functionality concerning activation and the donor age. It seems that the
decreased amount of Bcl-2 in activated lymphoblasts in aging might be one factor
contributing to immunosenescence.
This higher susceptibility to apoptosis in aging might be due to an enhanced production and/
or not satisfactionally elimination of reactive oxygen species in aging, thereby leading to
apoptosis. Mitochondria are the major site, where free oxygen radicals are produced. In aging,
mutations accumulate in mtDNA, due to its near vicinity to radical formation (Mecocci et al.,
1994). The mutant mtDNA leads to mitochondria with impaired respiratory function
(Anderson et al., 1998; de Grey, 1997). In addition, ROS act as intracellular messenger and
mediate lymphocytes activation  (Dalton  et al., 1999) as well as apoptosis  (Buttke and
Sandstrom, 1994) by interacting with redox-sensitive transcription factors like NFkB.
Reduced glutathione (GSH) is an important antioxidant factor in the cell. Depletion of
intracellular GSH inhibits T-cell function (Droge et al., 1994). Recently, it could be shown
that the levels of GSH decrease in aging in human lymphocytes (Wieshout and Peters, 1998).
The sugar 2-deoxy-D-ribose provokes oxidative stress in cells probably by depleting the
intracellular levels of reduced glutathione (Kletsas et al., 1998). It is involved in the formation
of free radicals  (Ceruti  et al., 1997), as it significantly elevates the level of ROS in
lymphocytes compared to untreated controls (Leutner, 2001). The apoptotic process initiated
with dRib can be blocked with N-acetyl-L-cysteine (NAC) a potent radical scavenger
(Schindowski et al., 1999). Therefore dRib is a useful tool to simulate oxidative stress in
human lymphocytes as shown by (Eckert et al., 1998). Here, it was found that with increasing
donor age, peripheral blood cells could cope worse with oxidative stress induced by
incubation with 10 mM dRib. Compared to spontaneous apoptosis, dRib induced apoptosis
increases more with age. A possible cause for this finding could be the decreased levels of
GSH found in aging lymphocytes (van Lieshout and Peters, 1998). It can be concluded that
the less GSH a cell contains the higher is the susceptibility to apoptosis induced by 10 mM
dRib. Moreover, dRib induces significantly higher levels of ROS in PBMC derived from agedDISCUSSION
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donor compared to younger ones. However, higher concentrations of dRib induce rather more
necrosis, but still apoptosis but the content of apoptotic cells induced by this stimulus did not
correlate with age. Interestingly, the percentage of 50 mM dRib induced apoptotic cells
correlates significantly with the content of lymphocytes basal expressing the activation
markers CD25, CD95 and HLA-DR. Apoptotic cells induced with lower concentration of
dRib (10 mM) did correlate as well with the expression of CD25. Correlation of 10 mM dRib
with CD95 and HLA-DR could not be done as their expression is age-related as well and is
therefore linearly related. It seems that dRib leads activated cells more in apoptosis than
resting cells, maybe by a different mechanism, providing a powerful tool to explore
lymphocyte apoptosis.
It is important to note that the age-related increased susceptibility of PBMC to dRib was not
found for staurosporine. Staurosporine-induced elevation of ROS  (Leutner, 2001)  and
staurosporine-induced apoptosis were not different in young or aged lymphocytes.
Staurosporine produced comparable levels of ROS as dRib did (Leutner, 2001). However, due
to the involvement of caspases in staurosporine-induced death signaling upstream of ROS
(Krohn et al., 1998), higher levels of apoptotic cells were reached in young as well as in old
subjects when compared to dRib-induced apoptosis. Staurosporine-mediated ROS serve rather
as a second messenger (Buttke and Sandstrom, 1994) and GSH is primarily not affected.
Obviously, only certain specific become mechanisms disturbed in aged lymphocytes.
In concordance to other groups it was found, that the basal expression of functional CD95
increases with age (Lechner et al., 1996; Phelouzat et al., 1997). We determined expression of
CD95 surface molecule as well as its function with an agonistic antibody leading to apoptosis-
specific DNA fragmentation. T lymphocytes from young donors expressed CD95 by about
12% less compared to elderly individuals, while only 0.3% of PBMC of young subjects
displayed apoptotic morphology after 24 hours of incubation with anti-CD95. In the group of
aged genders apoptosis could be induced in about 2.3% of the PBMC. These data implicate
that most of the expressed CD95-molecules on CD3
+ cells are not fully functional, maybe due
to a lack the FADD-protein (Fas-associated death domain). In aging, the number of functional
CD95 expression raises. This data concerning expression of CD95 on native CD3
+
lymphocytes are consistent with the findings of Phelouzat et al.  (1997), who reported that
enhanced susceptibility to apoptosis of T lymphocytes from elderly is associated with
increased expression of CD95-receptor. The frequency of CD95
+ cells may rise through
adulthood, but go on to decrease in certain but not all subsets in old age (Aspinall et al.,DISCUSSION
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1998). The amount of soluble Fas in the blood of elderly donors was also reported to be
significantly increased compared to young donors (Seishima et al., 1996). Moreover, several
studies have shown increased CD3- or PHA-mediated AICD in the elderly (Phelouzat et al.,
1996; Lechner et al., 1996, Potestio et al., 1998). This was found not to be due to IL 2
deprivation, nor was it associated with decreased Bcl-2 expression (Phelouzat et al., 1996).
Apoptosis in human subesets in aging
When analyzing the PBMC’s subsets, apoptosis is increased at basal levels in T-, B- and NK-
lymphocytes. In addition, in this small cohort investigated, only T cells show significant
changes concerning spontaneous apoptosis in aging. Depletion of GSH by dRib amplified the
age-relaed effects nicely in T and NK cells, however, in B cells treatment with dRib induces
as well necrosis, therefore levels of apoptotic cell death seemed to be apparently lower in
elderly than in young controls. Thereof, it can be concluded that all lymphocyte subsets are
affected by aging, however, the T cell subset seems to be particularly involved, concerning
apoptosis.
The aging process does not significantly alter the amount of Bcl-2 in the subsets.
Nevertheless, a positive correlation was observed when plotting Bcl-2 content versus the
percentage of apoptosis for each subset.
Basal, spontaneous and ROS-induecd apoptosis of the T cell subsets CD4 and CD8 correlated
significant with the donor’s age, indicating the close association of T cell apoptosis with age-
related changes. Moreover, both subsets seem to be effected in the same manner, indicating
that healthy aging influences T cells in general and no subset is preferred by these changes, in
contrast to AD. Therefore, it is interesting that the amount of anti-apoptotic Bcl-2 decreases
significantly only in CD8
+ cells with aging. In addition, a similar correlation as observered for
B cells was detected for CD4 T lymphocytes when plotting Bcl-2 content versus percentage
of apoptotic cells. It can be, therefore, speculated that B and CD8
+ T cells are responsible for
the same correlation seen in whole PBMC using ELISA technique (see  Figure  32). The
mechanisms and biological relevance for this finding remains to be elucidated.
Another recent study examining CD95 expression in the elderly found increased levels of
expression of both Fas and Fas-ligand on CD4 and CD8 cells, and these did not seem to
decrease at more advanced age (Agarwal and Gupta, 1998). In the Aggarwal study but not in
the Aspinall study the CD95 changes were noted on CD45RO
+ (e.g. memory) cells as well,DISCUSSION
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together with decreased levels of Bcl-2 and correspondingly increased levels of CD95
antibody-triggered apoptosis in all subsets with increased CD95 expression (Agarwal and
Gupta, 1998). In a different system, in which T cells were stimulated by PHA and cultured
with IL-2 for up to 6 days, apoptosis (not induced by CD95 mAb) was reported to be
increased in CD45RO
- but not RO
+ cells in the elderly compared to the young (Herndorn et
al., 1997). It was therefore suggested that differential susceptibility to apoptosis late after T
cell stimulation might contribute to explaining the preponderance of CD45RO
+ cells in the
elderly, although the differences actually measured in these studies were minimal.
Consistent with the findings of increased susceptibility to AICD ex vivo, CD4
+ T cell clones
aged in culture also become i ncreasingly susceptible to AICD (Pawalec  et al., 1996).
Moreover, although T cell lines derived from old donors upregulated CD95 more slowly than
those derived from young donors, their loss of ability to downregulate CD95 occurred faster,
resulting in more rapidly increased susceptibility to Fas-mediated apoptosis (Lechner et al.,
1996). However, the idea that increased levels of AICD are detrimental to functioning of the
immune system must be reconciled with data from several sources suggesting an age-
associated increase in resistance to apoptosis on the part of cells from various tissues
including lymphocytes. It was suggested that some of the manifestations of aging on the
immune system were related to downregulated apoptosis (Zhou et al., 1995). Some further
supporting data for the concept of decreased apoptosis in aged cells may be found in the
report of Lechner  et al. (1996) who found decreased inducibility of CD95 after CD3-
stimulation of old persons´ T cells compared to young. However, susceptibility to AICD of T
cell lines established from old donors was greater than those from young donors (Lechner et
al., 1996). Culture-aged CD4+ T cell clones show enhanced AICD compared to young cells
from the same clone, although they do not express higher levels of CD95 (Pawelec et al.,
1996).
In conclusion, aging leads to quite specific changes of the susceptibility of human
lymphocytes for programmed cell death. This knowledge will allow getting a more detailed
information about the additional changes taking place in AD.DISCUSSION
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Altered apoptosis in lymphocytes of aged mice and impact of antioxidative EGb761
treatment
In the present thesis, it was confirmed that lymphocytes derived from old mice are also more
vulnerable to dRib-induced apoptosis than lymphocytes from young mice. Proposing that
dRib exhausts the glutathione pool, cells that generate more ROS should be more prone to
apoptosis. Since apoptosis is significantly elevated in dRib treated cells from elderly mice,
one can conclude that lymphocytes derived from old animals as compared with young, either
generate more ROS during metabolism or are more sensitive to ROS. However, higher
sensitivity of old animals to dRib can not excluded.
Apoptosis is an important aspect in the aging processes in many tissues including brain and
immune system. Enhanced oxidative stress seems to be one major causal factor. Enhanced
vulnerability to oxidative stress-induced cell death has been found in this thesis for h uman
lymphocytes in aging as well as in Alzheimer’s disease (Eckert et al., 1998; 2001a). In order
to finally confirm the role of the aging process per se, we determined additionally basal,
spontaneous and ROS-induced apoptosis in lymphocytes of young and aged NMRI mice. In
addition, the influence of the radical scavenger Ginkgo biloba extract EGb761 on apoptosis
was studied in vitro and ex vivo after treatment over 14 days.
Basal levels of apoptotic lymphocytes increase only slightly with aging, most likely because
apoptotic cells are eliminated quite fast by phagocytotic cells. In concordance, it was shown
in this thesis that basal apoptosis of human PBMC revealed also only small changes in aging,
indicating either an increased incidence of basal apoptosis or decreased elimination of
apoptotic cells in aging. Moreover, it could be clearly demonstrated that spleen lymphocytes
are much more susceptible to cell death than PBMC.
By contrast, spontaneous apoptosis was more clearly elevated in PBL derived from aged
mice, suggesting that indeed enhanced vulnerability of the lymphocytes to apoptosis is
involved.
ROS occur as physiological intermediates in aerobic metabolism and are usually eliminated
inside cells by antioxidant pathways that require reduced glutathione (GSH) for regeneration.
dRib provokes oxidative stress in cells. There are growing evidences that the underlying
mechansim is diminishing the intracellular levels of GSH (Kletsas et al., 1998) and it seems to
be therefore involved in the formation of free radicals (Ceruti et al., 1997). Depletion of GSH
makes the cell defenseless against elevated levels of ROS, which can trigger the cell to
undergo apoptosis by DNA damage or directly act as second messengers in the apoptoticDISCUSSION
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pathway. Buttke and Sandstrom (1994) found that apoptosis in lymphocytes is often mediated
by ROS, considering that already low concentrations of peroxides can initiate apoptosis.
Therefore, dRib represents a useful tool to generate intracellular oxidative stress in
lymphocytes (Barbieri et al., 1994; Eckert et al., 1998). In the present thesis, it was found that
lymphocytes derived from old mice are more vulnerable to dRib-induced apoptosis than
lymphocytes from young mice. Proposing that dRib exhausts the glutathione pool, cells that
generate more ROS should be more prone to apoptosis. Since apoptosis is significantly
elevated in dRib treated cells from elderly mice, one can conclude that lymphocytes derived
from old animals as compared with young, either generate more ROS during metabolism or
are more sensitive to ROS. However, a higher sensitivity of old animals to dRib can not be
excluded.
Several  in vitro studies using primary neurons in tissue culture have already shown that
EGb761 can protect from oxidative stress-induced cell death (Bastianetto et al., 2000b; Chen
et al., 1999; Ahlemeyer et al., 1999; Ni  et al., 1996). The presented results confirm and
extend these findings by demonstrating that the protective effect of EGb761 is (1) also seen in
fully differentiated lymphocytes in vitro and (2) can also be observed after ex vivo treatment
where it seems to take place at lower concentrations. Moreover, these experiments reveal that
EGb761 treatment has a higher protective effect in cells derived from elderly animals and that
the degree of protection is similar in vitro and in vivo. In paralell, our laboratory demonstrated
that dRib enhances significantly the levels of ROS in peripheral lymphocytes isolated from
aged humans (findings of S. Leutner published in: Schindowski et al., 2000). Therefore, one
might speculate that the percentage of prevention by EGb761 is greater, as more radicals
generated by dRib can be eliminated. Even more important, apoptotic mechanisms needed for
the physiological elimination of cells (basal apoptosis) were not affected by the EGb761
treatment. This fact may be relevant to the physiological role of programmed cell death in
carcinogenesis, development, and homeostasis of immune system. However, “pathological
apoptosis” e.g. apoptosis induced by an additional stimulus, which seems to mimic enhanced
oxidative stress in pathological conditions like Alzheimer disease, can be significantly
prevented by Ginkgo treatment. Thus, the findings not only demonstrate that enhanced
vulnerability to oxidative stress-induced apoptosis is a common feature of aged lymphocytes,
but also that EGb761 might specifically interfere with this pathological mechanism, leaving
physiological aspects of programmed cell death rather unaffected.DISCUSSION
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Based on these findings, lymphocytes seem to represent a suitable model system for
monitoring drug effects on cell death mechanisms in further preclinical and clinical studies
using EGb761 or other antioxidant drugs.
Immunogerontology
In order to explore the rationale for incraesed apoptosis and several other altered features in
PBMC of AD patients, T cell functionality should be assesed in physiological aging first to
compare these findings with impaired changes evident in AD.
The incidence and severity of infectious disease is increased in the elderly. The relative
mortality rates of many infectious diseases in the elderly are more than twice those of the
young (Yoshikawa, 1997). Autopsy data on the very old suggest that the accepted prime age-
associated causes of death in the "younger old" (ie. cardiovascular, cancer) do not necessarily
apply to the very old. Studies from Leiden, Geneva and Tokyo have found the prime cause of
death to be i nfectious disease in the over 80´s (however, whether these were really
opportunistic infections is still not clear). An extensive study on major causes of death in
Japan suggests that unlike those causes showing deceleration or neutrality with advancing
age, those showing acceleration in old age (ie. pneumonia, influenza, gastroenteritis,
bronchitis) mostly involve infectious agents (Horiuchi and Wilmoth, 1997).
The decline of immune function with aging has been a subject in various studies, reviews, and
comments. However, unfortunatly most studies focus on only one event after mitogenic
activation, so that a novel whole blood activation assay was established in this thesis.
T lymphocyte-mediated immunity includes the primary immune response, effector functions
and immunological memory.  In vivo the primary immune respons begins usually in the
peripheral lymphoid organs when naive T cells are stimulated by professional antigen-
presenting cells (APCs). This step provides cell-cell contact, antigen recognition and
costimulatory signals and results in activation into effector cells and in generation of memory
cells, those cells that are not eliminated to teminate immune response. Reexposure (re-call) of
memory T cells to same or similar (cross-reactive) antigen causes a rapid effector response.
The T cell receptor complex (TCR) on T lymphocytes is involved in antigen recognition is
composed of a number of glycoproteins. The TCR is a heterodimer, usually (on 95% of all T
cells) consisting of an a and a b chain, linked via a disulphide bond. These molecules are
structurally related to immunoglobulins, having a variable (V) and constant (C) region. The VDISCUSSION
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region forms a domain that contains the antigen-binding site of the T cell receptor (Weir DM,
1999). The TCR complex is responsible for the recognition of specific mjor histocompatibility
complex (MHC)/antigen complexes and will be different for every T cell clone. However,
other membrane molecules are needed to form the functional TCR. On of these is the CD3
complex, that is present on all T cells and is involved in proper signal transduction through
TCR. Cytoplasmic residues are susceptible to phosphorylation. CD4 and CD8 molecules are
necessary for functional signaling and restrict binding of T cells to MHC I- (CD8) or MHC II-
positive cells (CD4).
TCR engagement, that was mimicked here by the lectin PHA-L that is believed to be quite
similar to that taking place in the organism, results in phosphorylation of tyrosine-residues
mediated by Src and Zap-70-family members  (Weiss and Littman, 1994), followed by
activation of Ras and Raf/MAP kinase cascade and PLC-g (phospholipase-g) that interacts
with PKC (protein kinase C). Gene expression is induced by the rapid inactivation of IkB-a
and subsequent nuclear migration of active NF-kB dimers  (Kuo and Leiden, 1999).
Ras/Raf/MAP kinase activation leads to oligomerization of Fos and Jun that form the
transcription factor AP-1. In addition, IP3 concentration raises due to PLC activity and
proceeds to release of Ca
2+ from intracellular stores. Elevated Ca
2+ levels initiate the
phosphatase calcineurin, which dephosphorylates the transcription factor NF-AT, thereby
becoming active (Janeway and Travers, 1995). Treatment of lymphocytes with phorbol ester
(PMA) plus Ionomycin bypasses the TCR engagement by direct interaction of the PMA with
PKC and by increasing the intracellular Ca
2+ levels due to ionophore Ionomycin. Altered T
cell functionality due to impaired TCR function and/ or decreased TCR-complex expression
should be avoided by PMA plus Ionomycin regimen (see summary in Figure 54).
A significantly decreased number of total T lymphocytes in CD3 and in the CD4 and CD8
subsets in aged humans was observed. However, the CD4/CD8-ratio remained unchanged
with aging. The enhanced incidence of apoptosis seen in physiological aging might be
associated with the decreasing number of CD3
+ cells with advanced age. A lack of T cells
may be one of the numerous causes of immunosenescence, since fewer cells providing
immune function are available to maintain immune homeostasis. In agreement with our
findings, a dramatical decrease of lymphocyte count has been observed during the last 3 years
before death in a prospective study (Bender et al., 1986).DISCUSSION
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Soluble CD8 receptor is a marker for T suppressor cell activation  (Lenkei  et al., 1998).
Reduced density of CD8 receptor on T suppressor cells from elderly could be related with
increased levels of soluble CD8. Interestingly, in neurological disorders like DAT increased
levels of soluble CD8 are involved as well (Singh, 1994).
Due to thymic involution, however, the number of untouched CD4 and CD8-cells declines
with increasing age and with the number of infections during life. Unprimed cells carry the
CD45RA isoform of the CD45-receptor, while memory cells express the CD45R0 epitope
(Vitetta et al., 1991). However, no significant changes of the CD4/ CD8 ratio with aging were
found (O’Leary et al., 1988; Yen et al., 2000). This is an interesting fact as some neurological
disorders (DAT and MS, for instance) show increased CD4/CD8-ratios (Shalit et al., 1995;
Crucian et al., 1995).
Mitogenic activation of T cells leads to the phosphorylation and activation of p56
lck kinase.
p56
lck associates with CD4 and CD8 costimulatory receptor molecules  (Abraham, 1991).
Here, it was shown that tyrosine phosphorylation was age-related decreased in CD4
+ cells.
CD8
+ lymphocytes display insignificantly reduced phosphorylation ratios. Recently, an
altered association of p56
lck with coreceptors such as CD4 was found in the elderly (Tinkle et
al., 1998), suggesting that alterations in p56
lck tyrosine kinase and its association with CD4
may underlie lowered T cell function during aging.
Moreover, in earlier studies of our laboratory lowered Ca
2+ mobilization after mitogenic
stimulation with PHA-L in lymphocytes derived from aged individuals (Eckert et al., 1997a;
1997b; 1998b) was determined.
CD69 was formerly known as activation inducer molecule (AIM) and is a 60-kDa
glycosylated costimulatory molecule for T lymphocyte proliferation, which is expressed after
ligation of CD3/T cell receptor complex. Although the physiological role of CD69 is still
unknown, crosslinking of CD69 induces proliferation. Expression of CD69 in T cells is
dependent on appropriate activation of several intracellular signaling pathways including IP3
production, increases in intracellular Ca
2+ and the activation of Ras/Raf-1/MAP kinase
pathway (Perfetto et al., 1997). In concordance with Rutella et al. (Rutella et al., 1999), this
thesis revealed that CD8
+ cells display more CD69-expression after PHA-L activation for 4
hours than CD4
+. CD4
+ and CD8
+ lymphocytes derived from aged persons had reduced CD69
surface expression compared to young ones. After treatment with phorbol ester and Ca
2+
ionophore, the expressed amount of CD69 was significantly higher than after TCR
engagement in both age groups. Moreover, a significant age-related difference in expressionDISCUSSION
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of CD69 was evident when bypassing the TCR complex with PMA and Ionomycin. These
data indicate that impaired expression of the activation marker CD69 in aging by engagement
and even by bypassing the TCR. However, reduced activation of lymphocytes from elderly
humans seems therefore not to be only due to lower expression of CD3 and/ or followed by
reduced signal transduction  (Fulop  et al., 1995) after TCR l igation, but also age-related
diminished transcription might be involved in our findings (Whisler et al., 1996).
Many earlier reports using different techniques to determine serum levels of cytokines
indicate that the lymphocyte’s response to mitogens is impaired in aged subjects
(Bruunsgaard et al., 2000a; Nagel et al., 1988; Murasko et al., 1986). In this study, we could
only detect a tendency of lymphocytes from young donors to produce more IL-2. However,
due to large standard derivation we could not show significant age-related differences with
this method. The relevance of decreased production of IL2  (Barcellini  et al., 1988;
Rabinowich  et al., 1985) in aging, the major growth factor for T cells, remains unclear.
However, this thesis revealed no changes in CD25 (a-chain of the IL2 receptor) expression
with aging. The role of interferons in aging is not clear yet. Decreased levels of interferons
(IFN-a and –g (Miller, 1980; Lio et al., 2000)) were found by some laboratories while other
investigators determined increased levels (Fahey  et al., 2000; Sakata-Kaneko et al., 2000;
Yen  et al., 2000). In addition, our data are in concordance with the latter showing that
activated T cells of both subsets from elderly individuals produced more IFN-g than from
young controls. The serum concentration of the inflammatory cytokine TNF-a increases with
aging (Bruunsgaard et al., 2000b). However, it remains to be elucidated which cells secrete
more TNF-a in the elderly. An increased activity of monocytes and macrophages (Sadeghi et
al., 1999; Han  et al., 1995) or NK cells  (Solana and Mariani, 2000), observed in aged
individuals, could be responsible for elevated levels of TNF-a as well. Moreover, in
neurological disorders that are related to neuroinflammation and increased activity of glial
cells, elevated levels of TNF-a and IL6 are detected as in DAT  (Singh, 1994) and in
parkinsonism (Dobbs et al., 1999).
A decreased amount of transcription factors (AP-1, NFkB and NFAT) have been observed in
aged individuals (Trebilcock and Ponnappan, 1996), resulting in fewer transcription of genes
after mitogenic activation. Since not only protein levels but as well mRNA levels of IL2 are
decreased in aging  (Barcellini  et al., 1988; Nagel  et al., 1988), reduced activation of
transcription factors surely is another aspect in immunosenescence.DISCUSSION
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Decline of immune function with increasing age is not restricted to T lymphocytes: several
groups reported of impaired B cells function  (Burns  et al., 1993; Paganelli  et al., 1992;
Antonaci et al., 1985; Hijamns et al., 1984). However, we could show that aging effects CD4
+
cells that interact with B lymphocytes. A defective T helper activity might contribute to an
altered B cell functionality and could account as one aspect for the altered humoral activity
associated with aging (Guidi et al., 1998). Natural Killer lymphocytes are supposed to be
involved in immunosurveillance against tumors and in viral defense. Their age-related
changes in activity are still controversly discussed through literature (Murasko et al., 1986b),
but most studies show increased activation of NK cells with advancing age. In the present
thesis a significant correlation with donor’s age of the percentage of NK cells within the
lymphocyte population was determined.
However, despite the findings discussed above, it remains the case that the precise clinical
relevance of T cell immunosenescence is hard to define. Indeed, there are studies suggesting
that the NK status of subjects may also be important or more important than T cells. Ogata et
al. reported that not the numbers but the functional activity of NK cells was a parameter
correlating with death (due to infection) in the follow-up period for 44 elderly subjects (1997).
Moreover, inclusion of T cell functional parameters has been shown to predict mortality in a
Swedish prospective study (Ferguson et al., 1995).
In most aging studies in human, individuals > 60 years are commonly considered "old".
Longitudinal studies are required to establish the critical changes within the immune system
and what may be associated with "healthy aging". There may be surprises, as in the recent
report that in the over-85´s, high cholesterol levels were associated with greater survival over
a ten-year follow-up (Weverling-Rijnsburger et al., 1997). Studies of the very old (i.e. the
survivors) may also be informative. Centenarians may be considered to be that very small
proportion of successfully aged individuals. Healthy centenarians are indeed found to have
well-preserved immune functions, much more similar to the "young" immune system than
average for less extremely old donors. Thus, as summarized by Franceschi (Franceschi et al.,
1995), T cell proliferative responses are well-maintained (albeit taking place more slowly),
the T cell repertoire still contains all Vß families, hematopoiesis is maintained, autoantibodies
are absent, and interestingly, there is a high level of lymphocyte genomic stability (low
spontaneous breaks etc., which otherwise are thought to increase with age in average, non-
centenarian, donors (King et al., 1994)).DISCUSSION
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The composition of the T cell compartment changes during aging as a result of antigen
exposure, clonal expansion and contraction, regulatory T cell interactions and memory cell
formation, and changed thymic output. Thus, many studies have addressed the question of
whether the numbers and proportions of T cells and other lymphocytes are altered during
aging. In general, alterations in numbers of T cells are relatively small and may be influenced
by underlying disease (Remarque and Pawalec, 1998), although not all studies agree on this
(Huppert et al., 1998). It is probably true to say that all in all, the consensus is that age-
associated alterations in T cell numbers are minimal (Pawelec, 1999). However, age-
associated changes in the proportions of T cell subsets have been repeatedly documented in
rodents and humans. Mice seem to show a relative loss of CD4 cells in the blood with age
compared to CD8 cells (Miller, 1997), and the same tendency may be true in humans,
although the small reduction in CD4 cells is also associated with poor nutritional status
(Masari and Lesourd, 1998). Accumulating evidence suggests that even where the overall
numbers of T cells are not obviously changed, and even within a particular T cell subset as
characteriazed above, there may be further age-associated alterations in terms of the
specificities of the TCR expressed. For example, whereas the TCR2 repertoire of CD4 cells in
mice was initially reported not to be obviously changed compared to young cells, the CD8
repertoire was found to be markedly altered in early reports, suggesting expansion of a small
number of CD8 cells during aging (Callahan  et al., 1993). In human, early reports also
indicated that it was the CD8 cells rather than the CD4 cells which were primarily affected in
this way. Thus, in CD8
+ but not CD4
+ T cells, up to 30% of the entire population may consist
of oligo- or even monoclonal cells expressing the same TCR-Vß markers (Possnett et al.,
1994). Within the CD8+ cells, these oligo- or monoclonal populations are prevalent in the
CD28-negative subset (Possnett et al., 1994) and the CD57-positive subset, which essentially
overlaps with the CD28-negatives (Battliwalla et al., 1996). It is interesting to note that it is
this CD28
-CD8
+ subpopulation which was identified many years ago as containing so-called
"suppressor" cells (Damle  et al., 1983). These data may explain the observation that
alterations in proportions of different T cell subsets may also be more marked in CD8+ than
in CD4+ cells of aged humans (Hoshino et al., 1993). However, this phenomenon seems not
be absolutely limited to CD8 cells (Crisi et al., 1996).
Depressive illness and affective disorders are associated with immune and cytokine alterations
(Zaharia et al., 1993; Irwin et al., 1987). Reductions of lymphocyte response to PHA and inDISCUSSION
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vitro IL2 production are effects of repeated stress in rats  (Batuman  et al., 1990). The
neurodegenerative disorder itself has proven effects on central and peripheral immune
competent cells as well (Eckert et al., 2001a; Garibaldi and Zhang, 1999). In this thesis it was
shown that the CD4/CD8-ratio of Alzheimer’s disease patients significantly correlates with
disease’s severity (measured as cognitive decline). Since there is no change of the ratio of T
helper to T suppressor cells associated with aging, the impact of the pathological increase of
CD4
+ cells and the decrease of CD8
+ cells seen in DAT should be further explored.
In conclusion, the age-related modifications of human peripheral lymphocytes are important
in order to elucidate additional changes taking place in neurological diseases of geronto-
psychiatric patients.
Increased apoptosis of peripheral lymphocytes from AD-patients
Earlier findings of our group indicate enhanced apoptosis in PBMC from AD patients
compared to elederly non-demented controls (Eckert et al., 1998; 2001a). One aim of this
thesis was to verify these results with different methods and to investigate the underlying
mechanisms. In order to understand the specific contribution of AD to the enhanced
susceptibility of lymphocytes to apoptosis it is of particular importance to determine the
cellular origin of the increased cell death. Apoptosis is regulated by genes that are expressed
in neuronal and non-neuronal cells. Accordingly, the enhanced vulnerability of lymphocytes
to apoptosis in AD patients might be due to a dysregulation of apoptosis-relevant genes or
related mechanisms, lowering the sensitivity threshold for apoptosis.
Basal, spontaneous and Fas-L induecd levels of apoptotic nuclei, analyzed with PI, were
significantly elevated in PBMC in AD. So, the findings by Eckert et al. (1998; 2001a) were
confirmed with a different cohort of AD patients and controls and with another method (flow
cytometry) to determine apoptosis, indiacting that the older findings were not limited to this
patient cohort or nucleosome ELISA.
Moreover, there was a significant correlation with the severity of the dementia: the lower the
cognitive performance of the patient was, the higher were the percentage of apoptotic PBMC.
This defect itself appears not to be sufficient to lead to a pathological leukopenia in AD
patients (see Table 4), probably since lymphocyte can be rapidly restored.
These data raises the questions why do PBMC of AD display more basal apoptotic cells and,
moreover, why are the cells more vulnerable to spontaneous and Fas-L induced cell death, as
well. What evoiremental conditions or genetical factors make the cells going into apoptosis?DISCUSSION
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First, it was essential to find out, if all cells of the PBMC (T-, B-, and NK-lymphocytes and
monocytes) were effected or only some subsets show this impaired behaviour.
Monocytes show in vitro an adherent form to plastic vessels, indicating that they are hardly
detectable by flow cytometry, using polypropylene (PP) tubes. Staining with CD14 mAb, as a
marker for myelotic cells, revealed that monocytes can be found in PBMC by flow cytometry
only in traces, though monocytes/ macrophages are obvious visible in the microscope, before
subjecting to the PP tubes (data not shown). Therefore, the flow cytometric-analyzed PBMC
consist mainly of lymphocytes, namely T-, B-, and NK-lymphocytes. For these reasons,
samples of AD patients, young and elderly controls were analyzed for apoptotic cell death for
each lymphocytes subset. All subsets showed typical age-related changes, however, those
changes were most prominent in T cells. In AD, elevated levels of basal apoptosis were
evident in T and NK lymphocytes, B cell apoptosis was not altered in demented persons.
Moreover, the sum of apoptotic cells in all subsets covers the amount detected with PI taking
into account the percentage content in the PBMC (apoptosis in T cells of elderly controls:
1.08%; apoptosis in B cells of elderly controls: 5.03%; apoptosis of NK cells in elderly
controls: 1.47%; apoptosis of T cells in AD patients: 1.54%; apoptosis of B cells in AD
patients: 4.89%; apoptosis of NK cells in AD patients: 2.78%. ￿ controls: (1.08% x 0.6596)
+ (5.032% x 0.1088) + (1.47% x 0.2436) = 1.618% apoptotic cells in PBMC by 7-AAD
staining in elderly controls. AD: (1.54% x 0.6979) + (4.89% x 0.1034) + (2.78% x 0.2332) =
2.229% apoptotic cells in PBMC by 7-AAD staining in AD). The following table shows the
determined apoptosis of PBMC with PI and the calculated data for PBMC determined with 7-
AAD. It is evident that there variations between both methods. It should be noted that only a
few identical individuals (patients and controls) were included in both studies. Most subjects
were different, a propable reason for the deviation. However, AD-patients show elevated
levels by both flow cytometric methods and by nucleosome ELISA (Eckert  et al., 1998;
2001a).
elderly control AD patients
PI (PBMC) 7-AAD (S of subsets) PI (PBMC) 7-AAD (S of subsets)
1.35% 1.62% 2.37% 2.23%
Table 14. Basal apoptosis in PBMC from AD patients and elderly controls.DISCUSSION
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Altered apoptosis in subsets of AD patients
It can be assumed that T cells provide the major impact on the apoptotic properties of PBMC
from AD patients, since they showed elevated levels in basal, spontaneous and Fas-L induced
apoptosis (due to small number of included volunteers failed to be statitstically significant).
Moreover, the percentage of basal apoptotic cells correlated significantly with the cognitive
decline of the patients. NK lymphocytes display elevated levels of apoptotic cells under basal
conditions, nevertheless, spontaneous and agent-induced apoptosis was not altered and there
was no correlation with the severity of the cognitive decline. Moreover, looking at the subset
distribution between AD patients and controls, there was an increase in the CD4/CD8-ratio.
For these reseons, the T cells were the subject of the following studies, though there are
mechanisms evident that affect NK lymphocytes, as well. As another fact, there is much more
literature and knowledege about apoptosis and its mechansims of T cells than of NK
lymphocytes.
The altered CD4/CD8-ratio gave the rationale to further investigate the apoptosis of the T cell
subsets, CD4 and CD8 T lymphocytes, by three color flow cytometry with 7-AAD. This
determination showed that in fact the cell death function of the T cells is impaited in AD.
CD4 lymphocytes display elevated levels of apoptosis compared to elderly controls. In
contrast, in the investigated cohort of patients, no significant changes compared to controls
were evident in CD8 cells, but interestingly, correlation with the cognitive performance of the
patients was detected, indicating that CD8 T cells became more vulnerable to apoptosis as the
disease proceeds. Earlier findings indicate that all CD4
+ lymphocytes are positive for A b
whereas only the majority of CD8
+ lymphocytes show A b-immunoreactivity (Suh  et al.,
1996). Assuming that A b induces oxidative stress and apoptosis in cells, this could explain
some aspects of our results. The overall amount of APP transcript in PBMC is not altered in
AD (Ledoux et al., 1995; Ebstein et al., 1996). However, APP is upregulated upon mitogenic
stimulation (Bullido et al., 1996; Fukuyama et al., 1994; Ledoux et al., 1993; Monning et al.,
1990).
The data concerning apoptosis of peripheral lymnphocytes in AD can be summarized as
follows: (1) Apoptotic levels are elevated in PBMC from AD patients and correlate with the
MMSS. (2) T- and NK- lymphocytes are the targets that show enhanced apoptosis in AD, B
cells are not altered. Only T cells show a relation to the MMSS. (3) The CD4/CD8-ratio is
increased in AD patients and there is a correlation with the MMSS. (4) CD4 lymphocytesDISCUSSION
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dispaly elevated apoptotic levels without correlation to the MMSS while CD8 lymphocytes do
not show significant altered levels, but correlate significantly with the MMSS.
Influence of ApoE genotype
30 patients were apoe-genotyped. 2 were e2/e3, 9 were e3/e3, 16 were e3/e4, and 3 were
e4/e4, indicating that in our cohort of demented patients AD was associated in 63% with e4.
In this study, patients that carry apoe4 displayed elevated levels of apoptotic cells compared
to non-apoe4 patients. Unfortionally, the number of patients is too small to determine a proper
statistical analysis for this finding. However, enhanced numbers of apoptotic nuclei were
found in whole PBMC as in CD4 and CD8 positive cells.
It was shown that ApoE suppresses glial activation, ApoE4 has a lower activity compared
ApoE3 and ApoE2 (Laskowitz  et al., 1997). Activated glia in AD is known to secrete
inflammatory molecules that mostly can pass the blood brain barrier. In addition, sera from
AD-patients with ApoE4 genotype induced microglial activation in vitro, indicating the
presence of factors (e.g. cytokines) that mediate immune activity (Lombardi et al., 1998).
Perhaps, these factors are responsible as well for the enhanced apoptosis observed in this
thesis.
The above mentioned findings raised the question for the objective of T cells to undergo
apoptosis in AD. Apoptosis of immune competent cells is a comon feature to maintain
leukocyte homeostasis. For instance, an immune response like an acute infection stimulates
antigen-specific T and B lymphocytes to get activated and proliferate. In order to teminate the
immune response, lymphocytes undergo apoptosis in absence of appropiate growth factors
(e.g. IL-2 for T cells) to eliminate the accumulated lymphocyte clones. Very littele of these
cells rescue for not yet fully eluciadated reasons as memory cells. This kind of physiological
apoptotic cell death was termed AICD (activation induced cell death).
Unfortunatley, it is not as easy to determine why the cell underwent apoptosis as it is do
differntiate between apoptosis and necrosis. It can be easily deteced wheter a cell dispalys
some apoptotic features like DNA-fragmenations, caspae-activity, surface presence of
phosphatidylserine (detectable by Annexin V-staining) etc. But it is still very complex to
determine the rationale for cell death, if it was not induced under in vitro conditions. RatherDISCUSSION
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comparable to someone commiting sucide without a farewell letter: only the fact of
commiting sucide is apparent, the reasons remain unknown.
If the found apoptosis were due to incraesed activation of the T cells, a possible result of the
chronic neuroinflammation ongoing in AD, subsequent activation of T cells should be altered.
Therefore, T cells from AD patients were activated via their T cell receptors (TCR) using
PHA-L and TCR were additionally bypassed using PMA and Ionomycin.
To determine changes specific for the subsets, all analyszes were done by three color flow
cytometry to distinguish between CD4 and CD8 lymphocytes.
Altered inducibility of T lymphocytes from AD patients
Compared with elderly non-demented controls, T cells of AD patients showed increased
phosphorylation of tyrosine residues and enhanced expression of early activation marker
CD69 as response to PHA-L traetment. Thsese effects are not related to changes in the TCR
density in contrast to physiological aging as bypassing the TCR shows the same result in
CD69 expression. Moreover, both T cell subsets (CD4 and CD8) reveal this incraesed
inducibility, indicating a general involvment of T cells in AD. In addition, proliferation of T
lymphocytes showed a disproportionate profile from AD patients. In healthy young and aged
control, CD8
+ T cells mainly trigger proliferative capacity. In AD, the T helper population
incorporated significantly more BrdU, indicating a higher percentage of proliferating cells,
while CD8
+ T cells revealed significantly decreased amount of cells with DNA synthesis
subsequent to PHA treatment. Those changes were only evident as a tendency when PMA and
Ionomycin were used for activation. The study in this thesis examining immunogerontology
revealed that ‘healthy’ CD8
+ T cells provide the major impact for T cell proliferation. The
lower content of proliferating CD8
+ lymphocytes in AD results in decreased proliferative
capacity when the whole PBMC are inspected. This could explain the decreased proiliferative
acticity found in PBMC from AD patients in several earlier studies (Shalit  et al., 1995;
Lombardi et al., 1999).
What are the rationale for the increased inducibility of AD T cells and the decreased
proliferation of CD8 T lymphocytes from AD patients? Earlier finding in this thesis showed
that T cell function decreases with aging, why do T lymphocytes derived from AD patients
show apparently better function? A valuable explanation would be the generation of
peripheral memory T cells in AD: Memory cells display incraesed ‘re-call’ activity, indicatingDISCUSSION
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a faster and more efficient inducibility upon TCR ligation. In the above mentioned
experiments we stimulated T cells with PHA in order to induce TCR mediated activation. If in
AD there is a higher percentage of memory cells in peripheral leukocyes, more T lymphocytes
should show the measured signs of activation. Interestingly, CD8
+ memory T lymphocytes
display increased Ca
2+ mobilization but decraesed proliferation (Schlunck  et al., 1990).
Earlier result (Adunsky et al., 1991; 1995; Ibarreta et al., 1997) could show enhanced Ca
2+
influx im PBMC from AD patients but decreased Ca
2+ increase in CD4
+ T cells (Grossmann
et al., 1993) and here we demonstrated decraesed proliferation of T cytotoxic/supressor cells
in AD. As mentioned in the introduction, chronic neuroinflammation in the AD brain is a
major feature in AD pathology. In this thesis it could be shown first in detail that peripheral
lymphocytes from AD patients seem to react with altered function to this chronic stimulus.
There are some hints that this encanced inducibility subsequently to mitogenic stimulation
might reflect a generation of memory T lymphocytes in AD patients. These data do not
support the hypothesis of Antonaci et al. (1990) that claims AD to be a distinct entity of
immunosenescence with decreased T helper function.
The data found in this thesis
support the assumption that the
activation of T cells and a
possible generation of memory
cells (summarizied in the
scheme on the left ) is a process
that seems to occur long before
the clinical onset of AD. In
addition, it seems to be mostly
finished in present AD patients
since we could not found any
relation with the cognitive decline in those experiments. Apoptosis of CD8
+ T cells, however,
did show significant correlation with the MMSS in patients suffering from AD, indicating that
here are processes evident that seem to be still ongoing, even after the clinical manifestation
of AD.
With our findings we can postulate that AD involves the peripheral immune system, but is
definitively not an advanced type of immunosenescence.DISCUSSION
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Is the observed enhanced apoptosis in AD a consequence of chronic activation
of the T cells, the so-called AICD (activation-induced cell death)? Generation of
activated T lymphocytes (possibly memory T cells) in AD as a result of chronic
neuroinflammation.
Here, we could demonstrate much data that supports the hypothesis of changes in the
peripheral immune system in AD. Those chanegs could be responsible for increased apoptosis
of T lymphocytes in the disease. Several other groups have found similar results indicating
altered lymphocyte function. However, most of the studies are lacking a meaningful
explanation for these observations.
Earlier results concerning impaired funtion of AD lymphocytes
Increased apoptosis
Enhanced levels of apoptotic PBMC from AD patients were found after 72 hours  in vitro
culture in the presence as well as in the absence of  a-CD3-stimulus or hyperthermia.
Interestingly, the number of Fas-R (CD95) increased on CD4 and decreased on CD8 cells
following this treatment in AD, but not in vascular dementia or Parkinson’s disease
(Lombardi  et al., 1999). The presence of an apoptotic factor in Alzheimer plasma was
proposed (Maesaka et al., 1999) due to observations, that AD plasma increased apoptosis
fourfold in a cultured cell line.
Altered Calcium homeostasis
According to the calcium hypothesis of brain aging, disturbances of free intracellular calcium
homeostasis [Ca
2+]i play a key role in pathology of Alzheimer's disease (Pascale and
Etcheberrigigaray, 1999). Earlier data from neuronal tissue culture support the contribution of
Ab to neurodegeneration in AD, probably by disruption of the intracellular Ca
2+ regulation
(Hartmann et al., 1994a; 1994b; 1994c, Müller et al., 1996b).
Elevated basal levels of free intracellular Ca
2+ in PBMC from AD patients were found
(Adunsky et al., 1991; 1995; Ibarreta et al., 1997) when compared to elderly controls, patients
with multi-infarct dementia or patients suffering from depressive illness. However, only some
investigated patients showed levated basal levels, but no one out of the control or multi-infarct
dementia group. In addition, B-lymphoblasts from AD patients revealed elevated basal levels,
as well (Ibarreta et al., 1997). Increased concentrations of intracellular Ca
2+ could indicateDISCUSSION
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that the lymphocytes are in an activated state. Moreover, treatment with super-optimal doeses
of PHA (100 µg/ml) revealed increased Ca
2+ influx in PBMC in AD (Adunsky et al., 1991;
1995). In concordance with our results concerning mitogenic activation, the authors could not
detect any correlation between the cognitive grade and the amount of Ca
2+.
The PHA-induced Ca
2+ response in circulating human lymphocytes of healthy volunteers is
affected by Ab and its fragment Ab25-35 in a fashion similar to its effects on central neurons,
whereas no effect of Ab on receptor-activated Ca
2+ response in neutrophils were found. The
amplifying effect of Ab on Ca
2+ signalling was significantly reduced in lymphocytes from AD
patients (Eckert et al., 1995). Moreover, Ca
2+ responses to Ab 25-35 were not different between
early- and late- onset AD patients. These findings indicate that the sensitivity of the
lymphocyte for the effects of Ab is reduced in a high percentage of patients with probable or
possible AD. As possible explanation a similar reduction of the sensitivity of the lymphocyte
membrane for the fluidity-decreasing properties of Ab  was observed. Finally, the inhibition
of the PHA-induced Ca
2+ response by tetraethylammonium (TEA) was lower in the AD group
compared to aged controls. This could suggest the presence of a K
+ channel dysfunction on
AD lymphocytes, as it has been shown on skin fibroblasts of AD patients (Etcheberrigaray et
al, 1994). Interestingly, in AD B-lymphoblasts, the Ca
2+ influx was increased after addition of
Ab25-35 or aIgM (Ibarreta et al., 1997).
A specific stimulation with a monoclonal  a-CD3 antibody has been reported to elict an
increased (Adunsky et al., 1991) or a decreased (Grossmann et al., 1993) intracellular Ca
2+
concentration in AD lymphocytes in comparsion with control cells. It should be taken into
account that the study from Grossmann and co-workers has been performed in CD4
+
lymphocytes thus non-CD4 population (e.g. CD8 T cells) might be responsible for the
incraesed Ca
2+ response shown in the previous studies.
Impaired proliferation
A marked reduction in the proliferative ability of AD PBMC upon mitogenic stimulation was
observed (Shalit  et al., 1995; Lombardi  et al., 1999). No data exsits throuhout literature
concerning proliferation of CD4 or CD8 cells in AD.
Remarkedly, Ab stimulates lymphocytes to express IL-2 receptor and to proliferate. However,
lymphocytes from AD patients do not show incraesed proliferation upon Ab exposure (Trieb
et al., 1996). The authors speculate that this might reflect T cell anergy in AD, due to chronic
contact to A b and suggest that autoreactive lymphocytes with specificity for metabolicDISCUSSION
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products of APP occur in healthy individuals. These cells may be of relevance for the
elimination of potentially amyloidogenic substances. This mechanism might be impaired in
AD patients.
Altered cytokine secretion
Basal expression of CD25, a part of the IL-2-receptor, was increased on CD4 and CD8 T cell
in patients suffering from AD (Ikeda et al., 1991b). Following stimulation with PHA, the
expression of IL-2-R was markedly reduced in AD (Shalit et al., 1995). In addition, the same
study showed a significant elevation of secreted IL-2 subsequent to PHA treatment. Soluble
serum levels of IL-2 and TNF-a receptors were increased and there was a negative
coorelation between sTNF-a-R and MMSS (Leblhuber et al., 1998).
When stimulated with lipopolysaccharide (LPS) that activates monocytes and macrophages,
levels of IL-1b, IL-10, TNF-a and IL-6 were significantly increased in whole blood cultures
of AD patients but not of vascular demented patients (Lombardi  et al., 1999). Moreover,
when the patient group was divided according to the disease’s stage, the average level of IL-
1b, TNF-a, IL-6 and IL-10 increased in severe dementia (MMSS: 10 ± 3).
The binding of IFN-g and IL-6 to T lymphocytes was reduced in AD (Bongioanni et al.,
1997a; 1998). The number of functional TNF-a-receptors was increased on T cell of
Alzheimer’s disease patients (Bongioanni et al., 1997b).
Altered expression of activation markers
An increase in HLA-DR expresssion was observed in AD and was more obvious in later
stages of the disaese (Shalit et al., 1995). Ikeda and co-workers (1991a; 1991b) found out that
HLA-DR was increased on CD4 and on CD8 T lymphocytes. However, other studies
(Lombardi et al., 1999) and in this thesis only a tendency of increased levels was observed.
The number of CD8
+ cells expressing CD28, a TCR-related co-stimulatory molecule, or
CD11b (Mac-1, Integrin on NK lymphocytes) was significantly decraesed in AD (Lombardi
et al., 1999), indicating imapired suppresor/cytotoxic T cell and NK lymphocyte function.
The activation markers CD26 and CD38 were incraesed on CD8 lymphocytes (Lomabrdi et
al., 1999). In CD4
+ cells, the percentage of CD25 and CD28 were significantly increased
(Lombardi  et al., 1999). CD28 mediates activation of naive T lymphocytes. The finding of
Lombardi and co-workers supports the disproportionante proliferation measured in CD4 and
CD8 T cells, possibly leading to incraesed CD4/CD8-ratio in the present thesis in AD. All thisDISCUSSION
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observations were specific for AD patients and could not be found in vascular dementia or
Parkinson’s disease (Lombardi et al., 1999).
The number of peripheral benzodiazepine (BDZ) receptors is decreased on lymphocytes from
patients suffering of AD (Bonngioanni et al., 1997c). The physiological role of the peripheral
BDZ receptors is still unclear, however, a strong relation to immunemodulating properties,
such as stimulation of human monocyte chemotaxis (Ruff  et al., 1985), modulation of
cytokine release (Bessler et al, 1992), enhancement of T cell-dependent antibody response
(Zavala et al., 1987) and energy metabolism (Anholt et al., 1986) is speculated.
Distribution of lymphocyte’s subpopulation
An increase of CD4 and a reduction of CD8 lymphocytes in relation to the stage of the disease
was found by Shalit et al. (1995). A decreased CD4/CD8-ratio was additionaly found by other
groups (Singh, 1990; Pirrtilä et al., 1992; Lombardi et al., 1999). They showed that this
alteration was mainly due to a decrease of CD8 cells in AD. No chnages concerning CD4 and
CD8 levels were found in vascular dementia or patients with Parkinson’s disease (Pirrtilä et
al., 1992; Lombardi  et al., 1999). Moreover, the percentage of CD7
+ cells, an antigen
expressed throughout lymphocyte differentiation, was reduced in AD (Lombardi et al., 1999).
In addition, it was recently demonstrated that Down’s Syndrome (DS) is associated with
impaired T cell function as well. PHA-stimulated proliferation of T lymphocytes is reduced
and cytokine produktion is altered (Park et al., 2000). CD4/CD8-ratio seems not to be altered
in DS while the levels of HLA-DR positive T cells are increased, as well (Rabinowe et al.,
1989).
Changes in other lymphocyte subsets
The percentage of B lymphocytes remains unchanged in AD (Pirrtilä et al., 1992). Moreover,
B lymphoblasts of sparadic and familar AD have reduced GSH levels (Cecchi et al., 1999).
Levels of anti-microglia (Lemke et al., 1999) and anti Ab (Xu and Gaskin, 1997) antibodies
are incraesed in sera of AD patients.
Interstingly, Lombardi  et al. (1999) found decraesed levels of CD56, a marker for NK
lymphocytes. In this thesis, no changes were discovered concerning pecentage of NK
lymphocytes were observed. However, here NK cells were detected with a comercially
available antibody mixture raised against CD16 and CD56, so that a loss of of CD56
+ cells
only might be not observed. In addition, enhanced cytotoxic response of NK cells from ADDISCUSSION
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patients to IL-2 was found (Solerte et al., 1996). In addition, IFN-g and TNF-a production is
enhanced in NK cells from AD patients in correlation with their Mini Mental State Score
(Solerte et al., 2000). There are hints that defects in protein kinase C may be involved in
altered NK cell activity in AD (Solerte et al., 1998).
T lymphocytes in the AD brain
Activated T cells (CD25 and HLA-DR positive) were found in cerebrospinal fluid of AD
patients (de los Angeles Robison-Agramonte et al., 1998), indicating that they do cross the
blood brain barrier in AD and might contribute to damage the barrier.
Earlier reports show that detectable amounts of invaded lymphocytes were found in AD
brains while remaining undetectable in normal aged control brains. Both, CD4 and CD8
antigens were identified in hippocampus and temporal cortex of AD patients (McGeer et al.,
1989; Fiala M, 2000), however T cytotoxic/suppressor lymphocytes (determined as CD8
immunoreactivity) are more dominant in AD brains compared to CD4/T helper inducer cells
(Itagaki et al., 1988; Rogers and Mufson, 1990). Highest staining activity was found in sites
with increased signs of gliosis (enhanced GFAP and HLA-DR expression).
In MS and EAE brains a disproportionate recruitment of CD8
+ T cells into the CNS by
professional antigen-presenting cells was found (Carson  et al., 1999). Data exsist that
activated astroglial cells selectively recruits CD8+ T lymphocytes while microglia seems to
interact more likely with CD4+ T cells (Sedgwick  et al., 1991). One can speculate that
peripheral changes in T cells might reflect ongoing changes in glial cells. However, the
relevance of this findings and their possible use a diagnostic marker should evaluted in further
studies.
Taking together all these findings, it becomes evident that T lymphocytes of AD patients are
in an activated state, a possible explanation for the incraesed apoptosis found in peripheral
cells of AD patients. Most of our and other data could indicate that AD patients provide a
higher percentage of memory T cells compared with non-demented aged controls. Those
memory cells could be possibly the result of the chronic neuroinflammation. This hypothesis
can explain most of the various findings summarized above concerning impaired activity of
peripheral lamphocytes in AD.
The following figure summarizes the data of AD T cells found in this thesis and by others.DISCUSSION
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Figure 81. Summary of data observed in the present thesis and by other groups of changes of T lymphocytes in AD.DISCUSSION
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There is some evidence that memory cells (in humans: CD45RA
- and CD45RO
+) are not
quiescent long-lived cells, but represent T cell clones in a constant state of activation. It may
be that unlike naive cells, memory cells do not require antigen to survive and proliferate, but
only the self MHC molecule (i.e. have a lower functional activation threshold; Tanchot et al.,
1997). Memory cells show incraesed activation and cytokine secretion upon stimulation and
display incrased levels of activation markers. Interestingly and in concordance with our
findings, do CD8
+ memory T cells show decraesed proliferation compared to CD4
+ memory T
lymphocytes (Schlunck et al., 1990).
To verify this hypothesis expression of CD45RA
- and CD45RO
+ should be determined in AD
lymphocytes in further studies. Moreover, if the presence of memory T cells can be confirmed
in AD, it would be rather interesting whether there were specific to plaques and their contents.
In addition, the incidence of increased levels of anti-brain antibodies in sera of AD patients
supports the hypothesis that the amount of memory B cells (plasma cells) is increased in AD,
as well. However, since there are not many data available on the physiological role of NK
bisides their important function in natural cancer prevention, it is rather difficult to speculate
on their mechanisms in neuroinflammatory diseases. Further resaerch is necessary to elucidate
the roles of the B and NK lymphocytes and their impact on neuroinflammation in AD.
The changes in immune cell function in AD patients and animal models described above
suggest the existence of an immunological component to the pathogenesis and progression of
the disease. How might this occur? One possibility is that the immune system normally plays
an important role in removing potentially toxic aggregating forms of A b from the brain,
thereby preventing plaque formation. Evidence supporting such a mechanism comes from
recent studies showing that APP mutant mice and APP/PS1 double mutant mice can be
‚immunized‘ by challenging their immune system with aggregated forms of A b (Schenk et
al., 1999). Mice so challenged may generate antibodies against aggregated A b, resulting in
suppression of Ab deposition in the brain, as well as clearance of previously deposited Ab.DISCUSSION
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Transgenic mouse models for AD
Oxidative stress, mitochondrial function, and intracellular calcium regulation are early and
important contributors to either apoptotic or necrotic cell death. In the present thesis apoptosis
and oxidative stress-induced cell death in lymphocytes of transgenic mice carrying either a
single or multiple human Alzheimer-linked PS1 and APP mutations were investigated.
Consistent with the rationale that different PS1 mutations within the same molecule cause
more dysfunction and higher Ab1–42 levels than one alone (Citron et al., 1998), we found a
higher accumulation of apoptotic cells in lymphocytes from mice carrying multiple PS1 or
APP mutations (PS1 M5 Tg, APP-SDL Tg, respectively).
Our results concerning apoptosis in Tg animals bearing FAD related mutations additionally
indicate that comparable disturbances in apoptosis regulation due to PS1 and APP mutations
can be detected not only in brain but also in peripheral cells such as lymphocytes.
Furthermore, lymphocytes from mutant APP or PS1 Tg mice showed an increased
susceptibility to cell death compared to T cells from PS1 wt Tg mice or non-Tg littermate
controls. Already basal levels of apoptotic cells were elevated in APP and PS1 mutant mice.
However, spontaneous or ROS-induced in vitro apoptosis was extremely increased in
lymphocytes from APP-SDL Tg mice, but not in PS1 M146L Tg mice. In contrast, necrotic-
type cell death was elevated in both PS1 M146L and PS1 M5 Tg mice (Eckert et al., 2001b).
These findings suggest that PS1 may enhance vulnerability to both types of cell death. Mainly
the severity of insult, cellular homeostasis, and preexisting damage may determine the pattern
of cell death to be either more apoptotic or more necrotic in nature. Additional experiments,
e.g., assessing caspase-3 activation, might be needed to clarify whether cell death as observed
in lymphocytes from PS1 and APP-SDL transgenic animals belongs to the apoptotic or
necrotic pathway. PS1 mutations on the one hand sensitizes PC12 cells, neuroblastoma cells,
or primary neurons from PS1 M146KI mice to apoptosis (Guo et al., 1997, 1999b; Tanii et
al., 2000) and on the other hand make hippocampal cells from PS1 M146KI mice more
vulnerable to necrotic insults (Guo et al., 1999a).
Very interestingly, some evidence is provided that a similarly increased vulnerability to
oxidative stress-induced DNA damage is present in lymphocytes from FAD patients bearing
PS1 mutations (Parshad et al., 1996). Whether this is solely due to an increased production of
neurotoxic A b1–42 by mutant PS1 or whether additional mechanisms are involved, is not
known yet. Apoptosis is often mediated by oxidative stress and ROS (Buttke and Sandstrom,
1994). Our results are therefore in accordance with findings demonstrating reduced activitiesDISCUSSION
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of cytosolic superoxide dismutase and glutathione reductase in the brain of the same
transgenic animals (Leutner et al., 2000) and with data from lymphoblasts of FAD patients
with mutant PS1 indicating altered levels of reduced glutathione (Cecchi  et al., 1999). They
are further consistent with findings demonstrating increased vulnerability of PS1 M146KI
hippocampal neurons to lipid peroxidation after exposure to Ab (Guo et al., 1999).
An association between PS1 and Bcl-2 (Alberici  et al., 1999) or Bcl-XL, another
antiapoptotic member of the Bcl-2 family (Passer et al., 1999), has been found. Therefore,
redistribution of cytochrome c, one of the best known downstream activators of the apoptotic
cascade, could be one of the crucial events influenced by PS1/Bcl-2 interaction.
However, the molecular mechanisms by which FAD PS or APP mutations enhance apoptotic
activity in this context are not known. One can speculate that mutant PS1 may generate
molecules with proapoptotic activity or may negatively regulate the antiapoptotic effects of
Bcl-2 family members, possibly by indirectly regulating the activity of Bax, finally leading to
enhanced cytochrome c release in response to an apoptotic signal (Guo et al., 1997; Passer et
al., 1999). One potential mechanism by which APP mutations enhance the apoptotic process
could be the increased production of Ab, which is able to induce apoptotic cell death. It has
been shown that differentiated PC12 cells expressing mutant APP show an increased basal
apoptotic activity (Zhao et al., 1997). Recently, our group could show that, in PC12 cells
bearing mutant APPsw, caspase-3 activity, indicative for ongoing apoptosis, was significantly
enhanced (Eckert et al., 2001c). Elevated caspase-3 activation has also been found in the
brains of AD patients (Stadelmann et al., 1999; Gervais et al., 1999) as well as in cell lines
transfected with mutant PS-1 (Kovacs et al., 1999; Guo et al., 1999). At present, it is not clear
whether these effects are mediated either by Ab-induced caspase activation, in that all FAD
mutations lead to increased Ab levels, or by more complex proapoptotic mechanisms.
Very importantly, our present findings in lymphocytes from PS1 and APP mutant transgenic
mice mirror very well comparable findings in lymphocytes from AD patients shown here in
this thesis.
Our mouse model shows AD-like pathology in APP- and APP-PS1-double transgenic mice.
At an age of 18, 6 months, respectively, plaque formation is observed in brains of APP695SDL
or APP695SDLxPS1 M146L transgenic mice (Moussaoui et al., 1999).
The transgenic mice used here are similar to the APP23 mice that were first reported to show
AD-like pathology. APP23 transgenic mice used in a study by Sturchler-Pierrat andDISCUSSION
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Staufenbiehl overexpress the human APP with the Swedish double mutation only under the
control of a neuron-specific promoter. Those mice show A b plaque formation starting at an
age of six months. Peripheral amyloid deposits are not detectable, indicating that all A b
originates from neural tissue. In addition, gliosis can be detected as early as the first small
deposits become discernible. While microglia activation is largely restricted to the plaques,
hypertrophic astroctyes are found also at a distance, but only in plaque containing brain
regions. Degenerative processes are obvious around compact amyloid plaques. It seems that
the APP23 mice develop plaque-associated early neurofibrillary pathology. Very
interestingly, this mouse models shows a loss of cholinergic fibers and neuron loss in the CA1
region of the hippocampus, hallmarks quite selectively for AD pathology. Moreover, when
crossed with PS1 transgenic mice carrying AD-relevant mutations, the double transgenic
offspring show enhanced plaque formation (Sturchler-Pierrat and Staufenbiehl, 2000).
Since all of these specific alterations can be picked up in lymphocytes from sporadic AD
patients or from FAD patients as well as from transgenic mice carrying FAD-specific
mutations, it seems possible that enhanced cellular vulnerability to cell death, represent a
pathological pathway for sporadic and familial AD.
Antiapoptotic action of PS1 C-terminal fragment
Moreover, PS1 wt Tg mice seem to be protected of apoptosis and basal and spontaneous
conditions. Jurkat leucemic cells transfected with a C-terminal construct of PS1 showed
increased resistance to apoptosis as well (Vezina et al., 1999). In addition, similar findings
have been described for PS2 and its C-terminal fragment ALG-3 (Vito et al., 1996). Here, we
detected this phenomenon even under in vivo condition in PS1 wt Tg mice. As transgenic
mice express more PS1, the human and their endogenous murine PS1, it seems that those
effects are due to a gene-dose effect. PS1 interacts with anti-apoptotic Bcl2 family members
that differentially regulate sequential stages of progenitor cell survival (Mehler and Gokhan,
2001). It is further known that PS protein interact with Ca
2+ binding proteins (Buxbaum et al.,
1998) and PS1 mutants sensitize to apoptosis as demonstrated above. If maintenance of
intracellular Ca
2+ concentration is a physiological function shared by PS and Bcl2, one can
speculate that PS overexpression may stabilize their reciprocal association. The enhanced
apoptosis of cells bearing PS1 mutations might reflect the loss of this anti-apoptotic
mechanism. Moreover, recently we could show that antioxidative system in brains derivedDISCUSSION
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PS1-transgenic mice display elevated activity when compared with littermate controls
(Leutner et al, 2000). Possibly here the same mechanism is evident, as oxidative radicals are
mediators of apoptosis. Further experiments to explore the nature of this finding are currently
under investigation.
In this study it was clearly shown that C-terminal fragments of Alzheimer’s disease related
PS1 generated during apoptosis provide an antiapoptotic action, similar to that previously
reported for PS2 and its C-terminal fragment ALG-3.
To our knowledge, we are the first to demonstrate this antiapoptotic effect of C-terminal
fragments of the Presenilin family ex vivo in cells derived from PS1-transgenic animals. As
transgenic mice express more PS1, the human and their endogenous murine PS1, it seems that
those effects are due to a gene-dose effect.
PS1 interacts with anti-apoptotic Bcl2 family members that differentially regulate sequential
stages of progenitor cell survival (Mehler and Gokhan, 2001). It is further known that PS
protein interact with Ca
2+ binding proteins (Buxbaum et al., 1998b) and PS1 mutants sensitize
to apoptosis as demonstrated above. If maintainace of intracellular Ca
2+ concentration is a
physiological function shared by PS and Bcl2, one can speculate that PS overexpression may
stabilize their reciprocal association.
The rationale of the antiapoptotic action of PS1Cas during caspase activation remains to be
elucidated. It could be possible that the PS1/ Bcl2/ BclXL interaction represents one of the yet
still rare negative feedback mechansim in apoptosis regulation.
It should be expermintally explored whether PS1 mutants are able to bind to Bcl2 family
members or not. The enhanced apoptosis of cells bearing PS1 mutations might reflect the loss
of this anti-apoptotic mechansim.
Mover, recently we could show that antioxidative system in brains derived PS1-transgenic
mice display elevated activity when compared with littermate controls (Leutner et al., 2000).
Possibly here the same mechanism is evident, as oxidative radicals are mediators of apoptosis.
Peripheral cells as model in AD research
Recent findings suggest that genetic and environmental factors may facilitate the
neurodegenerative process of AD, by acting at different points in a feed-forward cyclical
neurodegenerative cascade that shares features with other neurodegenerative disorders (Eckert
et al., 1995b). Primary abnormality in cellular calcium signaling in the pathogenesis of someDISCUSSION
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inherited forms of AD, and the implications of this defect for all cases of AD might be a
general defect in neural tissue in this disorder. The possibility that dysregulation of cellular
calcium homeostasis is central to the pathogenesis of AD fits nicely within the well-
established role of calcium in regulating synaptic changes that underlie learning and memory,
and the involvement of calcium overload in the pathogenesis of a range of neurodegenerative
conditions (Mattson et al., 2001). Moreover, emerging evidence for alterations in calcium
signaling in cells of the immune system suggests to us a pivotal role for altered calcium
signaling in immune dysfunction that occurs in AD patients. During the past decade
considerable evidence has accumulated suggesting that perturbations in the regulation of
intracellular Ca
2+ levels contributes to the pathogenesis of AD (Mattson  et al., 1993). For
example, overactivation of glutamate receptors, and other conditions that result in a sustained
elevation of intracellular Ca
2+ levels, can induce alterations in the neuronal cytoskeleton
similar to those seen in neurofibrillary tangles. By increasing Ab production and decreasing
sAPP production, alterations in APP processing that result from presenilin mutations can
disrupt cellular calcium homeostasis and render neurons vulnerable to degeneration and death
(Mattson et al., 2001).
Studies of fibroblasts and lymphocytes from patients with late-onset sporadic forms of AD
have also revealed defects in calcium signaling (Eckert et al., 1993a).
While histological studies in postmortem brain tissue indicate enhanced features of apoptotic
cell death such as DNA fragmentation (Stadelmann et al., 1999), evidences for an enhanced
cellular vulnerability to apoptosis mainly originates from studies using lymphocytes from
sporadic AD patients (Parshad et al., 1996; Eckert et al.,1998; 2001a; Mecocci et al., 1998).
Very importantly, the present findings in lymphocytes from FAD associated transgenic mice
reflect comparably findings in lymphocytes from AD patients found in this thesis and by
others (Parshad et al., 1996; Eckert et al., 1998; Lombardi et al., 1999). Since these specific
alterations can be picked up in lymphocytes from sporadic AD patients or from FAD patients
as well as from transgenic mice carrying FAD-specific mutations, it seems possible that
enhanced cellular vulnerability to cell death represent a common pathological pathway for
sporadic and familial AD caused by mutations in PS1. The present thesis demonstrates that
we could bridge the gap between research using transgenic animal models or transfected cells
and studies using tissue from AD patients.DISCUSSION
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Future prospectives
How does the information get from the CNS to the periphery?
Infiltration across the blood brain barrier
Activation and loose-tethering of blood-borne leukocytes to cerebrovascular endothelial cells
involves intracellular adhesion molecules-1 (ICAM-1) on endothelial cells and its integrin
receptor on leukocytes, the lymphocyte function-associated antigen-1 (LFA-1). Crosslinking
of ICAM-1 activates T cells and macrophages, resulting in the production of pro-
inflammatory molecules (e.g. INF-g, IL-1 and NO). Induction of NO and cytokines alters the
permeability of the blood brain barrier, increases ICAM-1 and LFA-1, and induces another
adhesion molecule, vascular cell adhesion molecule-1 (VCAM-1), on endothelial cells and
glia (Merrill and Murphy, 1997). VLA-1 was identified to play a crucial role for the entry of
CD4
+ T cells (Baron et al., 1993). Once cells have crossed the blood brain barrier, they are
directed to migrate toward gradients created by chemoattractant chemokines. The small
cytokines can be quite specific in determining the immigration patterns of lymphocytes and
macrophages to certain inflammatory regions and are capable of enhancing activation by
integrins through redistribution of adhesion molecules, thereby modulating leukocyte-
endothelial cell interaction (Merrill and Murphy, 1997).
However, the fate of brain-infiltrated lymphocytes remains to be elucidated. Older theories
describing immune privileged zones like the CNS claim that activated T lymphocytes are
subjected to apoptotic cell death via the Apo/Fas-pathway (Janeway and Travers, 1995). But
latest research validates that the brain and neural cells definitively provide immune activity
(see Figure 82). Probably some infiltrated lymphocytes can re-enter the blood brain barrier
and mediate their information in the periphery. Moreover, invaded activated lymphocytes
secrete cytokine and inflammatory molecules that cross the blood brain barrier. In the
periphery those molecules are able to stimulate other leukocytes.
Possible future therapies to treat AD
There are several new ideas for treating and preventing AD. Apoptosis of peripheral blood
lymphocytes and mitogenic activation of T lymphocytes could represent a good tool to
monitor these new therapeutic strategies from periphery with minor invasive methods. The
most promising novel therapies are as follows:DISCUSSION
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Inhibitors of secretases
The identification of  b-secretase in 1999 (Yan  et al., 1999) and the progress in the
characterization of the still unknown g-secretase over the last two years has provided new
opportunities to develop therapies to inhibit secretase activity. To many researchers, inhibition
of secretase activity appears to be one of the most promising strategy for preventing AD
(Citron, 2000). At this point there is no evidence of additional functions of Ab, so that are no
serious concerns about reduction of this metabolite. However, there are possible remaining
pitfalls for this therapy: (1) Secretase are present in many body cells and APP may not be the
only and most relevant substrate and (2) amyloid production is the top of the cascade and
dementia is at the bottom. Therefore, secretase inhibition might be not useful to treat AD but
to prevent AD in earlier years.
Immunization with Ab
Immunization of transgenic mice carrying the London APP mutation (APP-V717F, PDAPP-
mouse) with A b1-42 prevents amyloid deposition and astrocystosis in young PDAPP mice
(Schenk  et al., 1999). In elderly mice, immunization appears to arrest the progression of
amyloidosis. Immunized mice developed and maintained high serum antibody titer against Ab
One possible mechanism of action is that anti-Ab antibodies facilitate clearance of Ab either
before deposition, or after plaque formation, by triggering monocytic/microglial cells to clear
Ab using signals mediated by F c receptors. It has been suggested that anti-inflammatory
regimens might be of therapeutic value. The findings of Schenk and coworkers argue that an
alternative approach, one that augments a highly specific immune r esponse involving the
peripheral adaptive immune system, can markedly reduce pathology in an animal model of
the disease. Ab immunization appears to increase the clearance of amyloid plaques, and may
therefore be novel and effective approach for the treatment of AD. However, patients in later
stage of the disease are unlikely to benefit from this therapy.
Stemcells
A most exciting field of discovery, from the standpoint of therapeutic intervention in
neurodegenerative disease, is that even the adult CNS posses populations of neuronal stem
cells that are capable of proliferating and then differentiating into neurons and glial cells
(Scheffler et al., 1999).DISCUSSION
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 All earlier mentioned therapies (e.g. immunization, NSAID use) show their beneficial effects
only, if administered early, years to decades before the onset of AD. Conventional therapies
(anticholinergic treatment or use of antioxidant like EGb761) that focus on demented persons
do only slower the progression of AD about a year or two but are not capable for healing it.
The only therapy for healing AD would be to substitute the lost neurons thereby restoring
synaptic transmission. There are some hints that neurons generated from ecotopic stem cells
can integrate into neuronal circuits in the adult brain (Snyder et al., 1997). A neuronal stem
cell-based approach would most likely be applied to patients in the early stages of AD with
the hope of replacing damaged neuronal synapses and restoring learning and memory abilities
(Mattson, 2000).
The findings of this thesis represent a basis to generate a suitable peripheral testmodel to
monitor and evaluate new therapeutic approach.SUMMARY
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Summary
Aging and age-related diseases are becoming more and more important for our society and
our health care system. Alzheimer's disease (AD) is a disorder that destroys some parts of the
brain and is characterized by global cognitive decline including a progressive irreversible loss
of memory, orientation, and reasoning. “Healthy aging”, therefore, is one of the major aims
for modern medicine. Apoptosis, or programmed cell death, plays an important role for
example in fetal development, as well as for learning processes. T-lymphocytes usually
undergo apoptosis in order to terminate an acute inflammation.
The aim of this thesis was to explore the changes in the apoptotic mechanism of peripheral
lymphocytes from Alzheimer’s disease (AD) patients in contrast to physiological aging. The
experiments were conducted with lymphocytes of healthy volunteers of different ages, AD
patients and young and aged mice. Moreover, transgenic mice carrying familiar AD-related
mutations were examined.
The aging study of peripheral cells of ‘healthy’-aged volunteers revealed an age-related
increase of basal apoptosis. In addition, spontaneous apoptosis as well as apoptosis induced
by oxidative stress (ROS) or by Fas engagement were enhanced in aging. A closer look at the
subcellular basis of the lymphocytes (e.g. B-, NK-, CD4
+-, and CD8
+-T cells) determined that
all lymphocyte subsets were affected by aging. Therefore, it could be concluded that the
regulation of apoptosis is generally impaired in lymphocytes of aged persons. The increased
susceptibility to oxidative stress supports the ‘Free radical theory of aging’ that claims the
radicals to be the cause for the aging-process.
In mice an increase of basal, spontaneous and ROS-induced apoptosis was detected in T cells
from the spleen, as well. An oral treatment over two weeks with the Ginkgo biloba extract
EGb761 showed a clear reduction of ROS-induced apoptosis in the treated group.
Interestingly, basal and spontaneous apoptosis, e.g. physiological apoptosis, were not effected
by the plant extract. This is an important benefit for therapy since physiological apoptosis has
a great relevance in the elimination of cancer-cells for example. In conclusion, the anti-
dementive drug EGb761 reduces specifically ROS-induced apoptosis that a plays an
important role in aging as shown in this thesis.
Based on the data found in healthy aging, lymphocytes from AD patients were assessed for
apoptosis. The cells show enhanced levels of basal, spontaneous, and Fas-induced apoptosis.
In subsequent experiments it was demonstrated that mainly the T cells were responsible forSUMMARY
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the findings. However, the NK-cells provided an important impact as well. In concordance
with AD-affected neurons, peripheral lymphocytes of AD patients show clear signs of
apoptotic cell death. In addition, basal apoptosis of T cells and the CD4/CD8-ratio showed a
correlation with the severity of the dementia. Therefore, it could be speculated that apoptosis
is due to activation-induced cell death (AICD) that occurs in acute and chronic activation of
adaptive immunity. In AD there is a chronic neuroinflammation in the CNS triggering
degeneration of neural tissue. In order to explore this, the experimental model of
lymphocyte’s activation was established in healthy aging first.
The study included the detection of various events of lymphocyte’s activation on the basis of
the T cell subsets (CD4
+ and CD8
+). The inducibility to mitogenic stimulation clearly
decreased in both subsets in aging. In contrast, T lymphocytes from AD patients showed an
enhanced activation subsequent to mitogenic stimulation compared with age-matched non-
demented persons. Only proliferation of CD8
+ T cells was clearly reduced in AD. This data
could be clues that an increased generation of memory T cells due to chronic
neuroinflammation might be evident in AD. Memory T lymphocytes show increased
inducibility upon mitogenic activation. Interestingly, CD8
+ memory T cells display decreased
prolifertive capacity. Due to activation, cells die by apoptosis later on. It could be concluded
that AD patients display an increased amount of memory T cells compared to controls. The
data implicate that there could be a cross talk between inflammatory within the brain and
inflammatory cells of the periphery. This is an interesting point since the brain used to be
assumed as immune-privileged zone. According to the experiment, the information of the
diseased brain is transferred to white blood cells. The connection of those two compartments
might raise the opportunity to observe and probably to influence easily not-accessible regions
like the brain.
Transgenic mice carrying mutations in familiar AD-relevant genes (Amyloid-Precursor-
Protein, Presenilin-1, respectively) displayed enhanced levels of apoptotic T cells from the
spleen, as well. It seems that those mutated proteins influence the regulation of apoptosis.
Probably, they are involved in the increased cell death of T- and NK-cells, as well. Animals
overexpressing Presenilin-1 showed reduced levels of apoptotic cell death. It was
demonstrated with molecuar biology tools that Presenilin-1, processed during apoptosis, has
an anti-apoptotic effect.ZUSAMMENFASSUNG
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Zusammenfassung
Altern und damit verbundene Alters-bedingte Erkrankungen stellen ein enormes Problem in
der westlichen industrialisierten Welt dar.  Apoptose, der programmierte Zelltod, spielt bei
vielen pathologischen, aber auch bei physiologischen Prozessen eine wichtige Rolle, so zum
Beispiel in der Embryonalentwicklung sowie bei Lernprozessen. Lymphozyten
beispielsweise, die während einer Immunreaktion stark proliferieren, werden anschließend
apoptotisch eliminiert.
Ziel der vorliegenden Arbeit war die Erfassung von Veränderungen des apoptotischen
Verhaltens an peripheren Lymphozyten in der Alzheimer Demenz und zum Vergleich im
physiologischen Alterungsprozess. Die Untersuchungen wurden mit Lymphozyten von
gesunden Probanden unterschiedlichen Alters, Alzheimer-Patienten und Mäusen
verschiedener Altersgruppen  durchgeführt. Ausserdem wurden transgene Mäuse untersucht,
die mutierte Gene tragen, die für die familiäre Form der Alzheimer Demenz verantwortlich
sind.
Der Alt-Jung Vergleich von peripheren Zellen von “gesund”-gealterten Menschen zeigte
einen Alters-bedingten Anstieg der basalen Apoptoserate. Ausserdem waren die spontane, die
durch oxidativen Stress (ROS)- sowie Fas-induzierte Apoptose deutlich mit zunehmenden
Lebensalter erhöht. Eine genauere Untersuchung der einzelnen Zellsubtypen zeigte, dass
dieser Anstieg bei allen Lymphozyten (B-, NK-, CD4
+- und CD8
+- T-Lymphozyten) zu
messen ist. Man kann daher vermuten, dass die Regulation der Apoptose im Alter allgemein
in peripheren Lymphozyten verändert ist. Ausserdem legte sich eine verstärkte Vulnerabilität
gegenüber oxidativen Stress dar, eine weiterer Befund zur Stützung der “Free radical theory
of aging”, die den Radikalen eine ursächliche Bedeutung im Alterungsprozess beilegt.
In der Jung-Alt-Studie am Mausmodell zeigte sich sowohl an peripheren Blutlymphozyten als
auch an T-Lymphozyten aus der Milz, ein deutlicher Anstieg der basalen, spontanen und
ROS-induzierten Apoptose. Eine zweiwöchige perorale Behandlung mit dem Ginkgo biloba-
Extrakt EGb761 zeigte eine deutliche Reduktion der ROS-induzierten Apoptose, aber
keinerlei Beeinflussung der physiologischen basalen und spontanen Apoptose. Dies hat einen
besonderen Vorteil für die Therapie, da Apoptose physiologisch eine wichtige Rolle zur
Elimination bestimmter Zellen, wie beispielsweise Tumorzellen, hat. Das Antidementivum
EGb761 hat daher nur spezifisch Einfluss auf den oxidativen Stress-induzierten Zelltod, der,
wie hier gezeigt werden konnte, im Alterungsprozess eine grosse Rolle spielt.ZUSAMMENFASSUNG
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Basierend auf den Befunden zur Apoptose im physiologischen Alterungsprozess, wurden
Untersuchungen mit peripheren Blutzellen von Alzheimer-Patienten durchgeführt. Die Zellen
der Patienten zeigten eine Erhöhung der basalen, spontanen und Fas-induzierten Apoptose,
die bei Untersuchungen der Subtypen (B-, T- und NK-Lymphozyten) auf die T-Lymphozyten
zurück geführt werden konnte, die NK-Zellen aber auch deutlich betroffen waren.  Wie die
Neuronen im ZNS, so zeigen auch die peripheren Lymphozyten eindeutige Veränderungen,
die die Apoptose kennzeichnen. Ausserdem erwies sowohl die basale Apoptose der T-Zellen,
als auch das Verhältnis der CD4- zu CD8-positiven T-Zellen eine Abhängigkeit zum
Schweregrad der Erkrankung. Dies lies die Vermutung aufkommen, dass es sich bei diesem
verstärkten Zelltod um den Aktivierungs-induzierten Zelltod (AICD) handeln könnte, der bei
einer akuten aber auch chronischen Aktivierung der adaptiven Immunität auftritt. In der
Alzheimer Demenz kommt es zu einer jahrelangen chronischen Neuroinflammation, die mit
starker Degeneration einher geht. Um diesen Aspekt näher zu beleuchten, war es notwendig,
die Lymphozyten in vitro zu stimmulieren.
Untersuchungen, zur Aktivierbarkeit der T-Lymphozyten wurden zunächst wieder im
Alterungsprozess etabliert. Hierbei konnte deutlich in einer Studie, die mehrere Zeitpunkte
sowie die genauere Betrachtung der T-Zellsubpopulationen (CD4
+ und CD8
+) mit einschloss,
gezeigt werden, in wieweit das physiologische Altern die Immunfunktion beeinflusst. So
konnte insgesamt eine verminderte Aktivierbarkeit beider T-Zellsubsets von alten Probanden
festgestellt werden. Im Kontrast dazu zeigten sowohl CD4
+ als auch CD8
+ T-Zellen von
Alzheimer-Patienten eine verstärkte Aktivierbarkeit verglichen mit nicht-dementen Alters-
gemittelten Kontrollpersonen. Nur bei der Proliferation nach mitogenen Stimulieren zeigten
CD8
+ T-Lymphozyten eine geringeres Ansprechen. Diese Befunde könnten Hinweise darauf
geben, dass bei dieser Demenzerkrankung verstärkt  Gedächtnis-T-Zellen, wahrscheinlich
bedingt durch die chronische Inflammation im  ZNS, generiert werden. Gedächtnis-T-
Lymphozyten zeigen eine verstärkte Aktivierbarkeit nach mitogener Stimulation.
Interessanterweise, zeigen CD8
+ Gedächtniszellen eine geringere Proliferation. Aufgrund der
Aktivierung sterben die Zellen anschliessend apoptotisch ab. Daher liegt die Vermutung nahe,
dass bei Alzheimer-Patienten eine erhöhte Anzahl an Gedächtnis-T-Zellen im vorliegt. Diese
Befunde stützen die These, daß der im Zentralnervensystem stattfindende Zelltod über die
aktivierten Glia auch in das periphere Immunsystem überstrahlt. Über die Verknüpfung dieser
beiden Kompartimente des Abwehrsystems ist es möglich, Veränderungen in einer nichtZUSAMMENFASSUNG
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zugänglichen Region wie dem Gehirn zu beobachten und möglicherweise auch zu
beeinflussen.
Transgene Mäuse, die Mutationen (im Amyloid-Precursor-Protein- bzw. im Presenilin-1 Gen)
tragen, die für die familiäre Form der Alzheimer-Demenz verantwortlich sind, zeigen auch
eine erhöhte Apoptoserate an T-Lymphozyten aus der Milz, was darauf hindeutet, dass diese
Genprodukte einen signifikanten Einfluss auf die Regulation der Apoptose haben.
Möglicherweise sind diese Mechanismen auch am erhöhten Zelltod der T- und NK-Zellen
beteiligt. Bei Tieren, die das Wildtyp Presenilin-1 Protein überexpremieren, konnte, mittels
molekularbiologischer Methoden, gezeigt werden, dass dieses während der
Apoptoseinduktion prozessiert wird und einen antiapoptotischen Effekt ausübt.REFERENCES
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Figure 82. Comprehensive summary of inflammatory mechanisms in Alzheimer’s disease (adapted from Neuroinflammation Working Group, 2000)